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Background: Aging is a physiological process characterised by a progressive 
dysfunction in metabolism and impaired tissue repair capacity, eventually leading to 
organs’ and tissue degeneration. Low-grade inflammation is currently considered the 
main driver of aging. The measure of telomeres length in peripheral leukocytes (LTL) 
has been suggested as novel and reliable marker of aging. The aim of this PhD was to 
investigate the association between (LTL), chronic inflammation and common cardio-
metabolic risk factors. 
Methods: Four studies were conducted: 1) a case-control analysis of 356 cases with 
periodontitis (PD) and 206 controls to assess the differences in LTL between cases 
and controls, 2) a cross sectional analysis of 630 individuals with diabetes mellitus 
investigating the association between PD, LTL and gluco-metabolic factors, 3) a 
cross-sectional analysis of 1080 adolescents (13–16 years old) to investigate the 
association between LTL, inflammation and cardiovascular (CV) disease risk factors 
and 4) a 10 years longitudinal analysis in 2547 women and 2815 men to assess 
whether LTL predicted cardiac and vascular phenotypes. LTL were measured using a 
Real Time Polymerase Chain Reaction method in all studies.  
Results: Study I demonstrated that increased systemic inflammation and oxidative 
stress were associated with shorter LTL in cases with PD versus controls (P<0.05). 
Results from Study II confirmed that shorter LTL was associated with severe 
periodontal inflammation (p=0.04), increased endotoxemia and insulin resistance. In 
Study III LTL was inversely associated with C-reactive protein (P<0.001) and 
fibrinogen (P=0.001) in adolescents. Lastly in Study IV a faster rate of telomere 
shortening between 53 to 60-64 years was associated with subclinical atherosclerosis 
at 60-64 years (p=0.006). All results were independent of traditional CV risk factors.  
Conclusions: This PhD programme provides evidence in support of the use of LTL as 
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The medical advances of the 20th century have resulted in dramatic increases in 
life expectancy worldwide, with developing countries showing the most rapid gains 
(1;2). The predicted global population of people aged over 60 years is forecast to 
reach 2 billion by 2050 (3) and this raises concerns about the ability of public 
healthcare systems to cope (1).  
Increased life expectancy does, however, present new challenges to the human 
body, as it has to compensate for longer environmental exposures than our ancestors 
used to have. A lifetime of environmental burden may complicate a variety of clinical 
conditions (4), hence the incidence of age associated illnesses is expected to rise 
exponentially (5). As a result, global investment in aging research, over the past 25 
years, has increased focusing on population studies of healthy aging or frailty and 
their determinants. 
1.1.1 Chronic diseases and their relation with aging 
In 2010, the World Health Organization (WHO) reported that 
noncommunicable diseases (NCDs) including heart disease, stroke, cancer, chronic 
respiratory diseases and diabetes are the biggest causes of death worldwide, 
accounting for 63% of all deaths of the worldwide population (6). As mortality for 
NCDs is particularly high in the elderly, NCDs have been also defined as “age-
related” disease. Indeed, it has been estimated that, from the 36 million people who 
die every year from chronic NCDs, only 9 million are under 60 years of age and 90% 
of these occurred in low- and middle-income countries (7). As such, predisposition to 
NCDs of the oldest populations presents an increasing challenge in the most 
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developed societies, with a growing research interest and financial support provided 
in the attempt to identify their underlying pathophysiology.  
It is widely agreed that increasing chronological age is characterised by an 
increased vulnerability to stress, due to the decline in homeostatic reserve and 
secondary to dysregulation in multiple inter-related systems (8-11). The increased 
vulnerability to stress explains the increased risk of age-related diseases observed with 
increasing chronological age. However, a large inter- and intra-individual variability 
within sensory, motor, cognitive and health domains (12;13) are found among 
individuals of similar age, suggesting that chronological age is a relatively imprecise 
measure of an individual’s functional or health status. The concept of biomarkers of 
aging was developed to provide more information about an individual’s biological 
health or functional status than chronological age. Biomarkers of aging are 
quantifiable parameters that reflect biological aging, which potentially can identify 
those at risk of aging-related conditions, disease, and mortality. Biomarkers could also 
be used to monitor and evaluate interventions designed to delay the onset or delay the 
progression of aging-related disorders. For these reasons, much of the biological 
research into aging over the last few years has focused on the identification of reliable 
markers which could inform on the risk of developing age-related diseases (14-16).  
According to the American Federation of Aging Research, a reliable 
biomarker of aging should (17;18):  
1. Predict the rate of aging. In other words, it would tell exactly where a person 
is in their total life span. It must be a better predictor of lifespan than 
chronological age. 




3. Be able to be tested repeatedly without harming the person. For example, a 
blood or an imaging tests. 
4. Be something that works in humans and in laboratory animals, such as mice. 
This is so that it can be tested in lab animals before being validated in humans. 
In a 2005 review of the in vitro and in vivo evidence, von Zglinicki and Martin-Ruiz 
(19) found that small segments of DNA which cup the end of chromosomes, known 
as telomere length, satisfied several criteria for a biomarker of aging, as it changes 
with age, has high inter-individual variability, is linked to basic biology, and is 
associated with the risk of aging-related disease and mortality. The authors 
acknowledged that the majority of the evidence was cross-sectional and that many 
studies were underpowered. For a proper validation of telomere length as marker of 
aging and aging-related disease, however, it remained to be proved that telomere 
length biology is influenced by the same factors known or suggested to be in the 
causal pathway for aging and aging-related disease.   
Several epidemiological studies have shown that chronic inflammation and 
oxidative stress exposure are the main drivers of aging and aging-related diseases. 
Chronic inflammation is currently considered the major risk factor for cardiovascular 
disease (CVD), cancer, type 2 Diabetes, Alzheimer’s and Parkinson’s diseases. 
Biologically, it has been proved that chronic inflammation and oxidative stress 
exposure increase the risk of aging and aging-related diseases, by causing multiple 
cumulative cellular injuries and reducing cellular ability to repair and regenerate. The 
mechanisms by which inflammation and oxidative stress promote cellular aging 
include: (i) cumulative oxidative damage due to increased generation of free radicals 
(20;21); (ii) cumulative DNA damage coupled with declines in the ability to repair 
(22); and (iii) cellular senescence, a state in which cells no longer divide (23). The 
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ideal bio-marker capable of predicting predisposition to age-related diseases should be 
able to inform on all these biological processes.  
The aim of this thesis was to further validate the measure of telomere 
length as possible marker of aging and aging-related diseases, by exploring its 
cross-sectional relationship with chronic oxidative stress and inflammatory 





1.2.1 Telomere biology and cellular aging  
Research into cellular senescence has always attracted interest in medicine. 
The dominant view of the early 20th century, highlighted in Alexis Carrel’s 
publication ‘on the permanent life of tissues outside the organism’ (24), was that cells 
could grow indefinitely. It was not until 1962, that Leonard Hayflick challenged this 
dogmatic view by demonstrating how somatic cells had a limited capacity for 
replication (25). This phenomenon has since been termed ‘the Hayflick limit’, 
nowadays referred to as replicative senescence. A few years later, Elizabeth 
Blackbourne discovered an intracellular sensing mechanism that limits cell lifespan in 
culture: telomere length (26). After this discovery, several experimental and human 
clinical studies demonstrated clearly that the measure of telomere length stands at a 
junction of critical processes underlying human chromosome integrity and 
vulnerability to chronic illnesses including cancer, CVD and, more generally, age-
related diseases. The importance of Dr Blackbourne’s discovery was recently 
recognized worldwide as she has been awarded of the Nobel Prize in Physiology and 
Medicine in 2009 (27). 
1.2.1.1 Telomere structure 
Telomeres are ribonucleoprotein complexes capping the ends of chromosomes 
and are essential for chromosome protection and genomic stability. Without telomere 
capping, chromosomal ends could be recognized as sites of DNA double-strand 
breaks, leading to chromosome degradation by DNA repair mechanisms. 
Furthermore, telomere capping prevents end to end fusion of chromosomes during 
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cell replication (27-29). The telomere sequence consists of stretches of repetitive 
DNA (hexamers) with high guanine content (30;31).  
 
Figure 1.1 Simplified schematic diagram of telomere structure.  
Telomeres are located at the ends of linear chromosomes. In humans, they are 
composed of hundreds to thousands of tandem DNA repeat sequences: hexameric 
TTAGGG in the leading strand and CCCTAA in the lagging strand. Additional 
protective proteins are also associated with telomeric DNA and are collectively called 
shelterin (TRF1, TRF2, TIN2, POT1, TPP1). The 3′ end of the telomeric leading 
strand terminates as a single-stranded overhang, which folds back and invades the 
double-stranded telomeric helix. Adapted from Kovacic JC et al. Circulation 
2011;123:1650-1660. 
 
In humans, the telomere terminus consists of 4 to 15 kbp of the 
hexanucleotides 5′-TTAGGG-3′ and ends in a G-rich 3' overhang (G-strand overhang) 
(32;33). The G-strand overhang can fold back and invade the double-stranded region 
of the telomere, thereby generating a looped structure, known as the telomere loop or 
T-loop (34). The structure hides the 3' end from telomerase as well as from DNA 
repair and degradation activities, representing, therefore, a primitive mechanism for 
telomere protection (35).  
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Telomeres are bound by major protein complexes, the most important of 
which is known as shelterin (or telosome). Shelterin encompasses the Pot1-TPP1 
heterodimer, the telomere-binding proteins TRF1 and TRF2, and the interacting 
factors Rap1 and Tin2 (36). Shelterin has a key role in regulating telomere length as it 
stimulates telomerase (the enzyme responsible for telomere elongation) and confers to 
telomeres the ability to acquire a T-loop conformation (37;38).  
1.2.1.2 Telomere length regulation 
During each cell division, in most proliferating cells, there is a gradual 
decrease (~20- 200bp) of telomere length, as a consequence of the end replication 
problem (Figure 1.2) (39).  
 
Figure 1.2 End-Replication Problem. 
DNA polymerase requires an RNA primer to initiate synthesis in the 5'-3' direction. At 
the end of a linear chromosome, DNA polymerase can synthesize the leading strand 
until the end of the chromosome. In the lagging strand, however, DNA polymerase's 
synthesis is based on a series of fragments, called Okazaki, each requiring an RNA 
primer. Without DNA to serve as template for a new primer, the replication 
machinery is unable to synthesize the sequence complementary to the final primer 
event. The result is an end-replication problem in which sequence is lost at each 
round of DNA replication. 
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DNA polymerase can synthetize new DNA only in 5'-3' direction. Therefore, 
while the leading strand can be fully replicated until the end of the chromosome, as 
the synthesis proceeds in 5'-3' direction, in the lagging strand, the synthesis of new 
DNA depends on the addition of a series of fragments, called Okazaki, each requiring 
a RNA primer. When these RNA primers are removed, it is impossible for the DNA 
polymerase to synthesize the lagging-strand sequence that is complementary to the 
small region at the end of the chromosome (which is at least as large as an RNA 
primer). The net result of this process, known to as the end-replication problem, is the 
elimination of some telomeric repetitions with each round of cell division, resulting in 
a progressive chromosome shortening. Cell proliferation is therefore considered the 
most important cause of telomere shortening in all human tissues, and the presence of 
short telomere length in the elderly can be interpreted as the accumulation of cell 
divisions associated with life time tissue renewal (40). 
Aside from the end-replication problem, however telomere shortening can be 
further accelerated by a number of DNA damaging agents. Among these, exposure to 
high levels of reactive radical species (RS) has been the most widely studied 
(19;33;41-45). Due to their high guanine content, telomeres are highly sensitive to 
hydroxyl radical damage, which results in single-strand breaks of the telomere 
sequence. Damage can occur either as a direct effect or as an intermediate step in the 
repair of oxidative base modifications (8-Oxo-7,8-dihydro-2'-deoxyguanosine, 8-
oxodG) (46). While similar mechanisms of oxidative DNA damage have been 
described in other “guanine-rich” genomic regions, telomeres have been reported to 
be deficient in the repair of single-strand breaks (47). Subsequently, they appear to be 




The main compensatory mechanism of telomere shortening is the action of a 
specific enzyme called telomerase, which promotes telomere elongation (49). This 
enzyme contains two molecules, the telomerase reverse transcriptase subunit (TERT) 
and the telomerase-associated RNA component (TERC), as well as one molecule of 
dyskerin (50), acting as stabiliser of the complex (Figure 1.3).  
 
Figure 1.3 Structure of telomerase. 
Telomerase is the main mechanism for telomere length elongation. The telomerase 
enzyme consists of two molecules of the TERT subunit and two molecules of the 
associated TERC, which contains the template for the addition of new telomeric 
repeats. In addition, telomerase contains one molecule of dyskerin, a protein that 
stabilizes the telomerase complex. Telomerase recognizes the 3' end of the G-rich 
telomere strand and adds telomeric repeats de novo. 
In the majority of human tissues, telomerase is highly expressed during 
embryonic development, with a rapid down-regulation after birth. While certain cells 
including those in the hematopoietic lineage maintain the ability to activate 
telomerase in post-natal life, this is insufficient to prevent telomeres from shortening 
with aging (51;52).  
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Importantly, when telomeres become critically short, 
they lose the ability to form the T-loop and are recognised 
as sites of DNA damage. As this phenomenon cannot be 
repaired by endonuclease and DNA polymerase, it triggers a 
persistent activation of the DNA damage response (DDR), 
which leads to cellular senescence and/or apoptosis (53;54). 
These latter conditions are characterized by a permanent 
arrest of the cellular cycle through activation of the p53 and 
p21 checkpoints (55) (Figure 1.4).  
Furthermore, senescent cells lose most of their 
metabolic activity whilst apoptotic cells are rapidly 
removed from tissue by tissue resident macrophages. In both cases, these cells can no 
longer contribute to the metabolic activity of tissues and their accumulation is 
considered a cause of age-related deterioration of tissue function and reduced ability 
to respond to acute stress (56). As such, shortened telomeres might be indicators of 
tissue aging, low stress resistance and increased risk of disease.  
 
1.2.2 Telomere length in humans: from biology to epidemiology 
1.2.2.1 Epidemiological studies 
The hypothesis that shortened telomeres length predicts age-related disease 
was initially proposed in humans in 2000, when short telomeres in peripheral 
circulating cells were associated with increased risk of cerebrovascular disease (57). 
A few years later, Cawthon et al. published a study reporting an association between 
short leukocyte telomere length (LTL) and increased mortality rate (58). In a cohort of 
Figure 1.4 Critically 
short telomeres stop 
cell replication by 
activation of DDR. 
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143 normal unrelated individuals over the age of 60 years, Cawthon documented that 
individuals with shorter LTL exhibited a threefold and eightfold increase in mortality 
by CVD and infectious disease, respectively. Subsequently, several large 
epidemiological studies confirmed the association between short LTL and increased 
risk of CVD morbidity and mortality (58-64). Moreover, new strong associations 
were described between LTL and indices of obesity/insulin resistance (62;63;65-67), 
cancer (68;69), dementia (57;70), and a host of other age-related diseases. 
However, the evidence produced in these reports was inconclusive. Indeed, 
several studies including in elderly populations could not find associations between 
short LTL and cardiovascular (CV) mortality (table 1.1) 
Table 1.1 Studies which did not find association between telomere length and mortality 
Studies Population Age Method Results 





>85 yrs old qPCR Telomere length did not 
predict mortality or 
incidence of dementia 




of Aging Danish 
Twins + Danish 
1905 Cohort Study + 
Longitudinal Danish 
Centenarian Study) 
>70 yrs old TRF LTL did not predict 
mortality following 
adjustment for age 
Houben et al. (73) N=203 (Zutphen 
Elderly Study) 
 
>70 yrs old qPCR LTL did not predict all 
cause, cancer or CVD 
mortalities 




>70 yrs old qPCR LTL did not predict 
mortality 
qPCR = Quantitative Polymerase Chain Reaction; TRF: Terminal Restriction Fragment 
Furthermore, several reports could not replicate the associations between LTL 
and common CV risk factors, including dyslipidaemia, hypertension (75) and 
parameters of insulin resistance (76;77), nor with the incidence of cerebrovascular 
disease (78) or coronary heart disease (79).  
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Several reasons could account for these discrepancies.  
a) Exploratory epidemiologic surveys often do not correct for multiple variables, 
making it difficult to understand the relative contribution of different factors 
on cross-sectional and longitudinal measures of LTL.  
b) The majority of published studies are underpowered, due to high inter-
individual variation in LTL at birth and thereafter. The high inter-individual 
variation in LTL at birth and the effects of genetic factors, sex, and 
environmental pathogens on the rate of telomere attrition give rise to 
considerable variation in age-adjusted LTL. It follows that large numbers of 
individuals are required in observational studies (i.e. cross-sectional) to 
uncover potential links between LTL and age-related disease.  
c) The use of samples from the latter stages of the life span may lead to a 
“survival effect”. LTL has been linked with aging and diseases of aging, so 
that individuals with aging-related disorders or those prone to age faster 
appear to have relatively short LTL. It follows that (if the observations are 
correct) these individuals are more likely to die at a younger chronological age 
than their peers, leaving older survivors with telomeres which are relatively 
longer than expected in the general population. Thus, cross-sectional 
observations may over-estimate telomere length in the elderly and there may 
be less variation within this group. Such a reduced inter-individual LTL 
variation challenges the accuracy of current LTL assays, increasing the 
difficulties in detecting mortality differences related to LTL. For this reason, 
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case–control disease studies of the elderly have to be closely matched for age 
and results from extreme elderly cohorts interpreted with caution (71;72).  
d) Finally, the methods used to measure telomere length may not be sufficiently 
precise to decipher the links between leukocyte telomere dynamics and aging, 
diseases of aging, and longevity in humans.  
1.2.2.2 LTL assays: Southern blot vs quantitative-polymerase chain reaction 
Over the last 20 years, researchers have developed several methods to measure 
telomere length, including Southern blot, quantitative fluorescence in situ 
hybridization (Q-FISH), flow cytometry (flow-FISH), quantitative-polymerase chain 
reaction (qPCR) and single telomere length analysis (STELA). Table 1.2 reports pros 
and cons of the different methods. While Q-FISH, flow-FISH and STELA assays are 
the most accurate methods and can specifically measure individual telomeres per each 
chromosomal arm, they require intact cells for analysis, limiting their application to 
epidemiological and longitudinal investigations (80). Furthermore, most of these 
assays are laborious, time consuming and operator dependent when compared to other 
semi-automated techniques. This strongly affects reproducibility of the assay and 
limits comparison of results between different laboratories. It is not surprising, 
therefore, that the two major methods currently used to measure telomeres in 
epidemiological/clinical research are Terminal Restriction Fragments (TRFs) length 




Table 1.2 Advantages and limitations of the most common telomere length assays 
Assay Advantages Limitations 
Southern 
Blot 
 Absolute quantification of telomere 
length (in base pair, bp) 
 Reference technique 
 Good reproducibility in expert 
laboratories 
 The terminal restriction fragment length includes 
also the sub-telomeric region 
 High operator dependent 
 Requires good quality (DNA needs to be tested for 
integrity before use) and high amount of DNA 
(1µg) 
 Expensive, cumbersome, labor intensive 
 Quantification of smear patterns in autoradiograms 
is prone to error and data is often reported as a 
mean of the TRFs, yet the TRF distribution might 
not always be Gaussian. 
qPCR  High throughput (easily applicable to 
large epidemiological studies) 
 Cheap  
 Less operator dependent (can be 
completely automated) 
 Requires low amount of DNA (even 
60ng are enough) and maintains its 
accuracy on long term stored 
samples (it is not necessary to test 
DNA integrity before the assay) 
 Assessment of the telomeric region 
alone (without sub-telomeric 
fragment) 
 Relative quantification  does not provide absolute 
telomere length measures in bp) 
 High variability in the devices and methods used by 
different labs  makes difficult to compare results 
of different studies) 
 High risk of artefacts  every minute change in the 
efficiency of the amplification might be amplified 
during each thermal cycle, resulting in substantial 
variations in accumulating products, with 
considerable impact on the final result 
FISH  High accuracy 
 Can provide the measure telomere 
length in different cell phenotypes 
 Possible with low amount of cells  
 Opportunity to co-stain multiple 
intracellular markers together with 
telomeres – IMMUNOFISH 
 Time consuming 
 High operator dependency 
 Expensive 
 Requires complex post-acquisition analysis 
 Requires fresh cells  
 Should be performed only on cells in metaphase 




 High accuracy 
 Able to target the measure of 
telomere length in  specific cell 
phenotypes 
 Does not require cells in metaphase 
 Opportunity to co-stain multiple 
intracellular markers together with 
telomeres 
 Requires high amount of cells (at least 3 x106) 
 Difficult on stored blood  results can be affected 
by storing procedure 
 Expensive 
 Time consuming 
 Complex post-acquisition analysis 
 Does not provide an absolute telomere length 
quantification (although this information can be 
recovered using specific fluorescent beads)  
STELA  High accuracy 
 Allows measuring telomere length 
on specific chromosomes (i.e. 
chromosome 17 or chromosome X) 
 Enable the study of alternative 
pathways related to telomere 
erosion/elongation 
 Time consuming 
 High operator dependent 
 Expensive 
 Requires good quality and high amount of DNA 





Southern blot was the first technique used to measure telomeres length and is 
performed on the terminal restriction fragments (TRFs), generated by subjecting 
genomic DNA to restriction enzymes (e.g., Hinf I/Rsa I, Hph I/MnI I). The processed 
samples are resolved on gels and hybridized to a telomeric probe ([CCCATT]n). 
Autoradiographs are subsequently scanned and subjected to densitometric analysis. 
Despite being the most frequently used technology to quantify TRF, this approach has 
numerous drawbacks (see Table 1.2), the most important of which are the large 
amounts of DNA required for analysis, the high costs of reagents and the high 
operator dependency. Furthermore, the method provides only an estimate of the length 
of telomere repeats, as the restriction enzymes generate TRFs that consist of a mixture 
of canonical (strictly TTAGGG) repeats of telomeres and some non-canonical (sub-
telomeric) sequences proximal to the telomeric region. As sub-telomeric sequences 
can vary in length depending on the last restriction site at a given chromosome arm 
(84), this increases the heterogeneity of the TRFs, masking the real length of 
telomeric repeats (85).  
In 2002, Cawthon developed a novel method to measure telomere length using 
qPCR (82). Previously, the measurement of telomere by PCR amplification (using 
oligonucleotide primers, TTAGGG and CCCTAA) was considered impossible due to 
the high risk of hybridization between primers. To overcome this problem, Cawthon 
modified the oligonucleotide primers. They consist of a repeated pattern of six bases 
containing four consecutive paired bases followed by two mismatched bases (82). 
This modification prevents the primers hybridizing with each other, leaving the PCR-
amplified telomere products free of primer-derived products. Thus, with the qPCR-
based assay, final telomere length can be determined by the ratio between amount of 
telomere repeats (T) and that of single copy gene copies (S) in each sample (T/S 
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ratio), compared to a T/S ratio of a reference DNA sample. The introduction of a 
reference DNA sample has allowed standardization of the results across separate PCR 
runs (82).  
The qPCR technique is, relatively simple, cheap and of high throughput when 
compared to the TRF analysis. Moreover, it requires smaller amounts of DNA (~60 
ng) and, as it measures telomere repeat content rather than absolute telomere length, 
and can be safely used to analyse degraded DNA samples (80). Finally, the primer 
design also counteracts the contribution of the sub-telomeric region as each primer is 
complementary specifically to telomeric repeats. One of the main limitations of this 
method however is that it only renders relative (T/S ratio) and not absolute (bp) values 
of telomere length (80). Researchers have tried to overcome this problem by using a 
conversion factor to transform the T/S ratio into kilobases. This factor is derived from 
the slope of a regression line describing the relationship between the T/S ratios and 
the mean TRFs in ‘reference’ samples (58). As a host of variables are intrinsic to the 
PCR methods and the DNA samples used in different laboratories, the conversion 
factor may differ in individual studies and in DNA samples derived from different 
groups, e.g., old versus young people. However, the successful introduction of an 
oligomere standard to measure absolute telomere length (71;86) has partially 
circumvented this problem. Another major limitation of the qPCR based telomere 
length assay resides in its high risk of generating artefacts. Indeed, every minute 
change in the efficiency of the T and S reactions may be amplified during each 
thermal cycle, resulting in substantial variations in accumulating products, with 
considerable impact on the T/S ratio. 
In conclusion, while Southern blots and qPCR have specific limitations, the 
simplicity, low cost and high throughput ability, make them both reliable in 
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measuring LTL, with the qPCR technique being the preferable choice for large 
epidemiological studies due to its lower operator dependency.  
1.2.2.3 LTL heritability and dynamics in humans  
LTL dynamic is complex in humans. Age-adjusted LTL is highly variable 
because of inter-individual differences in telomere length at birth and the rate of 
telomere attrition thereafter (87-90). In principle, a person with faster age-dependent 
telomeres erosion may not always have shorter telomeres than his age-matched peer 
(i.e. if the former was born with longer telomeres). Although robust telomerase 
activity in fetal tissues (91) results in high synchronization of telomere length in all 
different somatic cells within a specific newborn, LTL variation among new-borns is 
known to be as wide as that found in adults (~4 kb) (89). Much of this variation is 
considered to be genetically determined (92-102). Indeed, data from twin studies 
estimates, the heritability of LTL to be between 0.36 and 0.84 (103).  
Currently, two main factors have been identified as accounting for most of the 
heritability of telomere length: gender and paternal age at conception. 
Nawrot et al were the first to describe a possible X-linked inheritance of LTL 
(97). They reported high synchronization of LTL between fathers and daughters, 
mothers and sons and daughters and among siblings, but found no association between 
telomeres of spouses or those of fathers and sons. Additionally, Akkad et al. observed 
a robust correlation of LTL between mothers and their newborns (104). While this 
evidence suggests the presence of an X-linked imprinting in LTL, Nordfjäll et al 
suggested a paternal mode of heritability (99;100). These results were later confirmed 
by Njajou who described a greater paternal heritable effect of LTL compared to the 
maternal counterpart (98). Although it remains unknown which maternal or paternal 
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mechanisms are involved in defining telomeres length heritability, this evidence 
clearly supports a strong influence of genetic factors on LTL at birth.  
Another intriguing observation made with regards to telomere length 
inheritance concerns the effect of paternal age on offspring’s telomere length. While 
the shortening of telomere length with age is well established in most proliferating 
tissues, sperm telomere length is an exception, as older men have longer sperm 
telomeres (105;106). This finding is likely to be determined by the high activity of 
telomerase in the testes (107;108). As offspring inherit half of their chromosomes from 
paternal sperm, it is not surprising that offspring of older fathers tend to have longer 
telomeres (105;106;109). The effect of paternal age at conception on their children 
was firstly observed by Unryn et al. in 2005 (109), and it has been since confirmed in 
several large cohort studies (105;106;110). Intriguingly, a recent investigation 
demonstrated that the age-related telomere length increase in sperm could lead to 
multigenerational, cumulative, and thus more biologically significant lengthening or 
shortening of telomeres (111).  
Several studies have investigated changes of LTL after birth. Cross-sectional and 
longitudinal analyses suggest that LTL shortens at a much faster rate (~200 kb/year) 
during infancy and early childhood compared to adulthood (~30-40 kb/year) (112). 
This higher rate of LTL shortening has been attributed to the rapid somatic growth and 
expansion of the hematopoietic stem cell (HSC) pool in the bone marrow. Indeed, at 
any age, LTL mirrors the length of telomeres in HSCs (113;114), and the higher 
demand for cell replication in the HSC pool is ultimately reflected in a faster rate of 
telomere shortening in peripheral leukocytes, their “daughter” cells. During adulthood, 




This is mainly due to:  
a. a shift towards a prevalent housekeeping HSC activity, necessary only to sustain 
its own self-renewal and to replace HSC’s lost through repeated replicative cycles; 
b. the inverse relationship between baseline LTL and rate of telomere length 
shortening, which makes shorter telomeres less prone to attrition than their longer 
counterparts (see the paragraph Unexpected findings from longitudinal 
measurements of LTL). 
1.2.2.4 LTL dynamic challenges LTL assays 
The reduced rate of LTL shortening in adults represents a major challenge for 
current techniques used to measure LTL in humans, especially for longitudinal 
evaluations of telomere dynamics in large epidemiological studies. The 
reproducibility of the LTL assay should be as high as possible to capture small 
changes in the rate of telomere attrition between individuals exposed to different 
environmental factors. The most reliable way to assess reproducibility of LTL assays 
in large-scale epidemiological studies is to run a subset of randomly selected samples 
on two different occasions and calculate the inter-assay coefficient of variation 
between the two set of measurements (though this could potentially underestimate the 
true coefficient of variation based on separate DNA extractions). 
An example of this problem is elucidated below. 
Example 
The average of duplicate measure of TRF length in subject A is 7,500bp 
LTL assay coefficient of variation is ~2%  
Question: What is the potential error in estimating the biological age of subject A 
using such a LTL assay? 
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1. Coefficient of Variation = (SD/Mean) 
2. SD = (Mean*coefficient of variation) = (7,500*0.02) = 150bp (0.15 kb) 
3. Telomere attrition is ~30 bp a year 
4. Error in estimating the biological age = 150bp/30bp a year = 5 years 
Therefore, using a method with only 2% of coefficient of variation it is possible to 
make an error in the biological age of the individuals of ~ 5 years. 
However, the coefficient of variation is calculated using standard deviation 
which, in the case of normally distributed data, defines the variability around the 
mean of only the 68% of the total population. Therefore, only 68% of the measured 
values of LTL will fall within the estimated coefficient of variation of 150bp.  
To further highlight the relevance of the problem, we can calculate the 95% 
coefficient interval for the measurement of 7,500 bp. This parameter provides a better 
estimate of the accuracy of a measurement, as it defines the range of values within 
which, changing the sample of interest, the LTL measurement, will fall with a 
probability (confidence) of 95%. In other words, repeating the assay on multiple 
samples, the calculated confidence interval (which would differ for each sample) 
would encompass the true population parameter 95% of the time. 
Therefore, proceeding with the calculation: 
1. 95% coefficient interval (CI): Mean±1.96*σ/√n 
2. 95% CI: 7,500±1.96*150/√1 = 7.21–7.79 kb  
The difference between these two extremes corresponds to a deviation of 20 yrs in 
putative biological age.  
This example contributes to explain the relatively low number of studies in 
which longitudinal measures of LTL has been reported so far, although longitudinal 
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evaluations of telomere dynamics are obviously a better choice than cross-sectional 
analysis to study LTL dynamic and its determinants in humans.  
1.2.2.5 Unexpected findings from longitudinal measurements of LTL 
A small number of epidemiological cohort studies have reported information 
on longitudinal variation of LTL dynamics (71;87;114-118). The most consistent 
finding originating from these reports is a paradoxical elongation of LTL in a subset 
of individuals despite their advancing age (~20% to 30%, depending on the study) 
(87;116;117). No clear mechanisms have been identified to explain this evidence, but 
several hypotheses have been formulated. 
i) It has been suggested that the duration of follow-up of these observational 
studies was not sufficient to counteract the intrinsic variation/error of the 
technique used to quantify LTL, resulting in an unreliable detection of the 
LTL attrition rate. As the rate of LTL shortening is extremely low, short 
follow up will result in small differences in the measure of LTL between the 
two time points. Such small differences are likely to fall within the intrinsic 
variability of the technique used to measure LTL. The only study confirming 
this hypothesis is that of Chen et al., including a subgroup of 271 participants 
of the Bogalusa Heart Study (119). Using southern blots they measured LTL 
at three consecutive time points (S1, S2, S3) with variable intervals (gap 
between S1 and S2 of 5.8 years, between S2 and S3 of 6.6 years and between 
S1 and S3 of 12 years) and demonstrated that LTL lengthening progressively 
decreased with longer follow up periods (between S1 and S2: 14.4%, between 
S2 and S3: 10.7% and between S1 and S3: 1.5%). Furthermore, using residual 
DNA aliquots of the same individuals who displayed telomere elongation, 
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they repeated the LTL measurements after 6 months and the paradoxical 
elongation was only confirmed in 1/3 of the samples. Whilst these data 
suggest that telomere elongation could be an artifactual finding dependent 
upon the low reproducibility of the assay used to measure LTL, it should be 
noted however that telomere elongation has been truly observed in all 
longitudinal studies of LTL. Additionally, the percentage of individuals with 
telomere lengthening is similar among all studies, despite the substantial 
differences in the reported inter-assay coefficient of variation and duration of 
follow up (87;114-118).  
ii) A second hypothesis suggests that the occurrence of acute infections can 
eventually affect the relationship between LTL and stem cells telomere length 
between baseline and follow up observations (87). Age-dependent LTL 
shortening would largely mirror telomere attrition in hematopoietic stem cells 
and progenitor cells, assuming that telomere shortening downstream of 
hematopoietic stem cells/progenitor cells is relatively constant. However, this 
phenomenon might not hold all the time. For instance, acute infection might 
transiently increase proliferation of peripheral mononuclear cells, resulting in 
a temporary increase in the difference between LTL and telomere length in 
hematopoietic stem cells/progenitor cells. This transient effect would not 
shorten telomere length in hematopoietic stem cells/progenitor cells over the 
life course of the individual, but it might affect LTL results in a longitudinal 
study of short duration.  
iii) An alternative hypothesis relates to the status of hematopoietic stem cells 
within bone marrow niches. Indeed HSC residing in the osteoblastic niche are 
largely quiescent and their mobilization into the vascular niche promotes their 
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transformation into proliferative HSC’s (120). It is possible that, in individuals 
with telomeres elongation, a group of quiescent HSC are mobilized into the 
vascular niche between baseline and follow-up examinations, resetting LTL 
above its length at the baseline examination. 
 
Although all the above-listed hypotheses are biologically plausible, they may 
be insufficient to account for the relatively high and consistent percentage of 
individuals presenting with LTL elongation in a number of observational studies. It 
could well be that LTL elongation is a true biological phenomenon, with a potentially 
important but still obscure clinical meaning. Indeed, in a sample of 236 randomly 
selected Caucasian participants from the MacArthur Health Aging Study (aged 70 to 
79 years), Epel et al. showed different trajectories of LTL (i.e. telomere shortening, 
maintenance and elongation) were associated with differences in CV mortality rate 
(121). Individuals with telomere elongation or stability had better CV outcome 
compared to those with telomere shortening. However, the relatively short follow-up 
of the study (only 2.5 yrs) raises several doubts on the ability of the qPCR based 
telomere length assay used in this study to capture the expected small difference in 
trajectories of telomere attrition. 
 
It has been repeatedly reported that the rate of LTL shortening strongly depends 
upon the baseline measure of telomere length, with shorter LTL at baseline associated 
with lower rates of LTL attrition at follow up (87;116-118). This finding is unlikely to 
be dependent upon the reduced sensitivity of the LTL assay, as it has been 
documented in all studies in which LTL was measured in a longitudinal fashion. 
Remarkably, several studies confirm a possible feedback regulation of the rate of LTL 
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shortening. Indeed, whilst telomere length is variable among different chromosomes 
(122) as well as between homologous chromosomes (123), it has been shown that it 
shortens faster in the homologous chromosome with the longer telomeres. The most 
likely mechanisms of this phenomenon include: 
a) oxidative stress exposure (124;125), because longer telomeres are bigger 
targets for free radicals, which attack the G triplets on the sequences. 
b) residual telomerase activity, which would preferentially add telomeric repeats 
onto the shortest telomeres as they are unable to adopt the T-loop 
conformation (123). 
An easier alternative explanation of this finding could be far from a biological 
phenomenon but represent a mere consequence of the mathematical coupling of the 
baseline and follow-up measure of LTL. Mathematical coupling is the effect that 
occurs when one variable directly or indirectly contains the whole or part of another, 
and the two variables are analysed using standard correlation or regression techniques 
(126-130). The most commonly observed form of mathematical coupling in medical 
research occurs by addition, subtraction, multiplication, or division of one variable by 
another (126). This is frequently encountered when one is investigating the change in 
outcome during follow up (i.e. following a specific intervention to test the 
effectiveness of a particular treatment) in relation to initial or baseline value (i.e. the 
outcome prior to the intervention). This is because the baseline is part of the change, 
and thus change and baseline are coupled algebraically (hence the term mathematical 
coupling). This then affects the statistical procedure of testing the null hypothesis, 
which is central to the interpretation of the correlation or regression analysis. Where a 
statistical analysis suffers from mathematical coupling, the null hypothesis being 
tested—that the coefficient of correlation or the slope of regression is zero—becomes 
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erroneous (131). Interpretation of results, and thus any purported evidence, from 
studies that analyse change with respect to baseline in this way are therefore 






The recognition of inflammation dates back to antiquity. The first to define 
clinical symptoms related to the inflammatory response was the Roman doctor 
Cornelius Celsus in the 1
st
 century AD. As documented by Celsus in his treatise De 
Medicina, the ancient Romans understood that tissue response to injury could be 
summarized by four principal signs: rubor (redness due to hyperaemia), tumor 
(swelling, caused by increased permeability of the microvasculature and leakage of 
proteins into the interstitial space), calor (heat associated with the increased blood 
flow and metabolic activity of the cellular mediators of inflammation), and dolor 
(pain, in part due to changes in the peri-vasculature and associated nerve endings) 
(132). It was only in the 19
th
 century, however, that Augustus Waller and Julius 
Cohnheim discovered the physiological basis of these four characteristic signs (133). 
They proposed that acute inflammatory responses were characterized by emigration of 
leukocytes from the blood vessels, accompanied by other changes in the local 
vasculature such as vasodilation and leakage of plasma into the interstitial space. In 
1858, Rudolph Virchow added a fifth postulate of inflammation termed functio laesa, 
to identify organ dysfunction which develops during the inflammatory process (132). 
While the initial signs only apply to acute inflammation accompanying wounds and 
infections, functio lasesa universally accompanied all inflammatory processes. The 
introduction of the concept of cellular phagocytosis and of the theory of cellular 
immunity by Elie Metchnikoff in the late 19
th
 represented the next milestone in our 
understanding of the inflammatory process. Through watching protozoa engulf 
particulate matter and examining blood leukocytes ingest foreign bodies she 
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discovered the phagocytosis process. Based on these findings, she emphasised the 
beneficial aspects of inflammation, pointing out the key role of macrophages and 
neutrophils in host defence and maintenance of tissue homeostasis (134). Subsequent 
milestones included the identification of different classes of serum components as 
crucial regulators of the inflammatory response.  
Over the recent decades, the introduction of high sensitivity assays for 
inflammatory markers has greatly increased the understanding of the 
pathophysiological mechanisms involved in inflammatory responses. Inflammation 
not only acts as first line of defence of the human body against external aggressions 
but, more generally, represents an adaptive response of the human body to transient or 
persistent perturbations in its internal homeostasis. 
1.3.2 Acute and chronic inflammatory responses safeguard the body’s internal 
homeostasis 
Homeostatic control mechanisms ensure that the internal environmental and 
vital parameters (such as glucose and oxygen concentrations) are maintained within 
physiological ranges defined at specific set points (135). External aggressions or 
internal perturbation of tissue homeostasis can cause deviation in some parameters 
beyond the physiological range, resulting in acute cellular or tissue stress that elicit in 
a transient adaptation to the new environment (acute inflammation). As a result, acute 
inflammation represents a short-term adaptive response to transient abnormalities. Its 
'purpose' is to remove the source of the disturbance, ultimately restoring functionality 
and homeostasis to the tissue. The ability to detect clinically the ongoing 
inflammatory response (i.e. using traditional inflammatory markers) is dependent on 
the nature and the degree of the underlying tissue malfunction. For example, very 
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mild stress might only cause local alterations that can be easily handled by tissue-
resident inflammatory cells (mainly macrophages and mast cells). More extensive 
dysfunction or damage, by contrast, may require recruitment of additional leukocytes 
and plasma proteins, causing a transient increase in the systemic levels of 
inflammatory cells and/or markers. 
If the abnormal conditions are sustained, more prolonged adaptive changes are 
required (chronic inflammation). The ongoing inflammatory state shifts the system to 
different and pathological set points that are better suited to deal with the extreme or 
persistent abnormal conditions. These adaptive changes generally occur at the expense 
of many other physiological processes and cannot be sustained without adverse side 
effects. Therefore, while an adaptive shift of endogenous set points can provide short-
term benefits, in a chronic phase it can become maladaptive, causing further 
alterations to the body’s homeostasis. This explains why, although chronic 
inflammatory responses are normally less aggressive than acute inflammatory 
reactions, they are currently considered the major contributors to the medical burden 
of industrialized societies (136). The decline in insulin sensitivity of skeletal muscle 
as a result of systemic inflammation provides a good example of this phenomenon 
(137;138). The transient decrease in insulin sensitivity during acute inflammation is 
potentially beneficial, as it allows the redistribution of glucose from one of its major 
consumers (skeletal muscle) to leukocytes. However, the decrease in skeletal muscle 
insulin sensitivity defines new set points of insulin production for pancreatic β-cells. 
These cells have the ability to increase insulin secretion to accommodate the new 
insulin sensitivity set point but can only maintain this over short periods. Therefore, if 
the inflammatory process is not resolved, the activity of pancreatic β-cells fails to 
compensate for the reduced skeletal muscle insulin sensitivity, and this may lead to 
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type 2 diabetes. The potential for adverse effects is intrinsic to any adaptive and 
persistent biological changes, regardless of whether these changes occur at the 
cellular, tissue or organism level.  
1.3.3 An overview of biological pathways involved in inflammation 
Although different cellular and molecular pathways characterize 
inflammation, all inflammatory processes can schematically be defined by the serial 
activation of four major components: inducers, sensors, mediators, and effectors 
(Figure 1.5). 
 
Figure 1.5 The inflammatory pathway. 
A generic inflammatory pathway consists of inducers, sensors, mediators and 
effectors. (see text for further explanation). 
 
Inducers are the inflammatory triggers that initiate the inflammatory response. 
They activate specialized sensors, which then elicit the production of a specific set of 
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mediators. The mediators then act on the effectors, the tissues and organs which are 
involved in the inflammatory process. The specific alterations induced in the effectors 
usually lead to the clinical manifestations of the inflammatory response. Indeed, the 
activity of the mediator determines specific changes in functions of tissues and 
organs.  
Inflammatory inducers have a crucial role in influencing the cellular and 
molecular pathways involved in the inflammatory states. They can be generally 
grouped as microbial and non-microbial factors (figure 1.5). There are, in turn, two 
classes of non-microbial inducers: the first includes allergens, irritants, foreign bodies 
and toxic compounds, while the second includes molecules exposed after tissue or 
cellular damage. While this classification is relatively simple, it has been recently 
complicated by a growing number of acute and chronic systemic inflammatory 
conditions where the inflammatory inducer remains unknown (Figure 1.5). These 
states of systemic inflammation accompany many diseases of the western world, 
including obesity, atherosclerosis, neurodegenerative diseases, and cancer. It is 
currently thought that the evolution of such inflammatory processes depends on a 
vicious cycle connecting inflammation and the pathological processes they 
accompany. For instance, obesity can result from excessive food intake which causes 
adipose tissue dysfunction (accumulation of ectopic fat and adipose tissue 
inflammation), leading to a chronic inflammatory state (139). In turn, chronic 
inflammation can promote obesity-associated diabetes by contributing to insulin 
resistance (140), further increasing the baseline generation of oxidative stress and pro-
inflammatory cytokines.  
The activity of the inducers is recognised by specific cells which are either 
resident in the local tissue or recruited from the blood stream (sensors). These cells 
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are part of the innate and adaptive immunity, two systems developed to protect the 
human body from exogenous and endogenous aggression (141). The innate immune 
system is composed of cells (resident mast cells and macrophages as well as 
neutrophils) with rudimental defensive capacity, able to recognise potential 
inflammatory inducers and initiate the inflammatory response (142). However, the 
inflammatory response which follows activation of the innate immunity is not specific 
and targets not only the possible inflammatory triggers but also the surrounding 
tissues. If such a response is not able to remove the aggression by the inflammatory 
trigger, the release of several chemotactic molecules from the cells of the innate 
immune system activates more specialised cells which are part of the more 
sophisticated adaptive immune system (macrophages, B and T cells) (143). These 
cells produce cytokines, antibodies and other immune-inflammatory reactants which 
selectively target the inflammatory inducer, increasing the chance of a complete 
resolution of the inflammation and reducing the damage to surrounding tissues (144). 
Therefore, the interaction between innate and adaptive immunity orchestrates the 
evolution of the inflammatory response by production of multiple inflammatory 
mediators (141-143;145).  
Inflammatory mediators can be classified into seven groups according to their 
biochemical properties: vasoactive amines, vasoactive peptides, fragments of 
complement components, lipid mediators, cytokines, chemokines, proteolytic 
enzymes and antibodies (133;146). Each mediator will determine specific changes in 
local tissues (i.e. vasodilation, destruction of the connective tissue or cytotoxic 
activity on local cells and on the inflammatory trigger) which, if the aggression by the 
inducer or the inflammatory response is particularly severe, will result in the clinical 
manifestations of the inflammatory process. 
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1.3.4 Acute inflammatory responses 
1.3.4.1 Cellular and molecular mechanisms involved in acute inflammatory 
responses 
The cellular and molecular mechanisms involved in acute inflammation are 
highly dependent on the nature of the inflammatory inducers. Therefore, they have 
been treated separately on the basis of the specific inflammatory trigger.  
1.3.4.1.1 Microbial inducers 
Microbial inducers are usually recognised by the presence of pathogen-
associated molecular patterns (PAMPs), a broad range of conserved molecular 
patterns commonly expressed on pathogens (whether pathogenic or commensal) but 
foreign to mammals (147). Examples of PAMPs include lipopolysaccharides (LPS), 
surface phosphatidylserine, and aldehyde-derived proteins, as well as modified forms 
of classical risk factors for atherosclerosis, including low-density lipoproteins (LDL) 
modified by oxidation or glycation. These molecules are detected by various 
scavenger and/or toll-like receptors (TLRs) of the innate immune system which are 
expressed on tissue-resident macrophages, neutrophils and mast cells (148).  
Ligation of scavenger receptors can lead to endocytosis and lysosomal 
degradation of the bound ligands (149;150), while engagement of TLRs can lead to 
the production of a variety of inflammatory mediators, including chemokines, 
cytokines, vasoactive amines, eicosanoids and products of proteolytic cascades (151-
155). Mediators amplify the inflammatory response, eliciting the production of a local 
inflammatory exudate. Plasma proteins and leukocytes (mainly neutrophils) normally 




The activated endothelium of the blood vessels at the inflamed site induces 
expression of surface selectins and integrins which interact with complementary 
ligands such as chemokine receptors on the leukocyte membrane allowing selective 
extravasation of neutrophils, while preventing the exit of erythrocytes (156). Upon 
reaching the affected tissue, neutrophils become activated, either by direct contact 
with pathogens or through the actions of cytokines secreted by tissue-resident cells. 
Activated neutrophils release the toxic contents of their granules, including reactive 
oxygen species (ROS) and reactive nitrogen species (RNO), proteinase 3, cathepsin G 
and elastase in an attempt to remove the inflammatory stimulus (157). As these highly 
potent effectors do not discriminate between microbial and host targets, collateral 
damage to host tissues is unavoidable (158).  
Although this sequence of events characterises most of the acute inflammatory 
processes evocated by microbial inducers, bacterial, viral, or parasitic factors can 
activate different sensors, mediators, and target tissues, such that the appropriate type 
of inflammatory response is induced. For example, viral infections induce the 
production of type-I interferons (IFN-α, IFN-β) by infected cells and the activation of 
cytotoxic lymphocytes (159), whereas infections with parasitic worms lead to the 
production of histamine, IL-4, IL-5, and IL-13 by mast cells and basophils (160).  
1.3.4.1.2 Non-microbial inducers 
The first class of non-microbial inflammatory triggers includes allergens, 
irritants, foreign bodies and toxic compounds (133). Allergens can be detected as they 
mimic the virulence activity of parasites, while irritants disturb the homeostasis and 
activate cells on epithelial surfaces. In both cases, the inflammatory response involves 
activation of mast cells and basophils because, similar to parasites, defence against 
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allergens and environmental irritants relies on expulsion and clearance mediated by 
the mucosal epithelia (161). Conversely, the inflammatory response evoked by 
foreign bodies is dominated by the phagocytic activity of macrophages (162).  
Intra- and extra-cellular molecules that are normally kept sequestered in intact 
tissues can be released after acute tissue or cellular damage, representing the second 
important class of non-microbial inflammatory inducers. During necrotic cell death, 
for example, the integrity of the plasma membrane is disrupted, resulting in the 
release of certain cellular constituents, including ATP, HMGB1 (high-mobility group 
box 1 protein) and several members of the S100 calcium-binding protein family 
(S100A8, S100A9 and S100A12) (163;164). ATP binds to purinoceptors (including 
P2X7) at the surface of tissue-resident macrophages, resulting in K
+
 ion efflux, and 
can cooperate with other signals to activate the NALP3 inflammasome (165). 
Similarly, HMGB1 and S100A12 engage the receptor RAGE (advanced glycation 
end-product-specific receptor; also known as AGER), which (at least in the case of 
HMGB1) associates with TLRs to induce an inflammatory response (166;167).  
Similarly, tissue injuries can cause damage to the epithelial cells, which 
normally separate the internal compartments from the external environment. This can 
cause “decompartementalization” and expose TLR receptors on macrophages, 
normally residing the lamina propria, which results in induction of a local 
inflammatory response. For example, damage to the vascular endothelium allows 
plasma proteins and platelets to migrate to extravascular spaces (156). A key plasma-
derived regulator of inflammation, the Hageman factor (also known as factor XII), 
becomes activated by contact with collagen and other components of the extracellular 
matrix. Activated Hageman factor acts as a sensor of vascular damage and initiates 
the four proteolytic cascades that generate inflammatory mediators: the kallikrein–
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kinin, coagulation, fibrinolytic and complement cascades (133). Platelets are also 
activated by contact with collagen and produce various inflammatory mediators, 
including thromboxanes and serotonin (133).  
1.3.5 Inflammatory resolution: a road to chronic inflammation 
Generally, inflammatory responses, evoked by tissue and cellular damage, 
exert beneficial effects as they promote tissue repair and help to prevent colonization 
of the damaged tissues by opportunistic pathogens. Their temporal evolution is 
restricted to the time necessary to eliminate the triggering insult and repair the local 
injury. Therefore, for effective resolution to occur, it is not only necessary to remove 
pro-inflammatory cells and molecules, but also to restore, as long as it is possible, the 
normal architecture and function of local tissues. Whilst termination of the 
inflammatory response is normally considered as a simple process which follows 
elimination of local pathogens, recent evidence demonstrated that this is a rather more 
complex process involving a number of highly regulated pathways (168). Cessation of 
proinflammatory signaling is a prerequisite that pre-empts removal of infiltrating 
granulocytes. During spontaneous resolution, neutrophils undergo apoptosis, a highly 
regulated cell death mechanism that prevents the release of histotoxic cellular contents 
(169). Alterations in neutrophil cell surface markers and morphological changes 
during apoptosis correlate with increased recognition by professional phagocytes, 
such as macrophages, that mediate effective clearance of dying cells (169;170). Once 
the pro-inflammatory environment has been removed, tissue restoration and return of 
tissue homeostasis become priorities. Successful post-inﬂammatory tissue repair 
requires the coordinated restitution of different cell types and structures, not only 
epithelial and mesenchymal cells but also extracellular matrix and vasculature. 
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Chemokines are critical to vascular remodelling after inﬂammation (171). Without 
appropriate restitution of the vasculature, altered tissue oxygenation may preclude 
normal repair, resulting in atrophy or ﬁbrosis. Atrophy is often accompanied by 
expansion of extracellular tissue elements, particularly collagen, resulting in ﬁbrosis 
and deposition of excess connective tissue. Fibrosis, sufﬁcient to interfere with organ 
function, is a major medical problem after inﬂammation of arteries caused by 
accumulation of cholesterol, inflammation of the liver caused by viruses, alcohol, 
toxins or schistosome infections, inflammation of the lung associated with asthma or 
radiotherapy, and inflammation of the bowel in Crohn's disease, where fibrotic 
strictures often require surgery. 
Persistent inflammatory stimuli or dysregulation of mechanisms of the 
resolution phase result in chronic inflammation (168), recognized to be a key 
underlying factor in the progression of a range of diseases, including atherosclerosis 
(172;173), arthritis (174), and chronic neurodegenerative diseases, such as 
Alzheimer's disease (175).  
1.3.6 Chronic inflammatory responses 
1.3.6.1 Cellular and molecular mechanisms involved in chronic inflammatory 
responses 
Chronic inflammatory responses can be triggered by each of the inflammatory 
inducers causing acute inflammatory reactions. Similarly to acute inflammatory 
reactions, chronic inflammatory responses can have microbial and non-microbial 
origins and the cellular and molecular pathways involved in chronic inflammatory 
states are strongly influenced by the nature of the inflammatory trigger.  
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If microbial inducers are not efficiently removed during the acute 
inflammatory response, the neutrophil and macrophage infiltrate is progressively 
replaced by T cells (142). This shift from innate to adaptive immunity provides a 
more finely focused response mechanism that requires the recognition of specific 
molecular structures (antigens) on the surface of the inflammatory inducer (176). The 
induction of an adaptive immune response begins when a pathogen is ingested by an 
immature dendritic cell in the infected tissue (177). These specialized phagocytic cells 
are resident in most tissues and are relatively long-lived, turning over at a slow rate. 
They derive from the same bone marrow precursor as macrophages, and migrate from 
the bone marrow to their peripheral stations, where their role is to survey the local 
environment for pathogens. Eventually, all tissue-resident dendritic cells migrate 
through the lymph to the regional lymph nodes where they interact with recirculating 
naive lymphocytes (178). The immature dendritic cell carries receptors on its surface 
that recognize common features of many pathogens, such as bacterial cell wall 
proteoglycans (178). As with macrophages and neutrophils, binding of a bacterium to 
these receptors stimulates the dendritic cell to engulf the pathogen and degrade it 
intracellularly. The function of dendritic cells, however, is not primarily to destroy 
pathogens but instead to carry pathogen antigens to peripheral lymphoid organs, 
presenting them to T lymphocytes (178). When a dendritic cell takes up a pathogen in 
infected tissue, it becomes activated, and travels to a nearby lymph node. On 
activation, the dendritic cell matures into a highly effective antigen-presenting cell 
(APC) and undergoes changes that enable it to activate pathogen-specific 
lymphocytes that it encounters in the lymph node (179). Activated dendritic cells 
secrete cytokines that influence both innate and adaptive immune responses, making 
these cells essential gatekeepers that determine whether and how the immune system 
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responds to the presence of infectious agents (179). Presentation of microbial antigens 
to T-cells is followed by activation of cytotoxic T-cells (180) and production of 
antibodies by B-cells (181) that selectively target those molecules which evoke the 
immuno-inflammatory responses. T-cells can differentiate into at least two sub-
phenotypes (known as T helper 1, Th1, and T helper 2, Th2) (182), which activate 
different patterns of inflammatory cytokines and control different limbs of the 
immuno-inflammatory processes (183) (Figure 1.6).  
 
 
Figure 1.6 Role of Th1 and Th2 cells in the immune-inflammatory response 
The adaptive immune response involves the generation of Th1 and Th2 cytokines. 
CTL: Cytotoxic T lymphocyte; Th: T helper. 
 
 
Th1 cells produce IL-2, TNF-α, and IFN-γ, and are associated with cell-
mediated immunity against intracellular pathogens (Figure 1.6), as well as being 
involved in delayed-type hypersensitivity skin reactions. Th1 cells also stimulate 
chemokines, which provide an important link between the recruitment of 
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inflammatory cells and adaptive immunity. Chemokines are pivotal in stimulating 
leukocyte migration from the blood to the tissues and can be secreted in response to 
Th1 cytokines, including IL-1 and TNF (184). By contrast, Th2 cytokines, such as IL-
4, -5 and -10, are involved in the control of extracellular helminths infections and 
circulating pathogens by enhancing antibody-mediated immunity (Figure 1.6). 
However, they are also associated with allergic diseases including asthma, allergic 
rhinitis and eczema (atopic dermatitis) (184). 
If the combined effect of macrophages and adaptive immunity is still 
insufficient to remove the inflammatory inducer, the persistent recruitment of 
inflammatory cells can lead to the formation of granulomas or tertiary lymphoid 
tissues (146;185). Formation of a granuloma follows the exposure of microbial (i.e. 
mycobacterium tuberculosis) and non-microbial (i.e. foreign bodies) inducers. 
Macrophages tend to aggregate around each other, forming a capsule of several 
cellular layers surrounding the pathogen (133;146). This process results in a 
sequestrum of the inflammatory inducer, neutralizing its ability to recruit and activate 
new inflammatory cells. Similar pathways of inflammation result from the activity of 
endogenous inflammatory triggers, such as crystals of monosodium urate and calcium 
pyrophosphate dihydrate (causing gout and pseudo-gout diseases, respectively) (186). 
Although the formation of a granuloma is effective in limiting the virulence of the 
inflammatory inducer, a state of chronic inflammation surrounding the pathogens can 
persist for decades inside this biological niche. The granuloma can reactivate at a later 
stage, causing a new acute inflammatory response. Globally, tuberculosis is the most 
prevalent example of chronic granuloma formation although similar processes have 
been described in other chronic disorders, including atherosclerotic plaques (187). 
When this inflammatory reaction is active enough to destroy the cellular walls, 
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products contained inside the granuloma are released in the surrounding tissues (i.e. 
lung), initiating another local and/or systemic inflammatory reaction. 
During local chronic inflammatory responses, some triggers can elicit 
systemic and chronic inflammatory states. Examples of this include AGEs (advanced 
glycation end products) and oxidized low-density lipoproteins. AGEs result from the 
non-enzymatic glycation of long-lived proteins (i.e. collagen) (188) and can determine 
crosslinking of the proteins they are attached to, leading to gradual functional 
deterioration in these molecules. AGEs are recognized by specific receptors localized 
on the surface of mononuclear phagocytes and lymphocytes (RAGE), which have 
inflammatory activity either alone (167) or in combination with TLRs (189). 
Accumulation of AGEs has been described under hyperglycaemic and pro-oxidative 
conditions, including type 1 and type 2 diabetes, renal failure, neurodegenerative 
states and in general aging disorders (188). Similarly to AGEs, oxidized low-density 
lipoproteins can trigger systemic vascular inflammation by activating sub-endothelial 
or circulating macrophages (172). When these cells attempt to remove oxidated low-
density lipoproteins from the sub-endothelial space using their scavenger receptors, 
they release potent oxidants, including the enzyme myeloperoxidase, that cause 
oxidation of other LDL-phospholipids and contribute to the chronic evolution of the 
inflammatory process (190).  
1.3.7 Chronic inflammation as common link between aging, frailty and age-
related diseases 
1.3.7.1 Epidemiological evidence 
Large population studies have repeatedly documented a 2–4-fold increase in 
serum levels of pro-inflammatory cytokines, such as IL-6 (also known as 
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“gerontologist cytokine”) (191) and tumour necrosis factor alpha (TNF-α), with 
advancing age (191-195).  
The most common explanation lies in the increased risk of chronic 
inflammatory diseases in the elderly which is likely to lead to increased 
concentrations of inflammatory markers in peripheral blood (193;196;197). However, 
‘successful aging’ (aging without co-morbidity) is still associated with low-grade 
inflammatory activity in vivo. Numerous studies of older adults indicate that levels of 
several cytokines (including IL-6 and TNF-α) increase with age, even in apparently 
healthy individuals and in the absence of acute infection (191;192;198-200). These 
findings are confirmed by studies involving centenarians and frail people.  
Centenarians are free of most age-related inflammatory diseases, despite their 
levels of circulating inflammatory markers being higher than those recorded in 
younger populations. Frailty is theoretically defined as a clinically recognizable state 
of increased vulnerability resulting from age-associated decline in reserve and 
function across multiple physiological systems, such that the ability to cope with 
everyday acute stressors is compromised (201-204). It can be considered an aging-
plus syndrome where common co-morbidities recorded in the elderly are not present 
but their risk is significantly increased. In the absence of a gold standard, frailty has 
been operationally defined by Fried et al. as meeting three out of five phenotypic 
criteria indicating compromised energetics: low grip strength, low energy, slowed 
waking speed, low physical activity, and/or unintentional weight loss (9). Notably, 
each of these phenotypic criteria can be partially explained by increased levels of 
muscular and systemic inflammatory burden. The evidence that circulating 
inflammatory markers, such as IL-6 and its surrogate C-Reactive Protein (CRP), are 
strongly related to frailty syndrome, further reinforces the possible causal relationship 
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between levels of systemic inflammation and frailty (205). Additionally, recent 
reports have documented that not only IL-6 and CRP but also other but less specific 
inflammatory bio-markers including total leukocyte and neutrophil counts as well as 
albumin concentrations are associated with higher risk of frailty (14). 
The association between aging, risk of age-related disease and increased levels 
of inflammatory markers raises an important question: what aspects of human biology 
underscore this association? 
1.3.7.2 Possible biological pathways   
1.3.7.2.1 The central role of inflammatory cells 
The recent increase in human life expectancy presents novel challenges to the 
inflammatory system, which must now cope with chronic antigen exposure, lasting 
several decades beyond our evolutionary past. Decades of exposure to damaging 
agents results in a progressive remodelling process of the human body. Profound 
changes in the body’s microenvironments through changes in protein abundance, 
composition and interaction are common findings during aging and represent 
continuous stimuli for the inflammatory system which must adapt its activities to 
establish new stable points for optimal bodily function (206). This continual antigenic 
stress leads to a progressive senescence of the immune-inflammatory system, 
characterized by accumulation of aged and activated immuno-inflammatory cells 
(207;208). As a result, a state of chronic low-grade inflammation develops, potentially 
contributing to the increased risk of age-associated frailty, morbidity, and mortality 
observed in the elderly. The attempt of the immune-inflammatory system to set new 
homeostatic set points to compensate for changes occurring over time in the human 
body leads to a process of immune-senescence, which is likely to explain the 
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increased level of circulating inflammatory markers (208). The accumulation of tissue 
stress and malfunction represent the immune-senescence inducers, with cells of the 
innate immune system, and particularly tissue resident macrophages, the main 
modulators of this process (207;209).  
Tissue-resident macrophages constitute 10–15% of the total number of cells in 
most tissues, and their activity is crucial for maintenance of tissue homeostasis in 
basal conditions. Their functions extend beyond host defence as they adapt their level 
of activation, cytokine secretion and phagocytic activity to the local environment 
(210).  Signals sent to macrophages from the surrounding tissue following stress 
differ from those sent in the basal state (211). For example, accumulation of dead or 
apoptotic cells in aged tissues leads to exposure of new antigens derived from 
modification or desequestration of intracellular proteins, lipids and nucleic acids. As a 
consequence, macrophages produce increased amounts and/or different sets of 
cytokines in the attempt to support tissue adaptation to the stressful conditions and 
restore its basal functionality. However, when stress or malfunction are extreme or 
irreversibly accumulate over time (such as during aging), the compensatory capacities 
provided by local macrophages are likely to be insufficient. Tissues might 'call for' the 
reinforcement of additional inflammatory cells, leading to a systemic inflammatory 
response and possible activation of adaptive immunity (212). The systemic 
inflammatory responses evoked by age-dependent tissue dysfunction are likely to be 
of lower magnitude than those due to infections or tissue injury and may explain the 
physiological increase of inflammatory markers observed during successful aging as 
well as during age-related diseases such as diabetes, cancer and atherosclerosis (208).  
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1.3.7.2.2 The central role of oxidative stress 
The process of immune-senescence and the consequent (chronic) up-
regulation of pro-inflammatory mediators (e.g., TNF-alpha, CRP, IL-6) during aging 
are currently considered to be primarily induced by an age-related redox imbalance 
that activates many pro-inflammatory signalling pathways (213). Maintenance of a 
precise redox balance is crucial for the optimal operation of homeostatic cellular 
activities. This status depends primarily on the balance between reactive species (RS), 
such as superoxide anions (·O2 
-
), hydroxyl radicals (·OH), nitric oxide (NO), 
peroxynitrite (ONOO
-
), and anti-oxidant defence systems, such as superoxide 
dismutase (SOD), catalase, glutathione (GSH), and thioredoxin (Trx) (214). GSH is 
the most abundant intracellular thiol redox buffer and helps maintain redox status and 
protect cells against electrophilic oxidative attacks (215). Mitochondria represent, by 
contrast, the primary source of oxidative factors in physiological conditions, as 
mitochondrial respiration is normally coupled with production of high amount of 
oxidative by-products (216). During aging, anti-oxidant defence systems (such as 
intracellular GSH levels) generally decline (217), while generation of RS (especially 
of mitochondrial origin) progressively increase (218). The up-regulation of the RS 
bioavailability observed during aging ultimately leads to higher levels of 
inflammation, by either direct or indirect mechanisms. 
1.3.7.2.2.1 Indirect mechanisms of RS-induced inflammation 
The indirect mechanisms by which RS can cause an increased inflammatory 
burden lies in their ability to modify the function of the three main classes of cellular 





Figure 1.7 Oxidative mediated cellular damage. 
Each intracellular macromolecule can be damaged by increased bioavailability of 
oxygen radical species. Oxidative damage to: A) proteins leads loss of catalytic 
activity, B) nucleic acids leads to activation of the DNA damage response or 
modification of mRNA, causing arrest of cell cycle and cellular senescence or 
apoptosis, C) lipids leads to increase membrane permeability and loss of the trans-
membrane homeostasis. These processes can lead to activation of the immune system, 
either because structural changes make macromolecules recognised as foreign bodies 
by the immune systems or because of decompartmentalization and exposure of 
antigens that normally are sequestered inside cells.   
 
This can lead to tissue malfunction and associated up regulation of the 
inflammatory response by several mechanisms: 
1. RS can react with cell membrane fatty acids and form lipid peroxides, 
resulting in permanently impaired fluidity and elasticity of the membrane, and 
consequent cell rupture (219) (Figure 1.7). Similarly, overproduced radicals 
can react with protein amino acids leading to their oxidation and cross-linking. 
Radical-protein reactions can permanently impair the function of important 
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cellular and extracellular proteins, including enzymes and connective tissue 
proteins (Figure 1.7). It has been estimated that oxidized protein in old rats 
may comprise 30-50% of the total cellular protein (220). DNA is another 
macromolecule which is highly susceptible to free radical attack. An oxygen 
radical interaction with DNA can break its strands or delete a base. This DNA 
damage can be a lethal event for an organism, as it can cause an irreversible 
arrest of cell replication (Figure 1.7). It has been estimated that, on average, 
more than 10,000 oxidative hits occur each day in the DNA of a single human 
cell (221).  
2. Structural changes induced by free radical damage have the potential to 
transform inert macromolecules into potent inflammatory inducers. One 
example is the conversion of inactive low density lipoproteins (LDL) into their 
highly pro-inflammatory counterparts (ox-LDL), a process determined by 
oxidation of the lipid and protein components of the lipoproteins (172).  
3. Functional changes induced by free radicals in membranes, proteins and 
nucleic acids lead to progressive cellular and tissue damage, followed by 
desequestration of endogenous antigens (Figure 1.7). For instance, increased 
exposure to oxidative stress seriously damages endothelial cells which not 
only become dysfunctional, but also lose integrity, progress to senescence, and 
detach into the circulation (156). As previously discussed, sites of 
“disendothelization” represent potent activators of the Hageman factor, which 
interacts with components of the extracellular matrix and initiates the 
inflammatory response by stimulating the kallikrein-kinin, coagulation, 
fibrinolytic and complement cascades (133). Oxidative damage to intracellular 
components has been suggested not only as the primary source of 
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inflammation during aging but also as the most important pathway accounting 
for the aging process.  
 
The “Free Radical Theory of Aging” proposed in the 1950s by Denham Harman 
(222), postulates that oxygen free radicals, formed endogenously from normal 
metabolic processes, play a central role in the aging process because of an increase in 
oxidative damage to macromolecules. This theory has since been modified to the 
“Oxidative Stress Theory of Aging” because oxygen species such as peroxides and 
aldehydes, which are not technically free radicals, also play a role in oxidative 
damage to cells. According to the former theory, the imbalance between pro-oxidants 
and antioxidants leads to oxidative damage in a variety of macromolecules with age, 
resulting in a progressive loss in functional cellular processes and to the emergence of 
aging phenotypes (223). 
1.3.7.2.2.2 Direct mechanisms of RS-induced inflammation 
Over the last few years, it has become clear that an increased bioavailability of 
RS can induce chronic inflammatory responses by direct mechanisms. Several studies 
demonstrated that, the pro-inflammatory effects elicited by oxidative damage to 
cellular macromolecules, gene expression of pro-inflammatory peptides such as IL-
1β, IL-6, TNF-α, cyclo-oxygenase-2 (COX-2), lipoxygenase (LOX), and inducible 
nitric oxide synthase (iNOS) are enhanced during aging by the redox-sensitive 
transcription factor nuclear factor-κB (NF-κB) (224-226). Similarly, current research 
suggests a central role for RS of mitochondrial origin (mtRS) in mediating the 
increased inflammatory levels observed in the elderly (218). While mitochondria are 
crucial for normal cell functions, their respiratory activity is coupled with the release 
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of high levels of RS which, in turn, act as signaling molecules, directly triggering pro-
inflammatory cytokine production (227-229).  
In order to prevent excessive accumulation of mtRS, cells developed a 
complex mechanism, known as mitophagy (more generally known as “autophagy”), 
to control the number of mitochondria within a cell by removing those which become 
dysfunctional and which produce a high amount of mtRS (230). Autophagy is an 
essential cyto-protective pathway and consists of the formation of autophagosomes, 
double-membrane vesicles that sequester organelles, proteins, or portions of the 
cytoplasm, which then fuse with lysosomes (231). As a result, the sequestered 
contents are degraded by lysosomal enzymes, and recycled as a source of energy 
(231). Autophagy may occur either as a general phenomenon, for instance when cells 
lack nutrients and mobilize their energy reserves, or it can specifically target distinct 
cellular structures such as damaged mitochondria (“mitophagy”) (232).  
Inhibition of autophagy results in the accumulation of damaged mitochondria in 
human cells, leading to an increase in the net amount of mtRS and pro-inflammatory 
cytokine production (229). Interestingly, autophagy appears to decline with age, and 
gene expression of key regulators in the autophagic pathway (i.e ATG5 and ATG7) 
are reduced in aging individuals (233). Additionally, major human age-related 
diseases characterized by an increased inflammatory burden (i.e. Parkinson’s and 
Alzheimer’s disease) have been linked to defects in mitochondrial autophagy (234-
236). These data strongly support a possible contribution of mtRS to the age-
dependent increase of the inflammatory burden. Interestingly, conditions that promote 
autophagy, such as caloric restriction and exercise, delay aging-associated 
degeneration (237), suggesting that autophagy exerts important roles also in 
controlling the evolution of aging. Stimulation of autophagy can increase the healthy 
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lifespan in multiple model organisms including mice and primates (238), while 
experimental inactivation of genes required for the execution of autophagy is lethal at 
the whole-body level, whereas tissue-specific knockouts induce organ-specific 





1.4 LEUKOCYTE TELOMERE LENGTH AND INFLAMMATION 
Both epidemiological and experimental studies suggest that inflammation, aging 
and age-related diseases are intimately related with each other and have proposed 
oxidative stress as the main link between them. However the potential molecular 
pathways accounting for these associations are yet to be defined.  
Ideally, this pathway but should be: 
1. Influenced by cumulative inflammatory and oxidative stress exposure,  
2. Epidemiologically related to the risk of morbidity/mortality for age-related 
diseases and 
3. Biologically involved in the mechanisms of cellular aging. 
Telomere length and its biology could easily account for the strong link between 
aging and inflammation, as it is centrally involved in the mechanisms of cellular 
aging, relates with the risk of morbidity/mortality for many age-related diseases and 
can potentially be affected by oxidative stress damage. However, the potential impact 
of long term inflammatory and oxidative stress exposure on telomere length has not 
been explored in humans. 
1.4.1 Potential pathways linking LTL with chronic inflammatory and oxidative 
stress exposure 
Prolonged or extreme conditions of tissue stress or malfunction (related to 
exogenous or endogenous aggressions) induce production of pro-inflammatory 
cytokines by tissue resident macrophages (210). These cytokines (directly or 
indirectly) stimulate proliferation and differentiation of new inflammatory cells 
(leukocytes) from the bone marrow, increasing leukocyte count in the peripheral 
circulation. The increased concentration of circulating leukocytes provides adaptive 
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benefits, as it increases the number of inflammatory cells available to restore local 
homeostasis. Once recruited to the site of injury, many of these cells however die, 
releasing their intracellular content in the surrounding tissues. Products of damaged, 
apoptotic and necrotic cells further amplify the inflammatory process, as they 
stimulate production of pro-inflammatory cytokines by tissue-resident macrophages 
(133). These inflammatory mediators circulate from the injured tissue to the bone 
marrow, increasing the rate of HSC replication and telomere shortening (240). As 
leukocytes originate from HSC, an increased rate of telomere attrition in these cells 
will be reflected in shorter telomere length measured in peripheral leukocytes (113). 
This pathophysiological response to tissue stress and/or malfunction is thought to 
account for the LTL shortening observed not only during inflammatory states, but 
also during the physiological evolution of aging.  
The increase in systemic oxidative stress, commonly associated with acute and 
chronic inflammatory states, is another factor which may increase telomere shortening 
in HSCs and peripheral leukocytes (42). There are two main mechanisms by which 
oxidative stress is presumed to accelerate LTL shortening (241):  
1. Through increasing the number of damaged telomere sequences and 
reducing the activity of telomerase in HSC. 
2. Through damaging genomic DNA which in turn leads to telomere 
independent senescence and apoptosis, diminishing the biological life of 
peripheral leukocytes. This enhances HSC replication to accommodate 
peripheral needs, indirectly shortening LTL.  
Although increased inflammation is commonly considered the cause of LTL 
shortening, recent evidence suggests that reverse causality and residual confounding 
might account for the relationship between LTL and inflammation. Indeed, the 
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persistent activation of the DNA damage response, due to critically shorter telomere 
length, activates production of pro-inflammatory cytokines (i.e. IL-6) in cultured 
human fibroblast (242). In this context, cellular aging reflected by shortened LTL 
represents a cause and not consequence of inflammation.   
1.4.2 Epidemiological evidence linking inflammation with LTL  
Whilst a number of observational studies (mainly cross-sectional) have 
explored the association between inflammatory biomarkers and LTL, evidence 
remains inconclusive. In women, Fitzpatrick et al., failed to find any association 
between levels of CRP and LTL in elderly individuals (63). In contrast, Richards et al 
reported an association between CRP and LTL in a population of 1207 middle-aged 
females (243). This association was partially confirmed by Aviv et al. who 
demonstrated that CRP is inversely correlated with LTL in premenopausal but not 
postmenopausal women (65). Regardless of the possible gender interaction, Bekeart et 
al demonstrated a negative association of CRP and IL-6 with LTL in middle aged 
male and female subjects free of overt CVD (75). Similar results were later reported 
by O'Donovan et al in an elderly population (aged 73 years) (244).  
Several studies, however, failed to find any association between inflammatory 
biomarkers and LTL. Indeed, in a population of 2744 elderly men included in the 
Osteoporotic Fractures in Men-Sweden study, Moverare-Skrtic and colleagues found 
no association between CRP and LTL (245). Similarly, Brouilette et al. could not find 
any association between LTL and circulating levels of CRP and fibrinogen in a sub-
analysis of the West of Scotland Primary Prevention Study, including 1544 males and 
female subjects aged 56 years (61). 
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1.4.3 Epidemiological evidence linking oxidative stress with LTL 
The association between LTL and parameters of oxidative stress exposure is 
one of a complex nature. Although the influence on telomere length of intra and 
extracellular levels of superoxide dismutase (246), glutathione dependent redox 
homeostasis, hydrogen peroxide and Cu(II), as well as Thiol-specific anti-oxidant 1 
(Tsa1) has been reported thus far in living yeast (247) and cultured cells (48;246;248), 
the extent to which these findings can be translated into humans remains unclear. 
Indeed, only a few studies have analysed the relationship between oxidative stress and 
LTL in large populations.  
Epel et al. found that psychological stress was significantly associated with 
increased oxidative stress, determined by F2-isoprostanes (F2-IsoP, a class of major 
oxidative by-products) levels quantified from a 12-h nocturnal urine sample (249). 
The study was performed in 58 premenopausal women who were biological mothers 
either of a healthy or a chronically ill child, the latter been a predictor of greater 
environmental exposure to stress. Lower telomerase activity and shorter telomeres 
were detected in the group with greater exposure to stress. The groups were matched 
with respect to age, smoking behaviour, and vitamin use, but the high-stress group 
had a significantly higher body mass index (249). Whilst this study suggests a role for 
oxidative stress in telomere length regulation in humans, the authors were unable to 
describe a direct association between levels of oxidative stress biomarkers and 
telomere length. 
In other studies, circulating levels or diet intake of antioxidant compounds 
(such as vitamins and minerals) have been used as possible surrogate markers of 
oxidative stress exposure. In a population of middle-aged people with type 2 diabetes, 
Salpea et al reported that a cross-sectional measure of plasma total antioxidant status 
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(TAOS) was associated in a linear fashion with LTL (250). Interestingly, within the 
same population, individuals carriers of the common functional variant 866G>A in 
the promoter of the human uncoupling protein 2 (UCP2) gene (which results in a 
reduced clearance of mtRS by UCP2 and is associated to reduced levels of TAOS) 
had shorter age-adjusted LTL when compared to common homozygous 866GG, 
suggesting a possible role for mitochondrial oxidative stress production in LTL 
regulation (250). On the other hand, Richards et al found serum vitamin D 
concentrations were positively associated with LTL (251). This association was 
observed in a population of 2160 women aged 18–79 y (mean age: 49.4) and persisted 
after multiple adjustment for age, season of vitamin D measurement, menopausal 
status, use of hormone replacement therapy, and physical activity. Interestingly, the 
direct relationship between short LTL and low vitamin D levels was stronger in 
subjects with increased concentrations of CRP (251). The same group subsequently 
reported a negative association between LTL and plasma homocysteine levels in 
1,319 healthy subjects recruited from the same population (243). This association 
persisted after adjustment for smoking, obesity, physical activity, menopause, 
hormone replacement therapy use and creatinine clearance.  Finally, Xu et al 
described longer LTL in participants of the Sister Study who consumed higher levels 
of vitamins (particularly vitamin C and D) compared to the rest of the population 
(252). 
All these studies provide indirect evidence for a possible role of oxidative 
stress in the regulation of LTL. Only one report to date showed a direct association 
between circulating levels of oxidative stress and LTL in humans. In this case-control 
study, Wolkowitz et al showed that LTL of 18 not medicated patients with major 
depressive disorder were shorter than 17 healthy controls (253). The authors described 
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a negative association between LTL and circulating levels of oxidative stress, as 
assessed by the ratio between F2-IsoP and the anti-oxidant vitamin C. 
1.4.4 Difficulties in exploring the association between LTL, inflammation and 
oxidative stress 
Exploring the association between LTL, inflammation and oxidative stress is 
further complicated by the different kinetics between LTL shortening and change of 
inflammatory markers. Whilst biomarkers of inflammation and oxidative stress 
presumably reflect the metabolic status at the moment of sample collection, LTL 
represents the cumulative burden of inflammation and oxidative stress over the 
individual’s life span (75;240;241). This difference may be critical in both healthy and 
disease populations. In healthy individuals, acute infections at the time of blood 
collection can determine an “artificial” increase of inflammatory markers such as 
CRP, IL-6 and fibrinogen. These inflammatory responses, however, are unlikely to 
impact on LTL dynamics, which requires prolonged exposure periods before damage 
can be detected. Similarly, in diseased populations (i.e. subjects with diabetes, 
periodontitis, rheumatoid arthritis or CVD), circulating levels of inflammatory 
markers are likely to be affected by fluctuations in the activity of the underlying 
disease and may not reflect the level of chronic inflammatory burden (254-262). A 
better estimation of inflammatory impact on LTL in humans would therefore require 
identification of novel inflammatory markers, providing information on the chronic 
rather than the acute inflammatory burdens.   
Another source of variability relates to the methods used to measure LTL and 
levels of circulating inflammatory markers. Highly sensitive biochemical tests for 
CRP and IL-6 quantification can detect very small differences in circulating levels of 
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these inflammatory cytokines. In contrast, laboratory techniques used to measure LTL 
are unable to detect such small differences (80;263). This problem can be further 
complicated in healthy populations. For example, one could decide to perform an 
analysis excluding individuals with abnormally high levels of CRP (i.e. >3mg/L) from 
a study cohort, assuming that these levels reflect the presence of the ongoing acute 
inflammatory response. The remaining population will be composed of individuals 
with mild differences in chronic inflammatory burden which presumably is reflected 
in a relatively small inter-individual difference in LTL. In this case, the LTL assays 
would not have sufficient sensitivity to capture such a small inter-individual 
difference. The reproducibility and sensitivity of the LTL assay is therefore the 
limiting factor for accurate and reliable analysis. 
Conversely, the lack of stable and reliable markers of oxidative stress limits 
our ability to explore an association between LTL and oxidative stress. Following 
their generation, free radicals react with surrounding macromolecules, making their 
half-life extremely short. Thus, direct measures of reactive oxygen species in 
peripheral blood are difficult to perform and often require the use of very expensive 
machines (e.g. electron paramagnetic resonance) and adoption of complicated 
protocols (264;265). Such characteristics limit their application and utility in large 
epidemiological studies.  
Researchers have therefore used alternative approaches to estimate levels of 
oxidative stress exposure, commonly based on the measure of the amount of structural 
damage to macromolecules resulting from interaction with oxidative species (266) 





Figure 1.8 Markers of oxidative stress derived from RS damage to macromolecules. 
Free radicals have a short half-life as they quickly interact with surrounding 
macromolecules, forming more stable compounds. Therefore, by-products derived 
from these interactions have been used as surrogate measures of total oxidative stress 
exposure.  
 
Several stable by-products of lipid, protein and DNA oxidation have been 
identified in biological samples, making the assessment of the oxidative stress 
exposure easier and less variable. Examples include: 
1. Serum lipid hydroperoxides (LOOH), generated from polyunsaturated fatty 
acids and representing primarily products of fatty acid peroxidation (267).  
2. Malondialdehyde (MDA), the by-product of the arachidonate cycle and a 
principle aldehyde product of lipid peroxidation in vivo (268). 
3. F2-IsoP, formed by the free radical catalysed peroxidation of phospholipid 
bound arachidonic acid (269).  
LOOH and MDA have been found to be elevated in chronic inflammatory 
diseases (e.g. diabetes) as well as with pro-oxidant behaviours (e.g. cigarette smoking) 
(270;271). In addition, urinary and plasma levels of F2-IsoP have been shown to 
correlate with pro-oxidant risk factors (272). Despite this evidence, stability and the 
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sensitivity of these markers has not been tested in humans and it remains unclear 
whether a single measure of lipid peroxidation can accurately reflect the total 
oxidative stress burden of the individual. Similar limitations can be described for by-
products of protein and DNA oxidation, making the interpretation of associations 
between oxidative stress and LTL difficult. As a result, it has been suggested that 
assays able to detect the total oxidative capacity of blood may be more informative 
than individual oxidative stress measures.  
 
1.5 CHRONIC INFLAMMATORY DISEASES: A METHOD TO STUDY 
THE EFFECTS OF CHRONIC INFLAMMATION IN HUMANS  
It is now recognized that a mild pro-inflammatory state is correlated with the 
major degenerative diseases of the elderly. This inflammatory state has been 
commonly measured by a range of biomarkers (such as CRP or IL-6) which reflect 
current levels of inflammation. However, these markers are unable to provide 
information on the individual’s inflammatory burden. As chronic inflammation is a 
pathological condition characterized by a continued active inflammatory response 
leading tissue destruction, and measures of tissue remodelling are more likely to 
reflect the cumulative inflammatory burden than levels of circulating inflammatory 
markers.  
In many cases, tissue remodelling is not only a consequence of chronic 
inflammation but also a marker of disease evolution. For example, the chronic 
inflammatory process involving the CV system during atherosclerosis determines a 
progressive thickening of the arterial wall, which can lead critical ischaemia and 
infarcts. Although several risk factors can contribute to the process of vascular 
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remodelling, it is now clear that these factors do not completely explain the evolution 
of CVD. Indeed, vascular remodelling can be detected in old individuals without a 
significant CV risk factor burden.  
In this thesis, periodontitis (PD) and CVD were used as models of systemic and 
chronic inflammatory burden to explore the relationship between measures of tissue 
remodelling and LTL. Furthermore, the association between LTL dynamic and 
vascular phenotypes was explored in a cohort of individuals with low CV risk factor 
burden in order to define the relationship between dynamic regulation of LTL and 
evolution of age-related disease. 
PD and CVD were used as: a) they are common in the general population, b) they 
share common mechanisms/pathophysiology with other age-related diseases such as 
cancer and type 2 diabetes, c) the degree of tissue remodelling is easy to quantify 
using non-invasive techniques and d) the amount of tissue remodelling is correlated 
with levels of chronic inflammation and relates to outcome. 
 
1.5.1 Periodontitis: a model of chronic and systemic inflammation associated 
with accelerated aging 
Periodontal diseases, including gingivitis and PD, are amongst the most 
commonly occurring chronic infections in humans, due to the anatomically unique 
periodontal structure and the nature of the pathogenic dental plaque biofilm infection 
(273;274). PD is characterized by bacteria-induced inflammatory destruction of tooth-
supporting tissues including  alveolar bone, and it remains a major cause of tooth loss 
in adults in both developed and developing countries (275).  
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In susceptible individuals, the disease is initiated by specific Gram-negative 
microflora which appears organized on the tooth root surfaces as a dental biofilm 
(276-278). The interaction between bacteria and local inflammatory cells results in the 
production of pro-inflammatory cytokines and chemokines, which recruit additional 
polymorphonuclear cells, monocytes/macrophages, T and B cells to the site (gingiva) 
(279-282). While host inflammation is normally able to remove the inflammatory 
inducers and restore local tissue homeostasis, in susceptible individuals, the bacterial 
aggression is not effectively counteracted by the host due to a dysregulation of the 
immune-inflammatory response (282;283). This leads to the formation of 
inflammatory infiltrates in the connective tissue adjacent to the gingival pocket 
epithelium (Figure 3.1). 
 
Figure 1.9 Progressive evolution of periodontal inflammation. 
Periodontitis is an oral infection caused by accumulation of a bacteria-containing 
biofilm around the teeth.
 
As this biofilm matures, more virulent bacteria cause an 
inflammatory reaction in the soft and hard tissues supporting the teeth. If the biofilm 
is not removed periodically, the initial inflammation of the gingiva (referred to as 
gingivitis) may develop into a more serious long-term destructive process 
(periodontitis) in which the periodontal ligament and bone supporting the teeth are 
progressively eroded. Left untreated, this may result in bleeding around the teeth, 





The cytolytic activities of granulocyte-derived enzymes as well as the cellular 
damage due to the increased levels of oxidative stress lead to a progressive destruction 
of the surrounding tissues, including the alveolar bone (284-287). This has a 
progressive impact, beginning with gingival recession and progressing toward tooth 
mobility, pathological migration, and, eventually, tooth loss (288). Retraction of 
gingival tissue and alveolar bone loss may be considered as clinical markers reflecting 
the amount of inflammatory periodontal exposure.  
Although there is not universal agreement in the definition of different forms 
of PD, the disease is commonly divided into two major variants: chronic and 
aggressive PD (289). Chronic PD marks a constellation of destructive periodontal 
diseases characterized by a long evolution of a moderate inflammatory process, which 
is usually diagnosed in adult age. In contrast, the aggressive form is highly 
destructive, usually diagnosed in young age and characterized by an inconclusive 
medical history, familial aggregation and a higher local and systemic inflammatory 
involvement (289). The highly active inflammatory process leads to the appearance of 
early clinical manifestations, reducing the time to the diagnosis and providing a 
higher chance for an effective treatment. 
It is now well established that PD affects not only oral health, but also results 
in a systemic inflammatory response, possibly due to entry of bacteria in the blood 
stream which cause activation of the host inflammatory response by multiple 
mechanisms. (290-293).  
Over the past 8 years, our group has undertaken an extensive characterization 
of the links between severity of the oral disease and levels of systemic inflammatory 
markers. We have shown that individuals with PD not only present increased levels of 
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CRP and IL-6 in peripheral blood, but also that these levels change accordingly with 
the evolution of the oral disease (254;255;294) (Figure 3.2).  
 
Figure 1.10 Changes of systemic inflammatory markers following intensive 
periodontal treatment 
Periodontal treatment is associated with acute changes in levels of systemic 
inflammatory markers. An acute increase of CRP, TNF-α, Interleukin-1 Receptor (IL-
1Ra) and IL-6 occurs immediately following dental treatment with a peak at 24 hours. 
The inflammatory markers recover one week following treatment and return to 
baseline values after one month. 
 
Furthermore, we have reported that changes in systemic inflammatory markers 
are associated with changes in systemic oxidative stress exposure (295). This data 
underscores the strong link between oral and systemic inflammatory involvement in 
individuals with PD, possibly explaining their increased risk of morbidity for age-
related systemic disorders. Indeed, PD has been recognised as a possible risk factor 
for several age-related diseases (275;296-298), including CVD (299;300), diabetes 
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(301-304), cancer (305;306), cognitive decline (307;308), renal failure (309-312), 
chronic respiratory diseases (313-316) and osteoporosis (317-320).  
Whilst systemic inflammation is likely to represent the missing link relating PD 
with a higher risk of mortality and age-related disease, the underlying biological 
pathways remain largely unexplored. Within the context of this PhD, PD represented 
a unique and useful model of local and systemic inflammatory disease and accelerated 
aging to explore the link between LTL, levels of oxidative stress and chronic 
inflammation. 
1.5.2 Atherosclerosis: an age-related disease led by inflammation 
CVD is the most frequent age-related disease in developed countries, followed 
by cancer. The most frequent cause of CVD is atherosclerosis, an inflammatory 
process of the vascular wall which determines focal thickenings of the innermost layer 
of the artery, the intima (321)(Figure 3.3).  
 
Figure 1.11 Evolution of atherosclerosis with age and duration of inflammation. 
Atherosclerosis is an inflammatory disease of the vasculature, characterised by 
accumulation of cholesterol in the innermost layer of the vascular wall, the intima. 
The progressive narrowing of the vessel due to lipid accumulation progressively 
reduce the blood supply to peripheral organs, leading to clinical manifestations of the 




The pathophysiological evolution of atherosclerosis is characterized by 
accumulation and retention of LDL cholesterol in the intima, particularly at sites of 
hemodynamic strain (322). Oxidative and enzymatic modifications of LDL particles 
lead to the release of inflammatory lipids that induce endothelial cell activation (323), 
characterized by reduced bioavailability of nitric oxide, increased production of 
oxidative metabolites and expression of leukocyte adhesion molecules (324). 
Monocytes recruited through the activated endothelium differentiate into 
macrophages (325). Several endogenous and microbial molecules can ligate pattern-
recognition receptors (TLR) on these cells, inducing activation and leading to the 
release of inflammatory cytokines, chemokines, oxygen and nitrogen radicals, and 
other inflammatory molecules, ultimately amplifying the local and systemic 
inflammation/oxidative stress levels and causing tissue damage (326-328).  
Figure 1.12 Biological pathways in the initiation of atherosclerosis. 
Excess LDL infiltrates and is retained in the sub-intima space at sites of 
hemodynamic strain. Oxidation of LDL leads to endothelial cell activation which 
mediates migration of inflammatory cells (mainly monocytes) in the sub-intima space, 
where they become activated, mature to macrophages and express TLRs and 
scavenger receptors. Adapted from Andersson et al.Clin Immunol 2010;134(1):33-46. 
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These early atherosclerotic lesions (known as fatty streaks) evolve with the 
accumulation of both intracellular and extracellular lipid and debris, which further 
activate inflammatory cells and contribute to oxidation of new LDL molecules 
(329;330). These newly formed oxLDL molecules increase recruitment and activation 
of other inflammatory cells, damage local endothelial and smooth muscle cells, thus 
creating a cycle which actively contributes towards progression of the local 
inflammatory process and lesions (331). Focal inflammatory responses acquire a more 
organised structure, with lipids and debris accumulating in a necrotic core surrounded 
by a fibrous cap, composed predominately of vascular smooth muscle cells and their 
secreted products (collagen and elastin) (332)(Figure 3.5).  
Figure 1.13 Evolution of atherosclerosis and organization of atheroma. 
The atheroma has a core of lipids, including cholesterol crystals, living and apoptotic 
cells and a fibrous cap with smooth muscle cells, collagen and elastin. Plasma 
lipoproteins accumulate in the central region of plaques (core). Several types of cells 
of the immune response are present throughout the atheroma including macrophages, 
T cells, mast cells and dendritic cells (DCs). The atheroma builds up in the intima-
media layer of the artery, progressively narrowing the arterial lumen by increasing 





All these steps cause a further increase in intima-media thickness, with 
formation of atherosclerotic plaques. Therefore, inflammatory cells and their reactive 
oxidant species represent crucial components in both the initiation and evolution of 
atherosclerosis. 
A decade ago, the treatment of common CV risk factors and the introduction 
of lipid lowering therapies were expected to prevent evolution of vascular remodelling 
which is involved in atherosclerosis. Lately, however, the increasing effectiveness of 
CV treatments has demonstrated that structural changes of the vascular wall can be 
detected also in individuals with optimal levels of CV risk factors, suggesting that 
intimal and medial thickenings as well as gradual loss of arterial elasticity may 
represent, at least in part, physiological processes observed during aging (333). It is 
now clear that aged vessels share a number of structural modifications with 
atherosclerosis (334-336). For example, aged vessels show fracture of the elastin 
lamellae and increased collagen deposition, which may lead to vessel dilation as well 
as increased lumen size and intima-media thickness (337). Furthermore, the increased 
collagen and decreased elastin content of the vascular wall, promoted at least in part 
by age-associated increases in glycated proteins, matrix metalloproteinase enzyme 
activity, and trophic stimuli such as angiotensin II signaling, impair vessel elasticity 
and hence promote vascular stiffness (338). These alterations are commonly found 
also in earliest phases of atherosclerosis (332). 
The strong connection between aging and atherosclerosis is confirmed by the 
evidence that a number of genetic diseases associated with premature vascular aging 
are commonly associated with CV complications including atherosclerosis. For 
example, Hutchinson Gilford progeria syndrome (HGPS) is a rare, fatal, and 
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progressive premature aging condition and young patients reveal accumulated 
collagen, fractured elastin lamellae, and a thickened intima, with some vessels 
showing advanced atherosclerotic lesions containing chronic inflammation, 
calcification, and vascular smooth muscle cell loss (339). Another example is the 
Werner syndrome (WS), a loss-of-function mutation in the WS ATP-dependent 
helicase (WRN), which shows a similar pathology and accelerated atherosclerosis 
(340-342).  
In addition to the evidence provided by rare genetic syndromes, there are 
strong connections between cellular aging pathways and atherosclerosis. There is 
increasing evidence that vascular smooth muscle and inflammatory cells within 
atherosclerotic plaques have accumulated DNA damage, and that vascular smooth 
muscle cells of atherosclerotic plaques undergo the consequences of DNA damage, 
including apoptosis and premature senescence (343). DNA strand breaks and 
chromosomal damage are present in circulating cells of patients with atherosclerosis; 
DNA damage correlates with a higher micronucleus index (a marker of genetic 
instability often recorded in aging cells) compared with healthy controls, and it is 
associated with disease severity (344). Vascular smooth muscle cells and 
macrophages express markers of DNA damage in plaques, including phosphorylated 
forms of the Ataxia Telangiectasia Mutated (ATM) and Histone 2A protein X proteins 
(γ-H2A.X) (345). Importantly, these markers increase with disease severity. In vitro, 
increased DNA damage can be observed in vascular smooth muscle cells derived 
from atherosclerotic lesions compared to those of normal arteries (345). Similarly, 
oxidative DNA damage and DDR markers appear in atherosclerotic lesions in animal 
models after fat feeding and in human plaques, and whilst some markers are reduced 
by lipid lowering, oxidative DNA damage persists (346;347). Finally, it is common to 
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observe DNA damage not only in genomic but also in mitochondrial DNA in 
atherosclerosis. For example, circulating cells in patients with severe coronary 
atherosclerotic disease exhibit a significantly higher incidence of the common 
mitochondrial deletion MtDNA 4977 (348), normally observed in aged cells.  
Over and above the role of the DDR, telomere length biology is another aging 
pathway which seems to play a central role in initiation and evolution of 
atherosclerosis. Shortened telomeres are evident in atherosclerosis, observed in plaque 
vascular smooth muscle cells (349) and endothelial cells (350) relative to the normal 
vessel wall, as well as in circulating endothelial progenitor cells (351). Also, LTL is 
shorter in patients with atherosclerosis compared with control subjects (61;352) and it 





The biology of LTL and its relationship with chronic inflammatory and oxidative 
stress exposure remains largely unclear in humans. Several epidemiological studies 
reported conflicting results on these associations. The purpose of this thesis was to 
explore systematically the association between LTL, clinical measures of chronic 
inflammation and oxidative stress exposure in humans. Furthermore, the relevance of 
these pathways in the evolution of age-related disease was examined. 
The specific aims of this project were to: 
1. Explore the association between markers of chronic inflammation and 
oxidative stress exposure with LTL.  
2. Investigate the relationship between measures of chronic inflammatory 
burden and LTL and their dependence on the metabolic status at the time 
of the evaluation. 
3. Define whether the adult association between shorter LTL and 
inflammatory markers is detectable at younger ages, further supporting the 
hypothesis that long term inflammatory burden is the main driver of LTL 
shortening throughout post-natal life.  
4. Define the contribution of the post-natal regulation of the rate of LTL 




3 GENERAL METHODS 
 
3.1 Vascular Measures 
The major problem in exploring the mechanisms implicated in CVD evolution 
however, relates to the long preclinical phase of the disease, so that the role of aging 
pathways on atherosclerosis is difficult to evaluate. Over the last twenty years, several 
non-invasive techniques have been developed to monitor changes of the vascular wall 
induced by atherosclerosis, enabling study of the pathways involved in disease 
initiation and evolution. Increased intima-media thickness and reduced vascular 
elasticity are common features of both vascular aging and atherosclerosis and can be 
easily measured using ultrasound techniques.  
 
3.1.1 Common carotid artery intima-media thickness  
Over the past decade the measurement of carotid artery intima-media thickness 
(cIMT) using high resolution B mode ultrasonography has emerged as a useful 
measure of atherosclerosis and its progression and for assessing CV risk. 
Measurement of cIMT is non-invasive, safe and well accepted by patients and it has 
been associated with the presence and extent of coronary atherosclerosis (355). In 
1986, Pignoli et al (356) demonstrated that measures of cIMT by ultrasound were 
closely correlated with histology (357), although some studies have documented that 
ultrasound estimation gives a slighter higher cIMT reading (356). The confirmation 
that cIMT is on the causal pathway for atherosclerosis is provided by several lines of 
evidence.  
1. Increased cIMT has been associated with higher risk of CVD. The Kuopio 
Ischaemic Heart Disease Risk Factor (KIHD) study (358), conducted in 1,257 
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eastern Finnish men, with a follow-up period of 2 years, evaluated 
ultrasonographic carotid findings with the risk for acute myocardial infarction. 
The presence of plaque was associated with an increased relative risk of 4.1 
(95% confidence interval [CI] 1.8 to 9.2) compared to individuals free from 
plaques. There was a 2.1-fold increased risk for myocardial infarction with 
increased cIMT >1 mm, compared to men free of these atherosclerotic lesions, 
and if used as a continuous variable, there was an 11% increase in risk for 
myocardial infarction with each 0.1-mm increase in cIMT. Differences 
between men and women in the association of cIMT and coronary artery 
disease (CAD) incidence were demonstrated in the Atherosclerosis Risk in 
Communities (ARIC) study (359). This study was conducted in middle-aged 
men and women free of disease at baseline, with a follow-up period of 4 to 7 
years. Hazard ratios for cIMT >1 mm adjusted for CV risk factors were 2.62 
(95% CI 1.55 to 4.46) for women and 1.20 (95% CI 0.81 to 1.77) for men. The 
Rotterdam study (360), however, found that the risk of myocardial infarction 
in women and men was similar, with odds ratios adjusted for CV risk factors 
of 1.26 (95% CI 0.89 to 1.79) and 1.25 (95% CI 0.91 to 1.72), respectively. 
More recently, investigators of the Carotid Intima Media Thickness [IMT] and 
IMT-Progression as Predictors of Vascular Events in a High Risk European 
Population (IMPROVE) Study showed that not only cIMT but also 
morphological changes of the common carotid artery (e.g. increased intra-
adventitia diameter) are strong predictors of CV events, independent of 
traditional CV risk factors included in the Framingham risk score (361).  
2. Exposure to well established CV risk factors has been associated with 
increased cIMT and that cIMT values have also been shown to be responsive 
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to pharmaceutical interventions. Several studies have shown that diabetes 
mellitus is associated with an increased cIMT and that duration of type 2 
diabetes is also an important determinant of increased cIMT (362;363). 
Increased cIMT has also been reported in individuals with 
hypercholesterolemia (364). Of all the traditional CV risk factors, 
hypertension has the greatest impact on cIMT, and this is due presumably to 
the associated medial hypertrophy (365;366). The association of cIMT with 
CV risk factors is evident from young age, as it has been recently 
demonstrated in the Bogalusa Heart Study (367). Therapeutic interventions 
including treatment with blood pressure lowering agents, lipid lowering agents 
as well as multifactorial interventions in high risk patients can slow the 
progression or even reduce cIMT (368-371). The Pravastatin, Lipids, and 
Atherosclerosis in the Carotid Arteries II (PLAC-II) study (372) demonstrated 
a lesser progression of cIMT with pravastatin compared to placebo (0.0295 
and 0.0456 mm/year, respectively). Similarly, a reduction in the progression of 
cIMT was reported following treatment with lovastatin, with a reduction of 
mean maximum cIMT of −0.009 mm/year compared to the progression of 
cIMT in the placebo group of 0.006 mm/year (373). The Measuring Effects on 
Intima-Media Thickness: An Evaluation of Rosuvastatin (METEOR) trial 
reported similar results, demonstrating that rosuvastatin therapy resulted in a 
reduction of the progression of maximum cIMT compared to placebo in 
middle-aged adults with low Framingham risk scores (FRS) and subclinical 
atherosclerosis, with changes of −0.0014 and 0.0131 mm/year, respectively 
(374). Furthermore, while the Monitored Atherosclerosis Regression Study 
found that dietary cholesterol, body mass index and smoking were important 
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determinants of the annual progression of cIMT, lifestyle modifications such 
as weight loss and smoking cessation have been associated with 0.13mm/year 
reduction in progression of cIMT (375).  
cIMT measurements are not only predictive of atherosclerosis evolution but can 
also inform on the physiological modifications of the common carotid artery. For 
instance, cIMT can be measured serially and this approach has demonstrated that 
cIMT increases significantly with age. Rates of progression in control groups have 
ranged from 0.006mm/year in asymptomatic to 0.06mm/year in individuals with CAD 
(376;377). Post-mortem studies indicate that the aortic wall thickening that occurs 
with aging consists mainly of intimal thickening, even in populations with a low 
incidence of atherosclerosis (336). Non-invasive measurements made within the 
context of several epidemiological studies indicate that cIMT increases 2- to 3-fold 
between 20 and 90 years of age, which also is the case in individuals rigorously 
screened to exclude carotid or coronary arterial stenosis (378). There is, however, a 
marked heterogeneity in cIMT among individuals of a given age. Although arterial 
remodelling with aging in otherwise healthy humans occurs in the context of age-
associated endothelial dysfunction (379), there is presently little information on the 
factors involved in progressive IM thickening with aging in humans. Gender and 
ethnicity are considered important non-modifiable factors influencing differences in 
cIMT. Several studies have reported thicker cIMT in men compared to women 
(379;380) and the Insulin Resistance Atherosclerosis Study found that ethnicity may 
also influence cIMT, which is greater in blacks, lower in Hispanics, and intermediate 
in whites (381-383).  
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3.1.1.1 Experimental technique 
Different ultrasound techniques have been used to measure cIMT. Although 
M-mode (Figure 3.6) has superior temporal resolution, this provides measurements of 
only a single point of thickness, rather than a segmental value.  
 
Figure 3.1 Example of M-mode cIMT acquisition.  
Although M-mode images provide superior temporal resolution compared to B-mode, 
the main limitation of this method of acquisition relates to the single point used to 
estimate cIMT. This considerably increases the chance of error during acquisition 
and reduces measurement precision.  
As carotid wall thickening is not uniform, a single value may not accurately 
represent the real cIMT value. Furthermore, M-mode or point-to-point measurements 
of B-mode images provide estimates of cIMT which are limited multiples of the pixel 
size. This increases the chance of errors and reduces accuracy in defining cIMT 
values, as changes in the structure of the arterial walls can have sub-pixel magnitude. 
In contrast, multiple measurements of several extended segment lengths reduce the 
chance of error and allow expression of cIMT values with higher precision (sub-
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pixelar level). Recently, echotracking devices equipped with semi-automated border 
detection programs have been used to measure cIMT (see below), and can calculate 
the average IMT during whole the cardiac cycle or separately for the systolic and 
diastolic phases (384). Measurements, however, are best acquired at the end-diastolic 
phase, because the systolic expansion of the lumen causes cIMT thinning (385).  
A number of different scanning procedures (reference site, arterial wall, 
direction of scanning) have been used to determine IMT. Most of the studies have 
measured IMT in the carotid artery but the best site of intima-media thickness (IMT) 
measurement is still a matter of debate. The common carotid artery (CCA) (1-2 cm 
proximal to the carotid bulb) has been examined in most studies whereas the internal 
carotid artery (ICA) and carotid bulb have been seldom studied (386). The CCA is 
easier to image as it is relatively close and parallel to the skin surface. In contrast IMT 
measurements in the ICA are more challenging (387). Although atherosclerotic 
lesions appear later in the CCA compared to ICA or bifurcation, the IMPROVE study 
demonstrated that changes in all sites seem to be equally strongly associated with risk 
of subsequent CV events (361). Apart from the carotid artery, other arterial sites such 
as the common femoral, brachial or radial arteries have been proposed for IMT 
measurements. While in the elastic CCA IMT is assumed to represent mainly intimal 
thickening, IMT of the more muscular peripheral arteries represents both a change in 
the intima and /or media layer (384). There is conflicting evidence on the predictive 
role of IMT thickening in the muscular arteries for future risk of CVD. The Angina 
Prognosis Study in Stockholm (APSIS) showed that IMT of the common femoral 
artery and plaques were related to the risk of CV death or myocardial infarction, while 
femoral IMT was related to CV death or myocardial infarction, as well as to 
revascularization. However, after adjustment for age, sex, smoking, previous CVD 
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and lipid status, cIMT failed to predict any CV event, whereas carotid plaques tended 
to predict the risk of CV death or myocardial infarction. Femoral IMT and plaques 
were also related to the risk of revascularization after adjustments (388). Other groups 
have reported an association between ventricular hypertrophy and IMT of both the 
common carotid and the brachial artery in patients with previous myocardial 
infarction. Another study showed that increased blood pressure was associated with 
increased IMT of the femoral artery but not the carotid artery (389). As a result, the 
CCA remains the preferred site for IMT measurements (384). A recent consensus 
Statement from the American Society of Echocardiography recommended that 
ultrasound images of the distal 1 cm of the far wall of each CCA should be obtained 
and compared with values from a normative data set. 
There have been a variety of cIMT protocols published with differences in 
scanning directions of CCA, corresponding to different views of the vascular wall 
(anterolateral/lateral/posterolateral). Acquisition of multiple views provides 
information on wall-thickness eccentricity (390). Most studies have measured cIMT 
of the far wall, while others averaged these measurements with those of the near wall 
(391). Importantly, one study, evaluated the accuracy of the ultrasound measurement 
of the near wall cIMT and found that this was 20% lower than the corresponding 
histologic measurement (392). Therefore, far wall images are more easily obtained, 
accurate and standardized. 
3.1.1.2 Experimental protocol 
The protocol used to measure cIMT in this thesis follows recent guidelines on 
cIMT measurement (380). Images were obtained with the subject laying supine in a 
temperature controlled room with slight hyperextension and rotation of the neck to the 
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contralateral side. A sonographer was positioned on top of the bed, behind the head of 
the patients (Figure 3.7A).  
 
Figure 3.2 cIMT acquisition technique. 
A) The subject lay supine with slight hyperextension and rotation of the neck to the 
contralateral side of acquisition. The sonographer (positioned on top of the bed, 
behind the head of the patients) places a high resolution ultrasound probe on the 
middle of the patient’s neck. The proximal part of the carotid bulb was identified in 
transversal plane. This allowed identification of the region of interest of the common 
carotid artery, 1cm below the bulb. B) With slow movements of the probe, the 
longitudinal axis of the artery was visualised. C) Images were optimised to obtain the 
best view of the intima-media thickness of the far arterial wall. The optimal 
longitudinal image was acquired continuously for 10 seconds and video-clips were 
stored for post-acquisition analysis. 
 
Images of both the right and left carotid arteries were obtained with linear-
array transducers with frequencies of 12 MHz, connected to a high-resolution 
ultrasound scanner (Vivid I or Vivid 7, GE Healthcare). The proximal part of the 
carotid bulb was identified, initially with a transversal plane to identify the segment of 
the common carotid artery 1 cm proximal to the bulb. The transducer was 
manipulated so that the near wall of the carotid artery was parallel to the transducer 
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footprint and the lumen maximised in the longitudinal plane (Figure 3.7B). The image 
was focused on the far wall and the zoom function was used to magnify the region of 
interest. The optimal longitudinal image was acquired continuously and recorded in 
DICOM format for 10 seconds to minimize variations. Using different angles of the 
ultrasound probe, images of the left and right common carotid artery were acquired 
with three different views: anterior, posterior and lateral (Figure 3.7 B and C). As the 
cIMT measurements were captured on the far wall, the use of different views during 
the acquisition allowed the measure of the posterior, anterior and medial cIMT, 
respectively. Once acquired, all recordings were analysed offline using an 
echotracking software equipped with semi-automated border detection system 
(Carotid Analyser, Medical Imaging Applications, Iowa, USA).  
3.1.1.3 Analysis of cIMT cineloops 
Cineloops were opened using the 
Carotid Analyser software and calibration 
was applied to define which distance on the 
image corresponded to the size of 1 cm. 
Following calibration, a region of 5 cm 
located 1 cm blow the carotid bulb and 
including both vascular walls was selected 
for analysis (Figure 3.8).  
An automatic edge detection line was placed at the interface between media 
and adventitia of both the proximal and distal vascular walls (Figure 3.9, purple lines). 
Once the cineloop was started, the software placed a second automatic edge detection 
line at the interface between intima and vascular lumen (Figure 3.9, yellow lines). 
Figure 3.3 Region of interest for cIMT 
measurements. 
A segment of approximately 5cm of 
CCA, located 1cm below the bulb was 
used for estimation of cIMT. 
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This allowed the software to automatically calculate, frame by frame: a) the intima-
media thickness (space included between the line defining the intima-vascular lumen 
interface and that defining the medial-adventitia interface) and b) the intra-adventitia 
lumen (space included between the lines defining the medial-adventitia interface on 
both vascular walls) (Figure 3.9). 
 
Figure 3.4 Automatic edge detector. 
Once the region of interest was identified an automatic edge detection line was placed 
between the media and adventitia (purple). Once the cineloop was started, a second 
detection line (yellow) was placed by the software at the interface intima-lumen. The 
distance between the purple and yellow lines defined the intima media thickness 
during analyses. 
 
As the software processes the cineloops frame by frame, at the end of each 
reading the information on the IMT and intra-adventitia lumen are provided as an 
average of the 10 seconds of recording as well as at end systole and end diastole. The 
end-diastolic frame of three consecutive cardiac cycles with a clear definition of the 
intima-media thickness were averaged to provide the final values of cIMT for the 




Phantom studies have shown that distances similar to the cIMT can be 
measured with B-mode ultrasound system with an axial resolution of 0.2 to 0.4mm at 
a precision of about 0.03 to 0.05mm (393). Reported intra-observer variability of 
cIMT has been reported between 2.4% to 10.6 % and inter-observer variability varies 
from 3.1% to 18.3% (394). Reproducibility of IMT measurement is better in studies 
limited to the common carotid artery far wall than in those which have included 
multiple measurements at different carotid sites. In addition, variability is less when 
mean IMT is measured compared to maximum IMT and also when measurements 
have been performed in more than one direction (395). Recently, the studies with an 
automated computerized IMT measurement rather than a manual cursor placement 
have reported the best reproducibility (395). 
3.1.2 Brachial artery distensibility 
Vascular remodelling results in changes in arterial elasticity which reduces the 
ability of the vessel to respond to changes in local blood pressure. Vascular elasticity 
is assessed by arterial compliance and distensibility. 
Compliance is defined as the change in volume per unit of pressure (ΔV/ΔP) 
and reflects the buffering function of the vessel (396;397). Arterial compliance is an 
important determinant of the afterload on the heart (396); a decrease in total arterial 
compliance contributes to a higher afterload. Arterial compliance (C) is related to 
arterial distensibility (D) and arterial volume (V) by the formula C=D×V (397). 
Distensibility, defined as the relative change in volume per unit of pressure 
([ΔV/V]/ΔP), is related to the elastic Peterson modulus (398) and is a determinant of 
stress on the vessel wall.   
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Distensibility of large and middle-size arteries is an important measure of CV 
phenotype (399), and a reduction in arterial distensibility causes: 1) an increase in 
arterial impedance, cardiac work and cardiac oxygen consumption, 2) a reduction in 
the diastolic portion of vital organ perfusion which is particularly pronounced for the 
coronary circulation and 3) an increase in systolic blood pressure, pulse pressure and 
indirectly or directly-generated trauma on the vessel wall with a resulting progression 
of atherosclerosis (397;398). 
Measuring arterial distensibility has always been difficult because of the need 
to assess accurately and concomitantly changes in vascular volume in response to 
changes in pressure over a wide range of values. This has led to a variety of indirect 
approaches, such as measurements of the 1) pulse wave velocity which varies in 
proportion with the stiffness of the vessel wall throughout the arterial tree 2) blood 
pressure and blood flow contour in a peripheral artery or the aorta to derive, 
particularly from the diastolic phase, the elastic recoil of the vessel and 3) 
diameter/pressure relationship in accessible arteries, to have measurements of local 
distensibility from which to infer more generalized changes in different conditions 
and diseases. The last approach has gained popularity because of the possibility to 
track accurately, noninvasively and continuously changes in arterial diameter in 
response to blood pressure changes in a number of vessels.  
Pulsed Doppler systems can estimate, transcutaneously, the time-dependent 
changes in arterial diameter relative to its initial diameter by assessing the 
displacement of the arterial walls during the cardiac cycle (distension waveform) 
(400-402). The displacement of the arterial wall can be recorded on a two-
dimensional B-mode echo-image by processing radiofrequency signals within a 
sample volume (either the vessel walls itself or the wall-blood interface) identified 
105 
 
along an M-line perpendicular to the artery of interest. The distension waveform of 
the artery normalized with respect to the local pulse pressure provides information 
about the local elasticity of the arterial wall (Figure 3.10). 
Figure 3.5 Ultrasound evaluation of resting arterial distensibility with 
radiofrequency (RF) echo tracking. Adapted from Urbina et al. Hypertension 
2009;54:919-950. 
 
Using this system, it has been established that the distensibility and 
compliance of the common carotid artery gradually decrease with age (403;404) as 
well as that arterial distensibility is impaired in adult patients with CV risk factors, 
including hypercholesterolemia (405), arterial hypertension (406-408), and diabetes 
mellitus (409). The high sensitivity of radiofrequency systems to analyse B-mode 
echo-images has also been used to show that brachial artery distensibility is reduced 
in children with higher levels of LDL cholesterol as well as in adolescents with 
adiposity and metabolic syndrome (410;411).  
Importantly, evidence is available that reducing the CV risk factor burden can 
improve arterial distensibility. The hypertension related changes in large artery 
distensibility can be improved by long-term antihypertensive treatment both in 
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isolated systolic and essential hypertension (412). It has been suggested that the 
increase in compliance with calcium antagonists (413) and ACE inhibitors (414) is 
mainly caused by an increase in distensibility, with a minor influence on large artery 
diameter. In contrast, isosorbide dinitrate increases the compliance of the carotid and 
brachial arteries mainly through an increase in large artery diameter (415). The effect 
of antihypertensive agents may also depend on the vascular territory. The diuretic 
amiloride/hydrochlorothiazide did not change carotid artery wall properties but did 
increase brachial artery wall properties (414). Long-term lipid-lowering treatment can 
improve the striking arterial stiffening in familial hypercholesterolemic individuals 
(405).  
The high sensitivity of radiofrequency systems to analyse B-mode echo-
images, the non-invasive and relatively easy acquisition protocols as well as the 
ability of arterial distensibility to reflect the level of CV risk factor burden in large 
epidemiological studies, have made this approach an attractive test to follow vascular 
remodelling, particularly in childhood and adolescence (as in study 3).  
3.1.2.1 Acquisition protocols and reproducibility 
Measurements were performed at rest, in a temperature controlled room. The 
subject lay supine on a couch, and after 10 minutes’ rest, the right brachial artery was 
imaged in longitudinal section 10 to 15 cm above the antecubital fossa with a 7-MHz 
linear array transducer and Acuson 128XP/10 (416). To measure arterial distension, 
the M-mode cursor was positioned at right angles to the arterial lumen over the 
clearest defined section of the artery on the B-mode image. A 5-second segment of the 
radiofrequency signal was recorded by a separate commercially available Wall 
Tracking System (Ingenious Medical Systems) at a rate of 800 Hz (1 frame/ms). The 
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initial frame (amplitude waveform) was displayed, and the operator selected two 
sample volumes coinciding with the arterial wall-lumen interfaces. The relative 
position of the walls within these volumes was measured every 25 ms (≈20% of the 
expected time for an upstroke) by use of a displacement detection algorithm based on 
the cross-correlation model for corresponding segments of the radiofrequency lines 
(Figure 3.11) (400). 
Figure 3.6 Example of radiofrequency signal to estimate brachial artery 
distensibility 
Example of wall tracking output, showing movement of anterior and posterior walls 
and the relative changes of arterial diameter (estimated as distance between the two 




Arterial distension is the mean diameter change between diastole and systole 
over the 5-second period. (417). Pulse pressure was measured in the left brachial 
artery with a Dinamap 1846SX oscillometric blood pressure recorder (Critikon Inc) at 
the same time that distensibility was measured in the right arm. This method has been 
shown to provide a representative measure of the pulse pressure in the right brachial 
artery during data collection (400). Coefficients of variation for diameter and 




3.2 Oxidative Stress Assays 
Most available methods for evaluating oxidative stress in vivo are inappropriate 
for large-scale use, limiting their application in clinical practise (266;419;420). The 
choice to use one specific biomarker as representative of the total oxidative stress or 
anti-oxidant state in specific patient categories is still controversial (266;419;420). 
Indeed, each disease can be characterized by increased production of different 
oxidative species, depending on their intracellular sources. While electron spin 
resonance (ESR) is currently considered the gold standard assay to measure different 
RS in biological samples (264), the method is complex and not available in most 
clinical laboratories. Furthermore, ESR uses different protocols depending on which 
oxidative species are targeted, requiring continuous adaptation of the experiment and 
machine parameters and introducing further complexity in the measurements. Ideally, 
the perfect oxidative stress assay should be easy to perform, reliable, quick and 
inexpensive. Automated analysers would allow processing of a large number of 
samples, avoiding manual sample and reagent handling, and reducing variability 
sources.  
Among the various commercially available kits, the reactive oxygen metabolites 
(dROM) and biological antioxidant potential (BAP) tests have been developed to 
assess in an automated, economic and reproducible fashion the total amount of 
oxidant and antioxidant species in different biological samples. 
3.2.1 d-ROM Test 
The d-ROMs test measures the blood concentration of hydroperoxides, a class 
of chemical oxidant species belonging to the wider group of reactive oxygen 
metabolites (421-423).  
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Hydroperoxides are generated by the oxidation of several molecules such as 
glucosides, lipids, amino acids, peptides, proteins, and nucleotides, making their 
levels independent of the source of oxidative stress. In the presence of free iron, 
hydroperoxides are able to generate alkoxyl and peroxyl radicals, according to the 
Fenton's reaction (424;425):  
ROOH + Fe
2+
  → RO• + OH- + Fe3+ 
ROOH + Fe
3+
  → ROO• + H+ + Fe2+ 
Such radicals are highly reactive and can quickly oxidise surrounding 
positively charged molecules, in order to recover their electron stability. By adding to 
the solution a stable and positively charged radical (N,N-diethylparaphenilendiamide 
radical) which rapidly interacts with the alkoxyl and peroxyl radicals becoming pink 
after oxidation, the d-ROM test photometrically measures the amount of alkoxyl and 
peroxyl radicals formed by degradation of hydroperoxides (423).  
 
Figure 3.7 d-ROM test. 
The reaction is started by adding a small amount of serum to a solution containing 
N,N-diethylparaphenilendiamide radical and an acidic buffer (pH 4.8). The solution 
is warmed up to 37°C. This detaches the iron ions from serum protein, making them 
available for the Fenton reaction and transforming the hydorperoxides in the samples 
in alkoxyl and peroxyl radicals. The latter rapidly react with the N,N-
diethylparaphenilendiamide radical, causing a change in the colour of the solution 
which shifts to pink. The intensity of the pink colour is directly related to the original 
amount of hydroperoxides in the sample and is readable using a photometer with 
absorbance at 505 nm. 
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Assay: 20μL of serum are diluted in a solution formed by: a) 10μL of a 
chromogenic mixture containing 10% of the positively charged N,N-
diethylparaphenilendiamide radical and b) 1ml of a buffer containing HCl with pH 4.8 
(Figure 3.12 A and B). The sample is warmed at 37°C for 1 minute. The combination 
of the high temperature and acidic environment allows detachment of iron ions from 
serum proteins, making them available for the Fenton reaction (Figure 3.12 B and C). 
Thus, the hydroperoxides in the samples are transformed in alkoxyl and peroxyl 
radicals which rapidly react and oxidize the N,N-diethylparaphenilendiamide (Figure 
3.12 C and D). This determines a progressive change in the colour of the solution 
(towards pink) which can be read by a photometer (absorbance at 505 nm) (Figure 
3.12 D). The final reading is dynamic and is performed immediately as well as at 1, 2, 
and 3 min following incubation. Obviously, the level of absorbance is directly 
dependent on the amount of the reactive oxygen metabolites present in the serum, 
according to the Lambert–Beer's law (423). A blank reagent obtained by replacing 
serum with distilled water and a standard with assigned value are included for each 
series of assays. The results of d-ROM test are expressed in arbitrary units called 
“Carratelli Units” (CARR U), according to the following formula: 
 
CARR U  = F(∆Abs/min) 
 
where F is a correction factor (approximately 9000 at 37°C according to the results 
obtained with the standard); (ΔAbs/min) are the mean differences of the absorbances 
recorded at 1, 2, and 3 min. Reference values of healthy subjects are between 250 and 
300 CARR U; conditions of slight, medium, and high oxidative stress are defined, 
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respectively, by values of 320–360, 360–400, and >400 CARR U; for values up to 
500 CARR U, a sample dilution is required (426). Results obtained with d-ROM test 
have been validated by electronic spin resonance spectroscopy and it has been 
experimentally established that 1 CARR U corresponds to 0.08 mg of H2O2/dl 
(423;426). Furthermore, it has been proved that, in vertebrate blood samples, results 
are stable also after refrigeration of the sample (427).  
In this study, the intra-assay coefficient of variation obtained by running 20 
randomly selected samples in duplicate was 3%. All analyses were performed in a 
blind fashion. 
 
3.2.2 BAP test 
This method evaluates the reducing power of a biological sample. A salt of 
trivalent iron FeCl3 is dissolved in a colourless solution containing thiocyanate which 
turns its colour to red due to the action of ferric ions. This solution is oxidatively 
saturated (all ferric ions are trivalent) and can be decolorized by the addition of blood 
serum due to the reduction of ferric ions to bivalent ions (Fe2+) caused by the action 
of serum antioxidants. The antioxidant potential of serum can be then evaluated by 
assessing photometrically the degree of decolorization which reflects the amount of 
reduced ferric ions i.e. the reducing capacity of blood (428-434). A sample of 
lyophilized serum with a known antioxidant capacity (provided with the kit) and 10 
µL of distilled water are used for calibration of the results. 
Assay: The procedure starts solving the lyophilized serum in 2mL of distilled 
water. It is then necessary to prepare three tubes mixing all reagents according with 
the following table: 
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Table 3.1 Reagents used for BAP test 




1ml 1ml 1ml 
FeCl3 salt 
(Reagent 2) 
50 µL 50 µL 50 µL 
Distilled water 10 µL - - 
Serum of interest - 10 µL - 
Solved lyophilized 
serum 
- - 10 µL 
 
After 5 minutes of incubation at 37°C, the absorbance at 550nm of the distilled 
water sample will be established by photometric reading and used as 0. Then, the 
decolorization of the other two samples will be measured and the intensity of this 
change will be directly proportional to the ability of the two serum samples (calibrator 
and tested sample) to reduce ferric ions (435).  
The results are obtained according to the following formula: 
     
  
                
and expressed in units of µmol/L (µmol of ferric ion reduced per L of sample). 
Normal reference values of BAP test are >2200 µmol/L. Values below 2000 µmol/L 
indicate an antioxidant deficiency status. The advantage of BAP test is that it provides 
a global measurement of many antioxidants, including uric acid, ascorbic acid, 
proteins, α-tocopherol and bilirubin (435). As it is easy to perform, has a good 
reproducibility, is cheap and can be easily applied to large population studies, the 
BAP test was used in the first study of this thesis to assess the biological antioxidant 
•  Calibrator Absorbance of blank sample • Absorbance of tested sample 
Absorbance of blank sample • Absorbance of calibrator 
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potential of the blood of subjects with and without periodontitis. All analyses were 
performed in a blind fashion. In the interpretation of the results, it should be 
recognised, however, that the BAP test has major limitations:  
 Whilst most antioxidants are able to reduce ferric ions to ferrous ions, not all 
are able to do so. This means that some antioxidants (such as carotenoids and 
SH-group antioxidants) will not be determined by this assay.  
 Substances other than antioxidants, are able to reduce the ferric ions into 
ferrous ions. These will cause falsely high results being obtained as these are 
not antioxidants (e.g. glucose, hydroperoxides, ethanol).Since the effects of 
proteins are weak, the assay practically measures non-protein total antioxidant 
capacity 
 
3.3 LTL assay 
 
3.3.1 Sample preparation  
3.3.1.1 DNA extraction  
The DNA extraction in this thesis was performed using a modified “salting-
out” method reported by Miller et al (436), unless otherwise specified. This method is 
based on 5 different steps: cell lysis, nuclear lysis, deproteinisation, DNA extraction, 
DNA precipitation and DNA recovery. Twenty millilitres of ice-cold cell lysis buffer 
(consisting of 0.32M sucrose, 5mM MgClg, 10mM  Tris-HCI with pH 7.5, 1% Triton-
X-100) were added to a 30 ml polypropylene tube containing 3-5 ml of whole blood. 
After inversion for 10 times to ensure thorough mixing, the tube was centrifuged at 
114 
 
1300g at 4°C for 10 minutes and the supernatant was discarded without disturbing the 
pellet. This washing step was repeated by re-suspending the pellet in 20ml of cell 
lysis buffer. Following the second washing step the pellet were re-suspended with a 
Pasteur pipette in 2ml of a nuclear lysis solution, containing 10 mM Tris-HCI (pH 
8.2), 0.4 M  NaCi, 2mM Na2EDTA (pH 8.0). After inversion for several times, 1 ml 
of a deproteinisation solution consisting of 5 M sodium perchlorate was added to the 
sample. The tube was placed on a shaker and the sample left in incubation for 30-45 
minutes. After incubation, 2ml of ice-cold chloroform (-20°C) was added to the 
sample using a glass pipette and the tube was inverted several times and centrifuged at 
1300g for 3 minutes at room temperature. The upper aqueous phase was recovered 
without disturbing the organic phase and transferred to a fresh 30ml polypropylene 
tube, using a Pasteur pipette. Ten millilitres of cold (-20°C) 100% ethanol was slowly 
added to the sample and, after a few minutes, the tube was inverted several times to 
precipitate the DNA. The white sediment of DNA was recovered with a sterile Pasteur 
pipette and quickly washed in 70% ethanol. The tip of the Pasteur pipette was placed 
into a 1.5 ml apex sterile tube containing 1 ml of Tris-EDTA (TE) buffer (10mM Tris, 
1mM EDTA) and cut proximal to the top of the tube. This was sealed and left 
incubating overnight at 37°C to allow complete dissolution of the DNA. Then, the 
samples were kept at 4°C for a minimum of 2 weeks to allow the viscous DNA to 
dissolve. 
 
3.3.1.2 DNA Quantification 
In all studies, the DNA concentration was measured with a Nano-Drop 
spectrophotometer, according to a standardised protocol (437). Absorption 
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spectroscopy has long been the method of choice to measure the amount of DNA or 
RNA in a solution (438). Purines and pyrimidines in nucleic acids absorb ultraviolet 
(UV) light because of presence of conjugated double bonds of the constituent purines 
and pyrimidine bases, which have maximal absorbance at wavelengths of 260 nm. 
Therefore, if a light source shines on a sample, the amount of light that passes the 
sample can be measured, and the amount of light absorbed by the sample can be 
inferred (439-441). For double stranded DNA, one optical density of 1 unit (normally 
indicated as OD260 or A260) corresponds to concentration of 50μg/ml, while for 
single stranded DNA and RNA it is equivalent to 40 μg/ml. Using the Lambert-Beers 
law which relates the absorption of light to the properties of the material through 
which the light is travelling, it is therefore possible to calculate by simple 
interpolation the concentration of nucleic acid in a specific solution. Furthermore, 
using spectrometry is possible to check the presence of contamination by organic 
compounds or proteins. Based on the same principle of the DNA, proteins normally 
absorb light at wavelengths of 280 nm while organic compounds absorb at 230 nm. 
Therefore, the A260/280 and A260/230 ratios define the purity of each DNA sample 
extracted compared to proteins and organic compounds, respectively (439-441). 
 
The Nanodrop spectrophotometer is composed of a sampling arm with two 





Figure 3.8 NanoDrop structure. 
A) With the sampling arm open, the sample is pipetted on to the lower measurement 
pedestal. B) The sampling arm is closed and the sample remains automatically drawn 
between the upper and lower measurement pedestals. Measurement initiates using the 
operating software on the PC. C) UV light is emitted by a xenon flash lamb located on 
the top pedestal and passes through the sample. A charge coupled device (CCD) 
detector records the residual amount of light on the bottom pedestal.  
 
On the top pedestal a xenon flash lamp emits light which is transferred 
through the sample by optical fibres (Figure 3.13 B). Once passed the sample, the 
unabsorbed light is captured by a charge coupled device (CCD) detector located in the 
bottom pedestal, which transforms incident photons in an electric charge readable and 
quantifiable by electronic systems (Figure 3.13 C) The difference between emitted 
and captured light informs on the amount of absorbance at different wavelengths 
therefore defining the concentration of different compounds in the interrogated 
solution.    
Assay: Samples were removed from the freezer and thawed in the refrigerator 
overnight to avoid excessive evaporation of the TE/DNA solution. On the morning of 
the following day, cryovials were centrifuged for 1 minute at 3000rpm and transferred 
in 96 well plates under sterile conditions. These plates constituted the stock DNA 





gently pipetting up and down with a multichannel pipette. Using other sterile 96 well 
plates, a working solution was prepared for each sample by diluting 10 μl of the stock 
solution with 100 μl of nuclease and protease free water (Sigma). This further dilution 
reduced the amount of DNA lost for quantification, also provides a more accurate 
reading for those samples with excessively high concentration of DNA. Stock plates 
were re-stored in a -80°C freezer, while working solutions were left to stand for 15-20 
minutes at room temperature to ensure the complete diffusion of DNA throughout the 
water. While waiting, the computer and Nanodrop spectophotometer were turned on 
to allow the xenon lamp to warm up for approximately 15 minutes before reading 
samples. With the sampling arm opened, the upper and lower pedestals were cleaned 
using a soft laboratory wipe (Kimwipe) soaked with distilled water.  
Any measurement session was begun with a blanking cycle (using distilled 
water) to assure that the instrument was working properly and that the pedestal was 
clean. When the reading evidenced the presence of contamination, further cleaning 
and blanking cycles were performed until the spectrum was completely flat. Between 
each measurement, both pedestals were cleaned using soft laboratory wipes 
(Kimwipe, Kimberly Clark, USA). Once the blanking procedure was completed, 1.5 
μl of each sample (working solution) was sequentially loaded onto the lower 
measurement pedestal (Figure 3.13 A). The sampling arm was closed and a spectral 
measurement was initiated using the operating software on the PC (Figure 3.13 B). 
The sample column was automatically drawn between the upper and lower 
measurement pedestals and the spectral measurement made (Figure 3.13 C). When the 
measurement was complete, the sampling arm was opened and remaining sample was 
wiped from both the upper and lower pedestals using a soft laboratory wipe. Wiping 
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prevents sample carryover in successive measurements. Results are reported on the 
computer screen as shown in Figure 3.14.  
Figure 3.9 NanoDrop 
reading. The main (white) 
window on the screen 
reports the levels of light 
absorbance at 3 different 
wavelengths (230nm, 260nm 
and 280nm). The software 
calculates automatically the 
absorbance ratio 260/280 
and 260/230 (right and side). 
This informs on possible 
sample contaminations by 
organic compounds other 
than DNA. Furthermore, the 
amount of light with 
wavelength of 260nm 
absorbed by the sample 
provides its DNA 
concentration. 
 
The concentration of the DNA was provided in ng/μl. Furthermore, absorbance at 
A230 A260 A280 was graphically reported with corresponding number on the right 
side of the screen. This provided information on the concentration of organic 
compounds, nucleic acids and proteins present in the sample. From these values the 
software calculates: 
 260/280 ratio: ratio of sample absorbance at 260 and 280 nm. The ratio of 
absorbance at 260 and 280 nm is used to assess the purity of DNA and RNA. 
A ratio of ≥1.7 is generally accepted as “pure” for DNA. If the ratio is 
appreciably lower in either case, it may indicate the presence of protein, 
phenol or other contaminants that absorb strongly at or near 280 nm.  
 260/230 ratio: ratio of sample absorbance at 260 and 230 nm. This is a 
secondary measure of nucleic acid purity. The 260/230 values for “pure” 
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nucleic acid are often higher than the respective 260/280 values. They are 
commonly in the range of 1.8-2.2. If the ratio is appreciably lower, this may 
indicate the presence of co-purified contaminants.    
In this thesis, DNA concentration was assessed in duplicate in each sample and a 
novel measure was performed when the difference between the two readings was 
higher than 10ng/μl. For samples with high concentration of DNA and with persistent 
variability of the measurements, a further dilution 1:10 was performed as previously 
described and samples were re-measured. 
3.3.1.3 DNA standardization 
The concentration of each sample was manually standardized under sterile 
conditions to 15 ng/μl using the following formula: 
[WS] x V1 = 15 ng/μl x 50 μl 
where [WS] is the concentration of the working solution detected using Nanodrop, 
while V1 is the volume of the working solution to be used in order to obtain a final 
DNA concentration of 15 ng/μl in a volume of 50 μl. Therefore, for each sample a 
volume equivalent to V1 was added to the corresponding well of a new 96 well plate 
containing an amount of nuclease and protease free water (Sigma) equivalent to (50 μl 
– V1). For those samples with a DNA concentration of the working solution lower 
than 15 ng/μl (seven in total), the stock solution was used to make the final dilution. 
At the end of the standardization procedure, the concentration of each sample was 
checked again with Nanodrop, using the same procedure described above. 
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3.3.2 Real-Time PCR: principles and result interpretation 
Real-time PCR (RT-PCR, also known as quantitative PCR, qPCR) combines 
PCR chemistry with the ability to detect and continuously monitor the accumulation 
of reaction products (amplicons) after each amplification cycle. Real-time PCR has 
the ability to detect the presence and quantity of specific nucleic acid sequences 
(target nucleic acid), as well as to determine whether sequence variations exist. The 
amount of amplicons generated during each PCR cycle is directly proportional to the 
amount of template prior to the start of the run.  
3.3.2.1 Principles of PCR amplification and importance of thermal cycles 
PCR allows amplifying specific sequences of DNA (templates), which can be 
single or double-stranded. Two oligonucleotide primers that flank the DNA templates 
are needed to prime the amplification, together with deossi-Nucleotide-Tri-Phosphate 
(dNTPs), which are the four nucleotide triphosphates (adenine, guanine, cytosine, 
thymine), a heat-stable polymerase, and magnesium ions in the buffer. The reaction is 
performed by consecutive cycles at different temperature. In a standard PCR run, high 
temperature is applied to separate (melt) the strands of the double helical DNA. The 
temperature is then lowered to let primers anneal to the template in a highly specific 
and complementary fashion. Finally, the temperature is set around 72 °C, which is 
optimum for the polymerase that extends the primers by incorporating the dNTPs. 
Multiple repetitions of these three thermal cycles allows exponential accumulation of 
new templates, which will be ultimately ceased due to inhibitors of the polymerase 
reaction found within the template, reagent limitation and/or accumulation of 




Figure 3.10  The PCR temperature cycle.  
Each cycle starts by raising the temperature to about 95°C. This melts the double 
stranded DNA, making the single stands of DNA available for primer annealing. 
Following one cycle at low temperature (to let primers anneal), the temperature is set 
to 72°C to let the polymerase extend the primers. 
 
The melting temperature should be sufficient to fully separate the strands of 
the template, as a partial separation results in rapid re-annealling when the 
temperature is dropped, precluding the access of primers to the template. The required 
temperature and duration of the melting cycle depends on the length and sequence of 
the template, as well as on the instrument and reaction containers used (443). For 
instance, with short amplicons and containers with rapid heat transfer (e.g. glass 
capillaries), it may be sufficient to touch 95 °C and then immediately start the cooling 
phase. Because the original template is typically much longer than the amplicons 
dominating the later phase of each PCR run, the first cycle normally requires higher 
heating temperatures and longer melting times compared to the other cycles (442). 
The use of elevated elongation temperatures in the following cycles is more important 
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to melt any secondary structures that may form in the template and may block 
extension. For example, while amplicons are typically short with limited capability to 
fold, sequential runs of guanines may fold the template into a tetraplex structure, 
which is exceedingly stable and cannot be transcribed by the polymerase (444). 
Similarly, the presence of self-complementary regions between primers, particularly 
at their 3′-ends, can cause annealing of the primers (known as primer–dimer 
formation) and leads to premature ceasing of the PCR reaction with a specific 
amplification signal (445;446). Also the annealing temperature should be carefully 
defined as it influences the odds of primer-dimer formation, therefore the specificity 
of the amplification signal. Ideally, the annealing temperature should be only a few 
degrees below the melting temperature of the two primers (carefully designed to have 
the same or similar melting temperatures). This would allow them forming stable 
complexes with the targeted sequences but not with any other sequences, reducing the 
risk of primer-dimers alignment (445-447). 
 
 
3.3.2.2 Fluorescent probe used for product monitoring 
To follow up the reaction in real time, PCR needs a fluorescent reporter that 
binds to the product formed and reports its presence by fluorescence intensity (Figure 
3.16) in a concentration dependent fashion. A number of probes and dyes can be used 
as reporters.  
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Figure 3.11 Reporters used in real-time PCR and 
their mechanisms. (A) the molecular beacon, (B) the 
Taqman probe, (C) the hybridization probes, (D) the 
LightUp probe, (E) the simple probe, (F) scorpion 
primer, (G) sequence non-specific dyes (SYBR 
Green/BOXTO). Adapted from Kubista Mol Aspects 
Med. 2006;27(2-3):95-125. 
 
While some of them are sequence specific (Figure 3.16 A-F), those used for 
LTL assay are non-specific as they intercalate within each DNA molecules presenting 
a double strand conformation (Figure 3.16 G). In his initial work Higuchi used the 
common nucleic acid stain ethidium bromide, which becomes fluorescent upon 
intercalating into DNA (448). However, while classical intercalators interfere with the 
polymerase reaction, asymmetric cyanine dyes (including SYBR Green I used in LTL 
124 
 
PCR-based assay) do not present this limitation and have become more popular 
(Figure 3.17) (449;450).  
 
 Figure 3.12 The asymmetric cyanine dyes SYBR Green and BOXTO. 
These dyes have become popular as their intercalation within the double 
stand of the DNA does not interfere with the polymerase reaction.Asymmetric 
cyanines have two aromatic systems containing nitrogen, one of which is positively 
charged, connected by a methine bridge. These dyes have virtually no fluorescence 
when they are free in solution due to vibrations engaging both aromatic systems, 
which convert electronic excitation energy into heat that dissipates to the surrounding 
solvent. On the other hand the dyes become brightly fluorescent when they bind to 
double strand DNA, presumably to the minor groove, as rotation around the methine 
bond is restricted (451). Therefore, the increase in the fluorescence signal is recorded 
during polymerization, while fluorescence rapidly drops when the DNA is denatured. 
Fluorescent measurements are then performed at the end of the elongation step of 
each PCR cycle, allowing direct detection of the increasing amount of amplified 
DNA. Although the advantage of these fluorescent reporters is that they are relatively 
cheap as they can detect the increase in any pair of primers for any target, the 
aspecific nature of their binding gives rise to a fluorescence signal in the presence of 
any double stranded DNA, including undesired primer–dimer products (450). As 
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primer–dimer alignment interferes with the formation of specific products because of 
competition of the two reactions for reagents and leads to erroneous readouts, it is 
good practice to control for primer–dimer formation after each PCR run. This can be 
done by melting curve analysis after completing the reaction.  
Melting curve analysis is performed by following the change in fluorescence 
while the temperature is gradually increased. In normal conditions, the fluorescence 
decreases gradually with increasing temperature because of increased thermal motion 
which allows for more internal rotation in the bound dye (451). However, when the 
temperature is reached at which the double stranded DNA strand separates the dye 
comes off and the fluorescence drops abruptly (452). This temperature, referred to as 
the melting temperature, Tm, is easiest determined as the maximum of the negative 
first derivative of the melting curve. Since primer–dimer products typically are shorter 
than the targeted product, they melt at a lower temperature and their presence is easily 
recognized as a second or larger peak in the melting curve analysis (Figure 3.18). 
Figure 3.13 Melting curve analysis. 
Dye fluorescence drops rapidly when the DNA melts. The melting temperature (Tm) is 
defined as the inflection point of the melting curve, which is easiest determined as the 
maximum in the negative 1
st
 derivative of the melting curve. The amplicon produced 
from the targeted product is typically longer and melts at higher temperature than the 
primer–dimers. Adapted from Kubista et al. Molecular Aspects of Medicine 
2006;27:95-125. 
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3.3.2.3 Profile of PCR reactions and cycle threshold (Ct) 
In PCR methods which use SYBR Green I or, more in general, intercalator 
molecules to follow the reaction, the plot of fluorescence against the number of PCR 
cycles displays a typical profile where it is possible to identify three different phases: 
background, exponential and plateau (453).  
Figure 3.14 Real-time PCR 
profile for reaction carried 
with asymetric cyanine dyes. 
The 1
st
 phase is hidden under 
the background fluorescence 
where an exponential 
amplification is expected.  
The 2
nd
 phase is the 
exponential amplification that 




or plateau phase is defined as 
the attenuation in the rate of 
exponential product 
accumulation, which is seen 
concomitantly in later cycles. 
 
During the initial cycles the relatively low amount of product compared with 
the high concentration of the fluorescent reporter leaves most of the fluorescent dye 
suspended in solution and unbounded to the DNA. This results in a weak fluorescent 
signal, impossible to distinguish from the background (Figure 3.19, background 





accumulation of reaction products increase the number of fluorescent dye conjugated 
with double strand DNA molecules, leading to emergence of the fluorescence signal 
from the background. In this phase, fluorescence increases exponentially assuming 
amplicon doubling at every thermal cycle (Figure 3.19, exponential phase). The 
exponential phase of amplification normally persists for only few cycles (< 10) as 
some of the critical components of the reaction run out quickly due their highlighted 
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expendure. These can be the primers, the reporter, or the dNTPs (454). Also the 
number of polymerase molecules available may represent the limiting factor, in which 
case the amplification shifts from an exponential to a linear phase. The end of the 
exponential growth corresponds with the start of the plateau phase (Figure 3.19), 
where the fluorescence does not increase any more between different thermal cycles 
as either there are no more primer or polymerase molecules to produce new products, 
or there are no more reporter molecules available to bind the new amplicons. As 
factors that determine the passage from the exponential to the plateau phases equally 
affect all samples independently from their original concentration, all curves 
corresponding to the amplification response of each sample are expected to saturate at 
the same level. Hence, end-point PCR measurements do not provide information 
about the initial amounts of target molecules that were present in the samples; they 
only distinguish a positive from a negative sample (455). In the growth phase of the 
reaction, by contrast, the amplification is not conditioned by the limited availability of 
the reagents, making it possible to identify difference dependent on the original 
amount of target gene (TG) in the sample (456). As each template should generate 
two amplicons, the amplification curves normally present the same slope and appear 
parallel to each other during this phase. Therefore, the parameters that allow 
differentiation between samples is not represented by the rate of fluorescence 
increase, but by number of amplification cycles required for the amplification curves 




Figure 3.15 Cycle threshold  
The number of cycles necessary for each sample to reach the limit of fluorescence 
detection is directly related to the original amount of DNA or RNA contained in the 
sample. By comparing the cycle threshold of two samples is therefore possible to 
establish the difference in the expression of a specific gene or amount of DNA 
repetitions in the original samples. 
 
As the number of cycles is reported on the x axis of the amplification plot, 
differences between samples will be visualized as a right or left shift of the curves on 
this axis. Such a shift depends on the higher or lower number of cycles necessary to 
reach the exponential phase of the reaction, which is directly related to the original 
amount of the template present in the sample. Therefore, the definition of the 
fractional PCR cycle at which the reported fluorescence is greater than the minimal 
detection level (Ct) allows a precise estimation of the original amount of the template 
in the sample (458). The minimal level of fluorescence detection (threshold) is 
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defined using different methods by different instrument software, and most also let 
the user set it manually. The setting is therefore somewhat arbitrary and it does not 
affect significantly the differences between Ct values, though it affects the values of 
the individual Cts. These are also affected by the setting of the instrument (filter, 
channel, gain, etc.). Hence, one should avoid comparing individual Ct values between 
experiments, and include one reference per run to which all the other response curves 
can be related.  
 
3.3.2.4 Quantification and standardization of PCR results 
PCR technologies use two major methods to analyse the reaction results: 
absolute and relative quantification. In both cases a reference is introduced in each run 
and the final results are expressed as function of this reference.  
 
3.3.2.4.1 Absolute quantification  
In the absolute quantification method the reference is provided by a standard 





Figure 3.16 Absolute quantification 
A serial dilution of a reference sample with known DNA concentration is prepared 
and run together with the sample of interest. At the end of the reaction, a 
“calibration” curve is obtained by plotting the cycle threshold vs the original DNA 
concentrations of the reference sample. Once the calibration curve is available, the 
concentration of the sample of interest is obtained by overlaying its cycle threshold to 
the standard curve. 
 
 
For LTL analysis, the control template is represented by a DNA with known 
telomere length (e.g. 10.2 kb, Control-DNA high; TeloTAGGG Telomere Length 
Assay; Roche Applied Science) (71). In order to compare results and ensure similar 
amplification efficiencies between different runs, the same dilution series of the 
control template is introduced in each run. Following amplification of the standard 
dilution series, the standard curve is generated by plotting the log of the initial 
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template concentration against the Ct generated for each dilution (Figure 3.21) (460). 
If the aliquoting was accurate and the efficiency of the amplification does not change 
over the range of template concentrations, the plot of these points should generate a 
straight line. The comparison of Ct values of the unknown samples with those 
obtained from the serial dilution of the reference will allow quantification of initial 
copy numbers (or telomere length) in each sample (460).  
Ideally, a standard curve will consist of at least 4 points, and each 
concentration should be run at least in duplicate (the more points the better). The 
range of concentrations in the standard curve must cover the entire range of 
concentrations that will be measured in the assay as conclusions cannot be drawn 
from samples whose calculated initial quantity exceeds the range of the curve (461). 
The most important parameter which affects the accuracy of the absolute 
quantification method is the linearity of the fit between log of the initial template 
concentrations and the correspondent Ct value (459;460). The linearity is denoted by 
the R squared value (R
2
) and should be very close to 1 (Figure 3.21). A linear 
standard curve implies that the efficiency of amplification is consistent at all different 
template concentrations. Conversely, a standard curve that becomes non-linear at very 
low template concentration suggests that we are approaching the limit of the assay 
detection. Unknown samples with Ct values that fall within a non-linear section of the 
standard curve cannot be accurately quantified. The crucial assumption for an 
accurate quantification is that amplification efficiency of both the reference and 
sample reactions are very close each other (normally within 5%), and ranging between 
90% and 110% (460).  
With absolute quantification, therefore, serial dilutions of the target should be 
run as well and conditions of the reaction should be optimized to ensure the maximal 
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equivalence of the amplification efficiencies between target sample and control 
template (462). One hundred percent efficiency implies perfect doubling of amplicon 
each cycle. If the efficiency is significantly less, this implies the reaction is being 
slowed, condition which could depend on inhibitors present in the reaction mix or 
suboptimal primer sets or reaction conditions. By contrast, efficiencies significantly 
above 100% typically indicate experimental error which can be due to miscalibrated 
pipettors, contamination or formation of primer-dimer products. In order to exclude 
possible contamination of the reagents, it is good practice to add at least two no 
template control (i.e. samples containing only reagent without target and sample 
template) in each run, which should not produce a quantifiable fluorescence signal. 
 
3.3.2.4.2 Relative quantification 
In contrast with the absolute quantification method, relative quantification 
does not express the final results in absolute number of copies or length of the 
telomere sequences, but as a ratio between the concentration of the target template in 
the sample of interest and that in a reference sample (463). Therefore, relative 
quantification does not require a calibration curve or standards with known 
concentrations.  
The levels of target template across multiple samples is obtained by 
comparing their final Ct values with that obtained from the reference and reporting 
results as fold-changes relative to this reference. Thus the mentioned methods can be 




Figure 3.17 ΔCt method of relative quantification. 
To compare the concentration of the TG in sample A and B their Ct values are 
normalised for the Ct value of the TG in a reference sample, which remains the same 
in different PCR reactions. Therefore, the final concentration of the TG in sample A is 
provided by the difference between Ct value of TG in A and Ct value of TG in the 
reference sample (ΔCtA). Similar calculation is used to establish the concentration of 
sample B (ΔCtB). The different concentration of the TG between sample A and B will 
be then provided by the difference of their Ct values normalised to the reference 
sample. 
 
Importantly, introducing the same reference in multiple reactions will allow 
standardization of results between difference PCR runs. But the relative quantification 
procedure requires a further normalization step which introduces more complexity in 
the analysis of the final results. To achieve optimal relative expression results, 
appropriate normalization strategies are required to control for experimental error 
(466;467), and to ensure identical cycling performance during real-time PCR. These 
errors can be due to minor differences in the amount of starting DNA/RNA, quality of 
the DNA/RNA, or difference in PCR amplification efficiencies between samples 
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(468). Therefore, to ensure identical starting conditions, the relative expression data 
have to be equilibrated or normalized according to one of the following variables: 
 sample size/mass or tissue volume 
 total amount of extracted RNA or total amount of genomic DNA 
 reference ribosomal RNAs or reference messenger RNAs (mRNA) 
 artificial RNA or DNA molecules (= standard material) 
Normally, a “housekeeping” gene (HKG) is selected for this further normalization 
(Figure 3.23). As the HKG expression is expressed at constant levels between 
different samples or present in single copy within the genome, variation in its amount 
reflects variations in the concentration of the original RNA/DNA.  
 
Figure 3.18 ΔΔCt Method of relative quantification 
This method introduces a further correction which normalises results for the 
concentration of an housekeeping gene in the target samples as well as in the 
reference sample. As the HKG should be expressed at constant levels between 
different samples or present in single copy within the genome, changes in the 
concentration of the HKG gene will inform on possible differences in the amount of 
starting DNA/RNA, quality of the DNA/RNA, or PCR amplification efficiencies 
between samples within the same run or between different PCR runs. 
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Selection of an appropriate HKG represents one of the most sensitive parts in 
the set-up of a PCR experiment, particularly when we want to explore different levels 
of gene expression between different tissues or in different experimental conditions. It 
is expected that modest changes in the HKG expression between different tissues or 
before and after any specific treatment can dramatically affect the quality of the 
normalization and, subsequently, the final results of the experiment (Figure 3.23). 
 






Aim - to evaluate the difference in expression of a TG between two samples (A and B) 
assayed in 2 different days.  
Step 1 - Obtain the Ct values of the reference gene (Ref) as well as of the TG in 
the sample A (day 1) and B (day 2) (Figure 3.24A.A and 3.24.A.B, split in two 













Figure 3.19A Establshing Ct values. 
Each PCR run will provide the Ct values of the TG in sample A (A) and B (B) as well 
as that of the reference sample. 
 
 
Step 2 – Normalise TG for Ref.  
As Ref is the same sample in both reactions, its final Ct value should be the 
same in the run including sample A and B. Therefore, correction for Ref will allow 
adjustment for possible difference in the PCR instrument setting between the pre- and 
post-treatment runs. Moreover, it will inform on how many folds the expression of the 
gene of interest differs between sample A and sample B compared to the constant 
reference (Figure 3.24B).   












the Ct values of the 
TG in sample A 
and B, the 
difference between 
samples of the TG 
is calculated with 





Step 3 - Apply a further correction for the levels of expression of the HKG. 
 
Figure 3.24C From ΔCt to ΔΔCt. 
The same samples A and B are run a second time together with the reference sample 
to establish the concentration of the selected HKG. Normalization of the ΔCt for the 
TG in sample A and B with the ΔCt for the HKG in the same samples will allow 
correction for possible difference in amplification efficiency or original DNA 
concentration between sample A and B. 
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Assuming levels of expression of the HKG are not affected by treatment, a 
possible difference of the HKG levels following treatment will suggest that there was 
a change in one of the following steps between the two time points:  
a) the quality of the extracted mRNA  
b) the efficiency of the reverse transcription or  
c) the total cDNA concentration  
As each of these factors could equally affect levels of TG expression, 
correction of TG for HKG will allow correction of the final results for all these 
possible sources of variability. 
 
In the LTL PCR-based assay, the most widely used HKG are: β-globin, 
GAPDH and 36B4 (71;82;83). These genes are selected not because their levels of 
expression are constant in different experimental conditions, but because they are 
present in single copy in the genome. Therefore, their Ct values at the end of a PCR 
run provides information on the amount of genomes (e.g. the original amount of cells) 
that were present in the original sample. Consequently, normalization of the telomere 
results for these genes allows quantification of the average amount of telomere 
repetition per copy of genome (i.e. per cell) in the sample.  
Selection of one specific HKG to be used in the PCR assay depends on the 
level of experience of each laboratory. However, the amplification efficiency of the 
HKG reaction should always completely overlap with that of the telomere reaction. 
Selection of primers, the PCR setting and the concentrations of reagents should be 
optimized to achieve this goal. The amplification efficiency of the HKG and telomere 
reactions is commonly checked by standard curve analysis (71;82;83). As previously 
mentioned for the absolute quantification, serial dilutions of a randomly selected 
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sample are prepared and the telomere and HKG reactions are performed. Following 
amplification, a standard curve for the telomere and HKG is generated by plotting the 
log of the initial template concentration against the Ct generated for each dilution. The 
value of R
2
 will inform on the amplification efficiency of both reactions. This will 
allow comparison of the amplification efficiencies between HKG and telomere 
reactions, with optimisation of the primers and PCR setting. Furthermore, it will 
inform on whether the same amplification efficiency is maintained at different 
concentrations of the templates during the HKG and telomere reaction.   
3.3.2.4.3 Mathematical models of relative quantification 
The relative expression of a target template in relation to the reference gene, 
can be calculated using the comparative threshold method, also known ‘delta delta 
Ct’ (ΔΔCt) values (465). With this method, the amount of TG is estimated by 
calculating the number of folds it differs from the reference gene and normalizing this 
ratio for the amount of HKG in the sample. Therefore the formula used to obtain the 





where   
ΔΔCt =  ΔCt(sample) – ΔCt(reference) 
 
and ΔCt is the difference between Ct of the TG and that of the HKG in both target and 
reference samples (465;469)(Figure 3.24C). 
The number “2” of the formula relates to the assumption that, at each cycles, 
the amount of product doubles the original amount of the template. Subsequently, to 
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obtain accurate results with this formula it is crucial that the amplification efficiency 
of the target (e.g. telomere) and HKG reactions are the same and constant between 
different samples (possibly above 90%) (465). However, several conditions may 
cause significant variations in the PCR efficiency between different samples, possibly 
resulting in inaccurate estimation of gene expression levels with this method of 
quantification. The error can be calculated as a function of the PCR efficiency and the 
cycle number according to the formula: 




) x 100)] – 100  
where “E” represents the efficiency of PCR and n the cycle number. Therefore, if the 
PCR efficiency is only 0.9 instead of 1.0, the resulting error at a threshold cycle of 25 
will be 261%. The calculated expression level will be 3.6-fold less than the actual 
value. Thus, the ΔΔCt method should only be chosen if we are confident that the PCR 
efficiency of the TG and HKG are the same and do not change between samples, or if 
the difference in expression levels is sufficiently high to tolerate the resulting error. 
Changing PCR efficiencies between samples can result from several factors 
including different concentrations of PCR inhibitors or enhancers as well as variations 
in the RNA/DNA pattern extracted. As the efficiency evaluation is an essential marker 
and the correction is necessary for accurate real-time gene quantification (470-473), 
researchers have introduced the amplification efficiency parameter in the “delta delta 
Ct” or comparative threshold cycle method.  
The efficiency corrected calculation model, based on one sample (474) is 
expressed as: 





     (EHKG)






while the efficiency corrected calculation model based on multiple samples is reported 
as (462): 
 
   (ETG)
ΔCt TG (MEAN reference – MEAN sample)
 
   (EHKG)
ΔCt HKG (MEAN reference – MEAN sample)
 
 
The PCR amplification efficiency can be estimated by the standard curve 
method or by mathematical calculations which extrapolates this information from the 
slope of the exponential phase of the reaction. With the standard curve approach, 
efficiency can be determined by preparing a regression plot reporting on the x axis a 
serial dilution of the unknown and reference samples and on the y axis the 
corresponding Ct values. From this plot the amplification efficiency is provided by 
the following equation (453;475): 
E = 10 
[–1/slope] 
 
But preparing a dilution series of each target sample is laborious, costly (as it 
increases the amount of reagents and templates to be used in each PCR reaction), and 
takes time. To overcome this limitation, a single dilution series composed of a pool of 
all unknown RNA/DNA samples can be added to each PCR run. As this standard 
curve is obtained from a mixture of all samples run in the PCR reaction, the resulting 
“E” value should partially reflect all possible ‘positive and negative impacts’ on 
kinetic PCR efficiency. Although this solution can reduce time and cost of the 
reagents, it is still necessary to introduce a standard curve in each PCR reaction to 
estimate the amplification efficiency of each run and account for its possible changes 
between different runs.  
For this reason, a novel and more reliable method to calculate the 
amplification efficiency, known as the comparative quantification method, was 
proposed by the manufacturers of the RotorGene, a Real Time Theramal Cycler 




measurement of the relative fluorescence increase in the exponential phase of the PCR 
reaction and allows automatic determination of the real-time PCR efficiency sample-
by-sample, obviating the need for standard curves to generate efficiencies and 
controlling for efficiency differences between reactions (475). For each sample, a 
linear regression plot is drawn from at least four data points of the exponential 
amplification phase. The slope of the regression line represents the PCR efficiency for 
that sample (476;477). However, the investigator had to decide which fluorescence 
data of the exponential phase to include in the analysis and which to omit. If fitting is 
performed by eyes, its final result could be highly operator dependent as the growth in 
fluorescence rises quickly in exponential phase and it remains difficult to identify the 
exact point at which the fluorescence emerges from the background (the Ct value). 
Therefore, the lower threshold point of the fitting curve may inadvertently be set 
outside the exponential phase of product amplification, drastically influencing the 
slope of the curve (Figure 3.25).  
 
Figure 3.20 Estimation of amplification efficiency from the exponential phase of 
the amplification. The arbitrary estimation of the first point to include in the fitting 
line used to calculate the amplification efficiency can result in significant changes in 
the estimated amplification efficiency. In this example, the use of blue points rather 
than the red point results completely different slopes curves, which correspond to two 




To obviate this limitation, it was decided to use the second derivative of raw 
fluorescence values to help calculate the point at which the exponential phase of 
amplification begins (472;475). This point, termed the Take-Off Point (TOP), is 
equivalent to the Ct value and therefore used also to calculate the difference in the 
template amount between the reference and the target samples. In the Rotor-Gene 
software package the TOP is arbitrarily described as the point 80% below the second 
derivative plot peak (478)(Figure 3.26).  
 
Figure 3.21 Comparative quantification method. 
From the second derivative of the raw fluorescence data it is possible to estimate the 
maximum exponential growth of the product (peak of the parabola). The TOP, which 
is 80% below of the peak level, represents the point at which the exponential phase of 
the amplification begins. It is used to define the Ct of each sample and it marks the 
first of the four consecutive points used to calculate the amplification efficiency 




The first four fluorescent readings following the TOP in the second derivate 
plot are transposed into the original amplification plot and used to calculate the 
amplification efficiency during the exponential phase (478). In this part of the PCR 
reaction, the increase in fluorescence (F) is represented by the exponential growth 
model: 
Fn+1 = Fn * (E)  
where “n” is the cycle number and “E” is the measure of the efficiency of the reaction 
(amplification value). Therefore, by rearranging the formula it is possible to calculate 
an observed amplification (En) of each point included in the exponential phase of a 
reaction:  
(En) = Fn+1/Fn. 
Averaging the amplification over the first four readings following the TOP 
produces the amplification value of the sample (Es). Outlier amplifications are 
removed to account for noise in background fluorescence (478).  
In conclusion, using the comparative quantification method, the amount of 
gene product in any given sample relative to a designated reference sample is 
calculated by rearranging the comparative threshold cycle formula as follow: 
 
Relative Quantity (RQ) = (Es)
 ΔTOP (Reference – Sample)
.  
 
The RQ values for the TG are then transformed into a ratio of the HKG values for 
each individual sample: 
(ETG)
ΔTOP TG (Reference – Sample)
 
    (EHKG)





3.3.2.5 Protocol of LTL Assay 
In this PhD, LTL was measured with a PCR based assay in accordance with 
the original technique reported by Cawthon (82) and adapted for the Rotor-Gene 6000 
machine (479), unless otherwise specified. In each sample, the quantity of telomere 
repeats and the amount of genome were determined in comparison to a reference 
sample in two different quantitative PCR reactions. The single copy gene (SCG) 
36B4, which encodes acidic ribosomal phosphoprotein PO and is located on 
chromosome 12 (480), was used as HKG to inform on the amount of genome present 
in each sample. A null template control (NTC) sample was added to each SCG and 
telomere reactions to check for non-specific amplification (i.e. contamination of the 
reagents, not-specific product formation). Similarly, a reference sample, obtained by 
mixture of randomly selected clinical samples from a study previously conducted in 
our lab, was used to normalize SCG and telomere results and check consistency of the 
PCR reaction conditions between different runs.  
The primers used for the telomere and the SCG amplification were as in 
Cawthon's report (82): 
telomere forward: GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT 
telomere reverse: TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA  
SCG forward: CAGCAAGTGGGAAGGTGTAATCC 
SCG reverse: CCCATTCTATCATCAACGGGTACAA.  
Telomere primer pairs were designed by Cawthon to specifically amplify the 
telomeric hexamer repeats without generating primer-dimer products (82).  
DNA polymerase can extend each primer from its 3′-end when it is hybridized 
to telomere hexamer repeats but not when it is hybridized to the other primer. Six 
bases on the 5′-end of each primer are not complementary (base unpaired) with the 
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telomere sequence, even when the rest of the primer is optimally hybridized. The 
complements of these 5′-sequences are generated at the 3′-ends of all products that are 
completed in each cycle of the PCR, thereby blocking those 3′-ends from initiating 
DNA synthesis in the middle of telomere amplification products in subsequent cycles 
(Figure 3.27). SCG primer design was similar to those reported in other PCR 
applications where the 36B4 gene was used as the HKG. 
Figure 3.22 Telomere primer design.  
(A) Annealing of primers to genomic DNA. The telomere forward primer can 
hybridize to any available partially complementary 31 bp stretches along the strand 
of telomeric DNA oriented 5′→3′ toward the centromere. The telomere reverse primer 
can hybridize to any partially complementary 33 bp stretch along the strand oriented 
5′→3′ toward the end of the chromosome. In both of these primer–template 
hybridizations, every sixth base is mismatched, however, the last five bases at the 3′-
end of the primers are perfectly matched to complementary bases in the template. 
Addition of bases by DNA polymerase begins at the 3′-ends of the annealed primers 
and proceeds in the direction of the large arrows. (B) Annealing of primers to each 
other. The strongest possible hybridizations of the primers to each other involve a 
repeated pattern of six bases containing four consecutive paired bases followed by 
two mismatched bases, an example of which is shown here. The 3′-terminal base of 
each primer cannot form a stable base pair with the base opposite it, thereby blocking 
addition of bases by DNA polymerase. Adapted from Cawthon RM. Nucleic Acids 




Reaction conditions and concentration of the primers were similar to those 
described by Cawthon (479). In the telomere PCR, primer concentrations were 
135/900nM (forward/reverse) and the cycling profile: 95°C incubation for 10min, 
followed by 22 cycles of 95°C for 15s and 58°C for 120s. In the SCG PCR, primer 
concentrations were 300/500nM and the cycling profile: 95°C incubation for 10min, 
followed by 30 cycles of 95°C for 15s and 58°C for 60s. For both the telomere and the 
SCG PCR the final reaction volume was 25μl consisting of 1× SYBR Green, 1× 
qPCR mix (2× SensiMix NoRef DNA kit, Quantace, London, UK), 30ng of template, 
and the respective primer concentrations. The specificity of all telomere and SCG 
amplifications was determined at the end of every run by melting curve analysis. The 
presence of a single peak confirmed the amplification of a single and specific 
template. 
The comparative quantification method was used to generate the final results. 
At the end of the telomere reaction the number of telomere repeats in each sample was 
calculated using the formula: 
 
Telomere (T) = (Etel)
ΔTOP tel (Reference – Sample)
 
 
while the amount of genome presents in the same sample was estimated with the SCG 
reaction according with the formula:  
 
SCG (S) = (ESCG)
ΔTOP SCG (Reference – Sample)
 
 
The final results were obtained from the ratio between telomere and single 
copy gene (T/S) which represents the average number of telomere repeats per copy of 
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genome in the sample. Every sample (including reference and NTC) was run in 
duplicate and the average of the two measurements was used for statistical analysis. If 
at the end of the telomere or SCG reaction one sample presented a standard deviation 
> 0.2 between duplicate, both reactions were repeated for that specific sample. 
Similarly, when the NTC identified non-specific amplifications or the standard 
deviation between duplicates of the reference sample was >0.2, the telomere and SCG 
reactions were repeated for all samples included in the run.  
Validation of this PCR assay was previously performed by measuring 32 DNA 
samples of subjects aged 24 to 54years from the Cardiovascular Sciences Department, 
Leicester University DNA bank with both the standard Southern Blot (providing the 
size of TRF) and the currently described PCR-based method (479). The good 
correlation between relative T/S ratios measured by quantitative PCR and relative 
TRF lengths measured by the traditional Southern blot approach confirmed that the 
new PCR method does indeed measure relative telomere lengths. 
The coefficient of variation for each set of samples analysed in this thesis are 
reported in the single studies. 
3.4 Colorimetric assays 
In study 2, a symmetrical sandwich ELISA was used to determine the serum 
levels of insulin while lypopolisaccaride (LPS) was measured using a Limulus 
Amebocyte Lysate (LAL) colorimetric assay.  
3.4.1 Insulin assay  
ELISA’s combine the specificity of antibodies with the sensitivity of simple 
enzyme assays, by using antibodies coupled to an easily assayed enzyme (481). One 
of the most useful of these immunoassays is the two antibody “direct sandwich” 
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ELISA, which allows measuring the concentration of a specific compound in 
unknown samples. This ELISA is fast and accurate, and if a purified antigen standard 
is available, it can be used to determine the absolute amount of antigen in an unknown 
sample. The “direct sandwich” ELISA requires two antibodies which bind epitopes on 
the antigen (compound measured) that do not overlap. This can be accomplished with 
either two monoclonal antibodies that recognise discreet sites on the antigen or one 
batch of affinity-purified polyclonal antibodies (482).  
To utilize this assay, one antibody (the “capture” or first antibody) is purified 
and bound to a solid phase typically attached to the bottom of a microtitration well. 
The unknown sample is added to the well and left to incubate for few minutes/hours. 
During incubation, the target antigen in the sample reacts and complexes with the 
antibody bound to the solid phase. A second antibody (the “detection” antibody) is 
added during or at the end of this incubation period. This second antibody is 
conjugated with an enzyme and reacts with a separate antigenic determinant of the 
target molecule, thus completing the “sandwich”. Following the incubation of the 
secondary antibody, various washing steps allow removing the unbound secondary 
antibody. To determine the amount of target antigen complexed between the two 
antibodies, the substrate specific for the enzyme labelled to the detection antibody is 
added to the reaction. Ideally the enzyme substrates should be stable, safe and 
inexpensive. Substrates are colourless and are converted by the enzyme, to a coloured 
product, e.g. blue.  The final addition of an alkaline phosphatase converts the blue 
colour into yellow, making it possible the estimation of the optical density of the 




Figure 3.23 Direct Sandwich ELISA 
The sample is added to a well coated with specific antibodies which bind the antigen 
of interest. Antigen is “captured” by coating antibodies during incubation. The 
unbound antigen is washed away and enzyme conjugated second antibodies directed 
against a different epitope of the antigen are added. Binding of the second antibody 
during incubation completes the “direct sandwich”. Following a second washing step 
necessary to remove the unbounded second antibody, a colourless substrate is added 
and is converted to coloured product by the antibody-bound enzyme. The colour is 
then quantified in a spectrophotometer. 
 
Assay: All samples were thawed in a 4°C fridge overnight. Before proceeding 
with the assay the enzyme conjugated and wash solution provided with the kit were 
properly diluted as follow. 1 volume (1ml) of the 11x solution containing peroxidase 
conjugated mouse monoclonal anti-insulin antibodies (enzyme conjugated solution) 
was diluted in 10 volumes (10ml) of the enzyme conjugated buffer to obtain the 
correct amount of “working enzyme solution” necessary for a 96 well plate.  
Similarly, 1 volume (1ml) of the 21x concentrated washing buffer was diluted in 20 
volumes (20ml) of redistilled water to obtain the working wash solution enough for a 
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96 well plate. Six calibrator solutions containing serial dilutions and known 
concentrations of recombinant human insulin were added to each well in order to 
obtain a calibrator curve. This curve allows understanding the concentrations of 
insulin which correspond to different levels of absorbance. Therefore, by comparing 
the value of absorbance of each sample with the values obtained from this calibrator 
curve it is possible to obtain the absolute values of insulin concentration in the 
interrogated sample.  
25 μl of unknown samples and of each calibrator solutions were added in 
duplicate to a 96 well plate coated with mouse anti-insulin monoclonal antibodies. 
100 μl of working enzyme solution (containing the secondary mouse monoclonal 
antibodies specific for a different epitope on the insulin molecule and conjugated with 
the peroxidase enzyme) was added to each well followed by incubation on a plate 
shaker (700-900 rpm) for 1 hour at room temperature (18-25°C). During this 
incubation the insulin molecules of the sample complex with the antibodies bound to 
the microplate and with the secondary antibody dispersed in the working enzyme 
solution. After incubation, the reaction volume was discarded by inverting the 
microplate over a sink. 350 μl wash solution was added to each well to remove the 
unbounded secondary antibodies. The wash solution was discarded by firmly tap 
several times against absorbent paper to remove the excess of liquid. This washing 
step was repeated 5 times. Once all the excess secondary antibody was removed, 200 
μl of solution containing 3,3’5,5’- tetramethylbenzidine base (TMB) was added into 
each well to detect the bounded secondary antibody. The TMB solution was left in 
each well for 15 minutes at room temperature to allow complete reaction of all 
bounded enzymes with the detection solution. During this reaction, samples acquired 
a blue colour, the intensity of which is directly related with the amount of enzyme 
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(and secondary antibody) present in the each well. At the end of the incubation, 50 μl 
of a solution containing 0.5 M of H2SO4 was added to the wells to stop the enzymatic 
reaction. The plate was placed on a shaker for 5 seconds to ensure complete mixing. 
The addition of the stop solution shifts the colour from blue to yellow in a 
concentration dependent fashion. Plates were then read at an optical density of 450nm 
using a Dynatech MRX plate reader (Acterna, Aldermaston, UK) with the standards 
plotted as a sigmoid curve (Revelation software). Samples with a final insulin 
concentration ≥200 mU/l were diluted 1:10 and the assay was repeated. 
3.4.2 LPS assay 
The use of LAL for the detection of endotoxin evolved from the observation 
by Bang that a Gram-negative infection of Limulus polyphemus, the horseshoe crab, 
resulted in fatal intra-vascular coagulation, even if the bacteria were killed (483). 
Levin and Bang later demonstrated that this clotting was the result of a reaction 
between endotoxin and a clottable protein in the circulating blood cells (amoebocytes) 
of Limulus (484;485). Following the development of a suitable anticoagulant for 
Limulus blood, they prepared a lysate from washed amebocytes which was an 
extremely sensitive indicator of the presence of endotoxin. This led to the production 
and commercialisation of the LAL assay for endotoxin detection in biological 
samples, which was approved with guidelines by the FDA in the 1987 (486).  
According with this assay, Gram-negative bacterial endotoxin present in the 
samples catalyzes the activation of a proenzyme in the LAL. The initial rate of 
activation is determined by the concentration of endotoxin present. The activated 
enzyme catalyzes the splitting of pNA from the synthetic colourless substrate Ac-lle-








This is measured photometrically at 405-410 nm, after the reaction is stopped 
with stop reagent. The correlation between the absorbance and the endotoxin 
concentration is linear in the 0.1-1.0 EU/ml range. The concentration of endotoxin in 
a sample is calculated from the absorbance values of solutions containing known 
amounts of endotoxin standard. 
Assay: All manual steps of the LPS assay were performed under a sterile hood, 
using endotoxin-free water (LAL Reagent Water, provided with the kit) and sterile 
pipettes in order to minimise the risk of endotoxin contamination. The test was 
performed using 96 well plates which were pre-equilibrated at 37
○
C in a heating block 
adapter. Meanwhile, four dilutions of the lyophilized endotoxin at a standardized 
concentration provided with the kit were prepared for the determination of the 
standard curve. The lyophilized endotoxin was reconstituted by adding 1 ml of pre-
warmed LAL Reagent Water. As the concentration of lyophilized endotoxin may vary 
from 15-40 EU depending on the lot number, the actual concentration of endotoxin 
after this step corresponded to the value stated on the certificate analysis. For 
example, if the value reported on the vial of lyophilized endotoxin was 20 EU, after 
reconstitution with 1 ml of LAL Reagent Water, the concentration of the endotoxin 
stock was 20 EU/ml. The first dilution containing 1.0 EU/ml was prepared in a 
suitable container by diluting 0.1 ml of the endotoxin stock solution with (κ-1)/10 ml 
of LAL Reagent Water, where ‘κ’ equals to the concentration of endotoxin in the 
stock solution. For example, if κ=20 EU/ml, then 0.1ml of κ was diluted in 1.9ml of 
LAL Reagent Water, (20-1)/10ml, to obtain the first dilution containing 1.0 EU/ml of 
Proenzyme  Active Enzyme 





endotoxin. Following, 0.5 ml of this 1 EU/ml solution were transferred in a new 
container and 0.5 ml of LAL Reagent Water was added to obtain the second 
endotoxin dilution (0.5 EU/ml). Similarly, 0.5 ml of the 1 EU/ml solution was 
transferred in a vial containing 1.5 ml of LAL Reagent Water to obtain the third 
endotoxin dilution (0.25 EU/ml). Finally, 0.1 ml of the 1 EU/ml solution was 
transferred in a vial containing 0.9 ml of LAL Reagent Water to obtain the last 
dilution of endotoxin (0.1 EU/ml). Once all dilutions were prepared, 50 µl of the 
target sample or of the dilution series were added in duplicate into the appropriate 
microplate well. Each series contained a blank well control, where the samples or 
dilutions were substituted with 50 µl of LAL Reagent Water.  
At time T=0, 50μl of LAL were added to the first column of microplate wells 
using a multi-channel pipettor and reagent reservoir. The sequence of column as the 
LAL is added was taken into account in order to be consistent in the order of reagent 
addition from row to row, and in the rate of pipetting. Once the LAL was dispensed 
into all microplate wells containing samples (or standards), the microplate was briefly 
removed from the heating block adapter and repeatedly tapped on its the sides to 
facilitate mixing. The plate was returned to the heating block adapter and covered. 
Following 10 minutes, 100 μl of substrate solution (prewarmed to 37°C ± 1°C) were 
added. The substrate solution was pipetted following the same order of the LAL and 
trying to maintain a consistent pipetting rate. Once completed the addition of the 
substrate solution, the microplate was briefly removed from the heating block adapter 
and repeatedly tapped to facilitate mixing. The plate was then returned to the heating 
block adapter and covered. The addition of the substrate caused a progressive change 
in the colour of the solution, which became yellow. Following 16 minutes, 50μl of 
stop reagent was added maintaining the same pipetting order as in of LAL and 
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substrate addition. The plate was again removed from the heating block and tapped to 
allow proper mixing. The absorbance of each microplate well was read at 405-410nm, 
using distilled water to adjust the photometer to zero absorbance.  
Serum inhibition of LPS detection with the LAL tests is possible (487-494), 
particularly when using the colorimetric assay. This inhibition results in a lower, final 
Δ absorbance, indicating lower levels of endotoxin than what may actually be present 
in the test sample. Therefore, the lack of product inhibition should always be tested. 
In this thesis, the possible inhibition of the LAL reaction was determined for each 
sample using the method reported in the kit instruction. To verify the lack of product 
inhibition, an arbitrary dilution (1:5) of test sample was spiked with a known amount 
of endotoxin (0.4 EU/ml). To prepare a 0.4 EU/ml endotoxin solution in the diluted 
sample, the 1.0 EU/ml solution was diluted 1:2.5 using the diluted sample as the 
diluent. The spiked solution was assayed along with the unspiked samples and their 
respective endotoxin concentrations were determined. If the difference between these 
two calculated endotoxin values was not equal to the known concentration of the 
spike ± 25%, this suggested the presence of inhibitory factors to the LAL reaction in 
the sample and the sample was further diluted before the LPS assay. 
Using this method, the coefficient of variation obtained from a randomly 
selected set of 30 samples of study 2 which were run in two different days was 3.27%. 
 
3.5 Statistics 
All data are expressed as mean±SD unless otherwise stated. A number of 
parametric and non-parametric tests were used in this thesis. Parametric tests were 
used whenever possible (i.e when the data were normally distributed, or could be 
easily transformed to normality). If the data could not be easily transformed, non-
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parametric tests were performed. Normality of the data was assessed by plotting 
histograms and applying the Kolmogorov-Smirnov test of normality. Stata version 8 
and SPSS version 10 analysis packages were used for the analysis of the data. 
Parametric tests used were independent t-test, paired t-test and one-way analysis 
of variance (ANOVA). In the case of studies where the means of more than two 
variables were compared by t-tests a Bonferroni correction was applied. This states 
that when 3 or more variables are considered the resultant “p value” was multiplied by 
all possible comparisons. For example, if 3 groups were used the outcome of A vs. B 
vs C would be multiplied by 3 (as it would be possible to compare A:B, A:C and B:C) 
and only if the result was still less than 5% it would be considered statistically 
significant. In chapter 4, the rate of LTL shortening was estimated as conditional to 
the baseline measure. 
In all studies significance was defined as α-value of less than 5%, indicating 
that the chance of the null hypothesis still being true even though the difference is 
greater than the critical value was less than 5%.  
 
3.6 Ethics  
All studies presented in this thesis were approved by local research Ethics 
Committees. As study 4 and 5 involved recruitment of participants in different parts 








In humans, a common approach used to define the impact of cumulative 
inflammation on biological pathways involved in disease evolution relies on selection 
of chronic diseases characterized by high levels of inflammation. For example, 
diabetes (495;496), PD (497) and rheumatological diseases (498) have been used as 
models to investigate the possible inflammatory mechanisms involved in the initiation 
and evolution of CVD. While this approach can be considered reasonable, it does not 
take into account the variable burden of inflammation which characterizes the 
different phases of resolution and reactivation of the underlying disease.  
Circulating inflammatory markers can inform on acute but not chronic 
inflammatory burden. For example, CRP is the most common inflammatory indicator 
used in large epidemiological studies but a statement of the AHA and CDC 
recommends evaluation of its circulating levels only in metabolically stable patients, 
underscoring its prognostic limitations in patients with chronic inflammatory diseases 
(499). In such conditions, CRP may be more affected by fluctuation of the underlying 
disease activity than providing information on the cumulative inflammatory burden 
(254-262;497). For example, in patient with PD, the dynamic states of exacerbation 
and remission, which can be described in terms of patterns of disease progression and 
regression, are likely to influence circulating levels of inflammatory biomarkers. In 
this case, a single measure of CRP does not provide information on the cumulative 
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inflammatory damage related to the oral infection, but will reflect the state of 
inflammatory activation at the time of blood collection. 
Prolonged exposure to high levels of inflammation stimulates adaptive changes 
which generally occur at the expense of many other physiological processes and 
cannot be sustained without adverse side effects, including local tissue remodelling 
and destruction. Therefore, an estimation of the cumulative inflammatory burden can 
be obtained by measuring the stage of target organ damage. For example, in patients 
at high CV risk, the inflammatory burden resulting from the lifelong exposure to 
common CV risk factors can be estimated by measuring the cIMT (marker of vascular 
remodelling) (500). Similarly, the estimation of the amount of periodontal support 
around the tooth by probing assessment (clinical attachment levels, CAL) is thought 
to reflect the cumulative effect of repeated episodes of activation and remission of the 
underlying inflammatory process (501). 
CAL is normally estimated by addition of the probing pocket depth score to the 
recession score. Probing pocket depth is measured from the free gingival margin to 
the base of the sulcus or pocket (Figure 4.1). As the free gingival margin can change 
due to acute inflammatory modifications of the local tissue due, for example, to tissue 
swelling, probing depth alone do not provide an accurate means to estimate the 
cumulative gingival damage due to repeated episodes of disease progression and 
regression. Levels of gingival recession, by contrast, are estimated measuring the 
distance between cemento-enamel junction and gingival margin (Figure 4.1). 
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Figure 4.1 Estimation of Clinical Attachment Level (CAL). 
Clinical attachment level is obtained from the addition of the probing pocket depth 
score (distance between the free gingival margin and base of pocket) to the recession 
score (distance between cemento-enamel junction – CEJ – and free gingival margin). 
Adapted from web image. Original image available for download at: 
http://www.newyork-dentalmalpractice.com/glossary/periodontal-disease/. 
 
In case of tissue overgrowth, the gingival margin is coronal to the cemento-
enamel junction and the recession score assumes negative values. On the other hand, 
in case of gingival tissue retraction compared to the cemento-enamel junction the 
recession score assumes positive values. In this study, CAL was used to inform on the 
lifetime exposure to the oral infective-inflammatory process.  
The primary aim of the study was to evaluate LTL in patients affected by 
periodontitis (exposed to chronic inflammation) compared to controls. The secondary 
aim was to ascertain the degree of association between measures of chronic 




4.2 Specific methods 
4.2.1 Population  
In a case control study design, 563 participants were recruited among subjects 
referred to the UCL Eastman Dental Institute in London between 2002 and 2006. 
Interviews were used to obtain participant's medical history (including smoking 
history) and current or previous use of medications. After this preliminary screening, 
all subjects with medical disorders other than PD (e.g. cancer, type 2 diabetes, 
hypertension and major CV/endocrine diseases), history and/or presence of other 
infections, systemic antibiotic treatment in the preceding 3 months, as well as those 
currently undertaking any medication were excluded from the study.  
All recruited patients underwent a clinical periodontal examination performed by 
a trained periodontist. Full mouth measures of probing pocket depth (PPD), recession 
(REC; measured as distance from the cemento-enamel junction to the gingival 
margin), and CAL (measured from the formula CAL=PPD+REC) were obtained at six 
sites per tooth in all participants. Following oral screening, patients were divided in 
two groups:  
 Cases: individuals diagnosed with severe generalized PD, defined by probing 
pocket depths greater than 6 mm and marginal alveolar bone loss > 30% with 
at least 50% of teeth affected (254).  
 Controls: subjects without any sites PPD and CAL ≥ 4mm after a basic 
screening periodontal examination or radiographic evidence of bone loss.  
Cases were further divided into those suffering from aggressive or chronic PD 
according to the American Academy of Periodontology (AAP) 1999 Consensus 
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classification (289). All patients gave written informed consent and the study was 
reviewed and approved by the Eastman/UCLH joint ethics committee. Several 
features make this population unique, such as:  
a. Consecutive recruited patients using strict selection criteria which allows 
excluding possible confounders of the relationship between LTL and 
inflammatory burden. 
b. The large availability of data on a wide range of factors known to influence 
measures of LTL, allowing extensive adjustments and the independent role 
of many parameters to be assessed.  
c. The oral examination was performed by an experienced periodontist, 
according to the most recent guidelines. 
 
4.2.2 Biochemical tests 
Before the dental examination, blood samples were collected from all patients 
for biochemical, oxidative stress and LTL assays. Leukocyte counts, lipid profiles, 
and glucose levels were assessed by standard biochemical testing. A high-sensitivity 
immunoturbidimetric assay (Tina-Quant CRP assay performed on a Cobas Integra 
analyser; Roche Diagnostics, inter-assay coefficient of variation = 2.1% on 20 
randomly selected samples, lower detection limit 0.03mg/L) was used to measure 
serum levels of high-sensitivity CRP, while levels of interleukin-6 were measured by 
a high-sensitivity enzyme-linked immunosorbent assay (Quantikine HS; R&D 
Systems, lower detection limit 0.038pg/mL). Intra-assay coefficient of variation for 
the IL-6 measures ranged from 1.9 to 4.9% (each sample in duplicates) while inter-
assay coefficient of variation was 4.1% (one sample in duplicate in each plate).  
162 
 
4.2.3 Oxidative stress assays 
In this study, D-ROM and BAP tests were used to estimate the total amount of 
oxidative metabolites and the antioxidant potential of each sample, respectively. 
4.2.4 Preparation of the DNA samples and LTL assay 
4.2.4.1 DNA Extraction  
DNA was already extracted starting from an aliquot of 10-ml EDTA blood 
sample and using the Nucleons BACC2 kit (Nucleon Bioscience, Coatbridge, UK), as 
previously described (502). Following extraction, the DNA was diluted in TE buffer 
(10 mM Tris and 1 mM EDTA) and stored in cryovials at -80°C. 
4.2.4.2 DNA Standardization 
In each sample the concentration of DNA was standardized following the 
protocol described in the “general methods”. 
4.2.4.3 LTL Assay 
LTL were measured using the technique described and 14 randomly selected 
samples were run in duplicates on two consecutive days. There was a significant 
correlation between the measurements obtained on the two different days using linear 
regression analysis (R
2
= 0.87; P<0.001, Figure 4.2).  
Figure 4.2 Correlation between T/S 
values obtained at day 1 and day 2 in a 
subset of the samples. 
The strong linear association between 
day1 and day2 T/S ratios obtained from 
the same subset of samples confirms the 
high reproducibility of the LTL assay 





Moreover, reproducibility was also assessed with Spearman's non-parametric 
test of pair-wise correlation. The correlation of the lengths' ranking, as measured on 
the two different days, was highly significant (Spearman Coefficient = 0.97, 
P<0.001). The coefficient of variation of the T/S ratios in the repeated measurements 
of the same sample was 3.15%, significantly lower than that documented by Cawthon 
in his original report (5.6%) (82). 
4.2.5 Statistical analysis 
SPSS (version 17, Windows) was used for all analyses. All data are presented as 
means and standard deviation (unless differently specified). Age and gender variables 
were used to identify comparable controls and not to perform individual case-
matching. Therefore, they were included as covariates in all analyses. Not-normally 
distributed variables were log-transformed as appropriate. Differences in continuous 
variables (including log transformed LTL) between cases and controls were tested 
with an independent t test. From values of T/S ratio, the absolute LTL measure (base 
pair, bp) was calculated for each sample by means of the regression line resulting 
from the association between T/S ratio and TRF measures, as previously described. 
When a statistically significant association was found, multiple linear regression 
models were fitted, including as covariates age, gender, ethnicity, lipid profile, and 
smoking differences. Spearman correlation analyses were used to assess the 
associations between the LTL and the various measures of systemic inflammation, 
oxidative stress, and PD in both the whole study population and the subgroups (cases 
and controls). The fully adjusted model was used to compare slopes of T/S by age in 
cases and controls. χ2 analyses were performed to detect differences in categorical 




356 participants were diagnosed with severe PD (503). The control group was 
composed of 206 individuals without clinical history or signs of PD or any other 
disease. A further analysis of the clinical characteristics of the cases identified 71 
patients with aggressive PD, while 285 subjects presented clinical features of chronic 
PD. Clinical and biochemical characteristics of the studied population are reported in 
Table 4.1, with subjects divided in case and control groups.  
Table 4.1 Characteristics of the study population  
Variables 
(mean±se) 
Controls (N=207) Cases (N=356) P value 
Age, years 46.8±0.7 46.9±0.4 0.905 
Gender, Male 88(42.5%) 165(47.8%) 0.410 
Smoking, Current 86(41.5%) 122(35.4%) 0.291 





 6.1±0.1 6.8±0.1 <0.001 
LDL, mmol/l 2.8±0.1 3.2±0.1 <0.001 
HDL, mmol/l 1.7±0.03 1.5±0.03 <0.001 
Tot Chol, mmol/l 5.0±0.1 5.3±0.1 0.017 
Triglycerides, mmol/l 1.3±0.1 1.4±0.1 0.359 
CRP, mg/l 1.3±0.5 2.1±0.2 <0.001 
IL-6, ng/ml 1.3±0.2 1.2±0.2 0.529 







T/S ratio 1.22±0.03 1.12±0.02 0.006* 
Values are reported as mean±standard error (se). * P values in fully adjusted models 
(age, gender, ethnicity, smoking and lipids). 
 
Individuals with PD had higher levels of inflammatory markers, including 
CRP (P<0.001) and leukocyte counts (P<0.001) compared to controls, independent of 
age, gender, smoking and body weight differences. Furthermore, greater total 
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cholesterol (P=0.003) and LDL cholesterol (P<0.001) levels, as well as lower HDL 
cholesterol (P<0.001), were observed in cases versus controls. Cases exhibited higher 
levels of reactive oxygen metabolites (d-ROM, P<0.001) and lower antioxidant 
potential (BAP, P<0.001) (Table 4.1). 
Mean and standard deviation of LTL in the whole cohort were 1.17 and 0.37 
T/S ratio, respectively. As expected, statistically significant inverse correlations were 
found between LTL and age (R=−0.2, P=0.001) in the whole sample, as well as in 
individual groups (cases: R=−0.1, P=0.04; controls: R=−0.2, P=0.01). Smokers had 
significantly shorter LTL compared to non-smokers (1.12±0.31 vs 1.20±0.41 T/S 
ratio; P<=0.001015). No statistically significant correlations were found between LTL 
and acute markers of inflammation, such as CRP and IL-6, nor with other biochemical 
parameters reported in Table 4.1. Notably, cases with PD exhibited shorter LTL 
compared to the controls (1.23±0.42 vs 1.12±0.31 T/S ratio; 8311±2723 vs 
7670±2632bp; P<0.001). Adjustments for age and smoking as well as for gender and 
ethnicity (variables that have previously been shown to be associated with LTL in 
cross-sectional studies) did not materially affect the observed difference between 
cases and controls (Figure 4.3).  
 
Figure 4.3 Difference of LTL 
between patient with 
periodontitis and healthy control 
Patients with PD had significantly 
shorter LTL compared to healthy 
control (P<0.001). This 
difference remained significant 
also after adjustment for age, 





In the whole population, as well as in patients with PD, a statistically 
significant negative association was found between LTL and reactive oxidative 
metabolites as assessed by d-ROM test (P=0.008, R=−0.2 and R=−0.2, P=0.03, 
respectively). Similar associations were not found in the control group (R=0.05, 
P=0.516) (Figure 4.4).  
 
Figure 4.4 Association between LTL and d-ROM. 
Scatter plot of leukocyte T/S ratios against serum d-ROM levels (R=-0.2, P=0.001), 
by Spearman Rank Correlation Test. Controls are drawn as open circles and cases as 
filled triangles. 
 
Furthermore, CAL was inversely related to LTL (Figure 4.5) and levels of 
oxidative stress metabolites in cases (P=0.003, R=−0.2 and P<0.001, R=-0.2, 







Figure 4.5 Association of CAL with LTL and d-ROM. 
There was a statistically significant association between CAL and LTL. This 
association remained significant after adjustment for age, ethnicity and gender 
(P=0.003, R=−0.2). 
 
When cases were divided into those with aggressive or chronic periodontal 
disease, both PD groups exhibited: 
a) higher serum levels of CRP (P<0.01, Figure 4.6C),  
b) higher levels of oxidative metabolites (f-ROM, P<0.05, Fig 4.6E),  
c) lower antioxidant potential (BAP, P<0.05, Figure 4.6F),  
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Figure 4.6 Differences of CRP, IL-6, LTL, d-ROM, BAP and Age between 
aggressive PD, chronic PD and healthy control groups. 
Means (± standard errors) of (A) log T/S, (B) age, (C) log CRP, (D) log IL-6, (E) d-
ROM, and (F) BAP of controls (n = 207) and chronic (n = 285) and aggressive 
(n = 71) periodontitis (PD) cases. *Statistically significant difference (P < 0.05) 
compared to controls using analysis of variance. **Comparison between chronic and 












Furthermore, while individuals with aggressive PD were younger (P<0.05, 
Figure 4.6B) than those with chronic disease and healthy controls, they presented with 
higher serum IL-6 levels (P=0.048, Figure 4.6D) than chronic cases. LTL was 
statistically significant shorter in patients with chronic PD compared to healthy 
subjects (1.12±0.31 T/S ratio, 7673±2632bp, P=0.01 vs controls), whereas no 
differences were noted between aggressive cases and controls (1.15±0.33 T/S ratio, 
7807±2632bp, P=0.201), nor between aggressive and chronic cases (P=0.571). 
Adjustments for age, ethnicity, gender, and smoking did not materially affect 
the LTL differences between groups (Figure 4.7). 
 
Figure 4.7 LTL differences between aggressive PD, chronic PD and healthy control 
groups following adjustment for age, ethnicity, gender and smoking. 
 
Figure 4.8 displays the regression plot of the predicted LTL values (obtained 
from the fully adjusted model which included adjustments for age, gender, ethnicity, 
and smoking) against the age (in years) of all participants, with regression lines and 




Figure 4.8 Scatter plot of predicted T/S ratios by age in cases and controls. 
T/S values are based on fully adjusted models - age, gender, ethnicity, smoking, lipids.  
Controls are drawn as open circles and cases as filled triangles. Filled line 
corresponds to the slope of T/S by age in cases and dotted lines to the slope of T/S by 
age in controls. P value of statistical difference in slope between cases (slope=0.002) 
and controls (slope=0.035) is 0.001. 
 
A steeper age slope was observed in cases (P=0.01) versus controls, suggesting 










This is the first report reporting an association between shorter LTL and PD. 
Diagnosis of PD was associated with shorter LTL, higher systemic inflammation and 
oxidative stress exposure compared to controls. Importantly, LTL was negatively 
correlated with total levels of reactive oxidative metabolites detected by d-ROM test 
and with severity of PD, assessed by clinical attachment level. These associations 
were independent of age, gender, ethnicity, and smoking differences. In subgroup 
analyses, LTL was shorter only in patients with chronic disease compared to controls. 
A diagnosis of aggressive PD was not related with shorter LTL, although levels of 
systemic inflammation in these patients were higher than those recorded in subjects 
with chronic disease. 
Takahashi et al previously analysed the association between PD and LTL. They 
reported no differences in LTL between subjects with and without oral disease (504). 
Their study, however, has important limitations. Firstly, the small number of patients 
might have precluded the identification of real differences in LTL as there is high 
inter-individual variability of LTL. Secondly, they enrolled only patients with 
aggressive disease, who are unlikely to have shorter LTL compared to healthy 
controls, as confirmed by our results. 
According to previous reports, PD patients showed increased levels of systemic 
inflammatory markers and oxidative metabolites (295;505;506), while their biological 
antioxidant potential was reduced compared to the control group. As inflammation 
and oxidative stress strongly affect the rate of LTL shortening (33;42;62), it is 
possible that the shortened LTL in PD patients resulted from long term exposure to 
these environmental factors. The chronic inflammatory response in patients with PD 
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induces an increase in the numbers of leukocytes in the circulation. Furthermore, the 
continuous bacterial aggression to the periodontium causes a heightened expenditure 
of inflammatory cells in the local inflammatory process, as they are sequestered and 
die in the attempt to remove the inflammatory trigger. The demands to maintain the 
numbers of leukocytes would promote an increase replication of cells up the hierarchy 
of the hematopoietic system, which ultimately involve the HSCs. The higher rate of 
replication and differentiation of HSCs determine a faster rate of telomere attrition 
due to the “end-replication problem”. This process is only partially compensated by 
telomerase, as several studies have demonstrated that, also in HSCs with residual 
enzyme activity, it is possible to detect progressive telomere attrition with subsequent 
cell divisions (507;508). Thus, the faster rate of telomere attrition in HSCs will be 
reflected in shorter telomeres of their daughter cells, the peripheral leukocytes (113).  
A further contribution to shortened LTL in patients with periodontitis might be 
provided by the increased levels of oxidative stress. Indeed, higher levels of oxidative 
stress augment the number of telomere repeats being lost per cell replication by direct 
or indirect mechanisms (33;42). The direct damage is dependent on double or single 
strand break of the telomeric DNA during cell division, which cannot be adequately 
compensated or repaired by telomerase activity (47). Furthermore, hydroxyl radicals 
can cross-link with guanine bases, forming oxidised products (8-oxodG) which stop 
elongation of telomeric repeats by telomerase and lead to a variable number of 
telomeric repetitions which remain un-replicated during each cell division (48;125). 
Over and above the impact on HSCs, these mechanisms of oxidative stress-
mediatedtelomere damage are likely to be particularly relevant in subsets of 
leukocytes which replicate in the peripheral circulation, such as lymphocytes. As 
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DNA polymerase is less efficient in repairing the telomeric than the genomic DNA 
following oxidative stress damage (47), the size of telomeres has been suggested as a 
measure of an individual's cumulative burden of oxidative stress (509). Our study 
confirms this potential role for telomeres, as LTL not only related with circulating 
levels of reactive oxidative species but also with markers of chronic evolution of PD, 
such as clinical attachment levels. Indeed, it is now well established that an excess of 
reactive oxidative metabolites, coupled with a depletion of the antioxidant capacity in 
gingival crevicular fluid (287;510;511), might be responsible for the chronic local 
activation of periodontal inflammation and progressively lead to gingival tissue 
destruction. Therefore, increased levels of oxidative stress might represent the final 
mediators of the association between LTL and clinical attachment levels.  
In contrast with this hypothesis was the finding that markers of systemic 
inflammation did not correlate with LTL, and patients with aggressive PD had higher 
levels of IL-6 but did not show shorter LTL. Several explanations might account for 
these findings. Firstly, fluctuations in the burden of bacterial aggression can cause 
acute changes of systemic inflammatory markers in patients with PD, making levels 
of CRP and IL-6 not informative on the cumulative exposure to inflammation 
(255;292). LTL dynamics are unlikely to be affected by acute changes of the 
inflammatory response. This might explain why LTL was not associated with 
inflammatory markers as well as why CAL, a clinical marker related to duration of 
PD, was associated with LTL but not with CRP or IL-6. Secondly, in our study, 
patients with aggressive PD were younger than those with chronic PD. This was an 
expected finding, as the clinical manifestations of aggressive PD tend to appear earlier 
and with worse presentations than those in chronic disease (274;289). Consequently, 
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while it is not surprising that inflammation and oxidative stress exposure were higher 
in aggressive patients than in the other two groups, these environmental factors could 
not have enough time to impact significantly on the slow LTL dynamics. 
The comparison between T/S ratio of our Q-PCR assay and TRF analysis had 
been previously reported (479). By means of the regression line resulting from this 
correlation, we calculated the corresponding telomere length in bp from the T/S ratio 
measured in each subject. These calculations resulted in a difference in LTL between 
cases and controls of 641 bp, reflecting a biological aging gap of approximately 21 
years (112). Although the role of LTL as marker of biological age is not completely 
accepted, there is evidence that patients with PD experience a higher mortality 
compared to healthy subjects (512;513). Söder et al demonstrated in a large 
longitudinal prospective study that young adults with PD have a significantly higher 
risk or premature death from neoplasms and CVD (512). These diseases are typically 
related with shorter LTL (61;68;69;352-354) and LTL has been shown to be inversely 
related with mortality rate (58;69;514). Thus, our current results provide a possible 
molecular pathway explaining the previously reported epidemiological associations. 
The observational experimental design of this study cannot exclude reverse 
causality (i.e. that shorter LTL could increase the risk of PD or accelerate the 
evolution of the disease). LTL is a marker of cellular aging and cells with critically 
short telomeres undergo apoptosis or senescence (28;40). As cells developing such a 
phenotype can no longer replicate, their accumulation in different tissues and organs 
marks a reduced ability to repair and leads to an increased susceptibility to 
environmental damage. Therefore, the shortened telomeres detected in patients with 
periodontal clinical attachment loss could result from deficient replication and repair 
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capacities of the local gingival fibroblast. Although we did not measure gingival 
fibroblast telomere length, a large body of evidence has shown that there is close 
correlation of telomere length in different tissues from the same individual (88-
90;113;515;516). It is therefore possible that people with short telomeres in their 
peripheral leukocytes also have short telomere length in their gingival tissues.  
Telomere length not only acts as an internal mitotic clock for somatic cells but 
also plays a key role in regulating several cellular functions, including the ability to 
produce pro-inflammatory cytokines (242). Therefore, the shortened LTL observed in 
PD patients could mark a general dys-regulation of the immune and inflammatory 
responses, which has been long considered as a possible reason for the higher 
susceptibility to the PD itself. As a result, the shortened LTL of PD patients may have 
a central role in perpetuating the oral inflammatory disease. The idea of a causal role 
for LTL in the initiation and evolution of PD, is supported by evidence that 
individuals with some genetic diseases associated with accelerated telomere loss in 
peripheral leukocytes, such as Down's syndrome, show an increased risk of PD when 
compared to controls (517). Further research is needed in this area, possibly including 
studies with longitudinal LTL measurements in patients with PD.   
A number of limitations should be discussed when interpreting our results. 
Firstly, both d-ROM and BAP are global measures of RS and therefore cannot inform 
on which exact RS or antioxidants have the stronger relation with PD and short LTL. 
Moreover, the lack of data on telomere length from gingival fibroblasts do not enable 
testing of whether, the loss of telomere length in peripheral leukocytes reflects a 
concomitant and more generalized aging process affecting in addition gingival tissues. 
While Takahashi et al did not find a significant correlation between LTL and gingival 
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fibroblast telomere lengths, this relationship was explored in only a few patients with 
the aggressive disease and further research is needed (504). Finally, the quantitative 
PCR-based
 
assay measures the average telomere length across all leukocytes
 
in the 
peripheral blood. Because of the significant difference in the total leukocyte count 
between cases and controls, we cannot exclude the
 
possibility that the chronic 
inflammatory state typical of patients with PD might have shifted the composition
 
of 
leukocyte subpopulations in a way that favoured cells with
 
shorter telomeres. Despite 
this, shorter telomeres in a specific leukocyte subpopulation predict the presence of 
short telomeres in other subgroups of mature white cells and hematopoietic progenitor 
cells (113;515). This suggests that our results are more likely to represent a 
generalized aging process involving all the different white cells in the peripheral 
blood as an expression of their common origin from the bone marrow hematopoietic 
stem cells. 
  
In conclusion, our data suggest that a chronic exposure to inflammation could 
represent the main cause of the short LTL recorded in patients with PD, with 
circulating levels of oxidative stress acting as the main mediator of the association 
between inflammatory burden and short LTL. Moreover, the evidence of shorter LTL 
detected in individuals with chronic periodontitis could provide a possible biological 
explanation for the reported higher mortality rate in these patients compared to the 
general population. Further research and longitudinal studies, however, are needed to 






Chronic inflammation is likely to have an impact on LTL as suggested by the 
association between markers of chronic inflammation and LTL 
Circulating levels of inflammatory markers are unable to capture the relationship 
between chronic inflammation and LTL 
Oxidative stress exposure is likely to represent the mediator of the relationship 
between chronic inflammation and short LTL  
LTL could represent a biological pathway explaining the higher mortality risk 
observed in patients with PD 
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5 STUDY 2 - The association between LTL and markers of chronic 
inflammation is independent from the short term metabolic control 
5.1 Introduction 
The second study explored whether, the association between short LTL and chronic 
inflammatory burden is independent from metabolic factors or concomitant diseases. 
A cross-sectional sample of patients with type 1 and type 2 diabetes mellitus was 
screened for presence of moderate to severe periodontal pockets versus gingivitis and 
LTL were measured. Circulating levels of LPS (which could reflect the amount of 
bacterial load on the periodontal tissue) and metabolic parameters were correlated 
with LTL, suggesting that continuous activation of the immune-inflammatory 
response may be a possible cause of LTL attrition. Finally, the study investigated 
whether a higher inflammatory burden reflected by the presence of shorter LTL was 
associated with diabetic complications (i.e. diabetic nephropathy). 
5.1.1 Diabetes and LTL 
The first report showing shorter LTL in patients with type 1 diabetes was 
published by Jeanclos et al and consisted of a cross-sectional, case-control study 
including 234 white men, of whom 54 had type 1 diabetes, 74 had type 2 diabetes, 
and 106 were control subjects (518). LTL was shorter in patients with type 1 but not 
in those with type 2 diabetes, compared to the control group. Subsequently, several 
studies have analysed the cross-sectional association between LTL and diabetes, 
reporting inconsistent results. In the Framingham Heart Study, Aviv et al. found 
shorter LTL in subjects with insulin resistance (62). However, the same group could 
not replicate these findings in the population of the Cardiovascular Health Study (63). 
In a longitudinal analysis involving a small group (n=49 participants) of the Bogalusa 
179 
 
Study, Gardner et al reported that the relative changes in telomere length over 10.1 to 
12.8 years were correlated with changes in insulin resistance and body mass index 
(66). In contrast, in a much larger recent study no associations were reported between 
diagnosis of type 2 diabetes and LTL, and LTL at baseline did not predict 
development of diabetes in 6 years of follow-up (519).  
The association between LTL and diabetes has usually been explained by the 
high levels of oxidative stress and inflammation normally found in patients with 
diabetes. Sampson et al showed increased oxidative DNA damage and shorter LTL in 
all subsets of circulating monocytes of diabetic patients compared to healthy controls 
(76). Importantly, a significant inverse relationship was described between levels of 
oxidative DNA damage and telomere length in the diabetic group. Similar results 
were obtained by Salpea et al, who studied a large population of 742 type 2 diabetes 
patients and 448 healthy controls (250). Diabetes patients had shorter LTL compared 
to healthy controls and plasma total antioxidant status was positively associated with 
the measure of LTL only in the diabetes group. Moreover, diabetes carriers of the 
functional variant (-866G>A) in the promoter of human UCP2 gene (associated with 
increased exposure to oxidative stress of mitochondrial origin) had shorter LTL than 
the more common homozygotes (-866G>G). 
The ability of LTL to mark chronic inflammation and oxidative stress 
exposure in diabetes may explain the higher rate of complications in patients with 
shorter LTL. Olivieri et al reported that type 2 diabetes patients with history of 
myocardial infraction have shorter LTL than those without CV complications (520). 
More recently, the same group demonstrated that among patients with diabetes, LTL 
became significantly and gradually shorter with the increasing number of diabetes 
complications (521).  
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However, the variable association reported between shorter LTL and diagnosis 
of diabetes suggests that, over and above the degree of inflammatory burden due to 
the metabolic disease, other factors may affect LTL dynamics. Diabetes care is 
complex and requires a multidisciplinary approach as many issues and comorbidities 
may influence levels of inflammation, the quality of metabolic control, the risk of 
complications and, eventually, patient outcomes (522). One of the most common 
comorbidities observed in diabetes patients is PD. Epidemiological data suggests 
susceptibility to PD is increased by approximately threefold in people with poorly 
controlled diabetes (523). Additionally, the risk of cardiorenal mortality and end-stage 
renal disease is three times higher in the diabetes population with severe PD than 
those without oral disease (301). However, biological pathways involved in increasing 
the risk of complications in patients with diabetes and PD remain unclear.  
Our first study suggested that the chronic inflammatory burden reflected by 
severity of periodontal remodelling/destruction may represent the main driver of 
shorter LTL in patients with PD. In the second project of this thesis, the association 
between severity of periodontal inflammation and short LTL was assessed with 
regards to metabolic factors, representing a possible biological pathway underlying 
the evolution of diabetes complications (i.e. diabetic nephropathy). 
A population of type 1 and type 2 patients with diabetes was screened for 
prevalence periodontal inflammation, in order to verify whether, the severity of 
gingival inflammation was related to shorter LTL, independently of the gluco-
metabolic control. Further, the influence of this association on the prevalence of 
diabetic nephropathy was assessed.  
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5.2 Specific Methods 
5.2.1 Population 
A total of 630 consecutive individuals referred to the Endocrinology 
Department of the University College of London Hospital were recruited for this 
study between May 2007 and September 2009 if willing to receive a periodontal 
screening and blood sample (371 with type 2 and 259 with type 1 diabetes mellitus 
based on the recent WHO definition). A physician collected participants’ clinical 
(diagnosis, disease duration, complications) and smoking history (current, former or 
never). Medical records were screened by a separate investigator to obtain 
information on current medications. Anthropometric measurements and blood 
pressure were assessed using standard techniques. After consenting, all participants 
underwent blood collection first and then an oral examination performed by two 
expert periodontists (NG, FD). Ethical approval was received from the NRES 
Committee London – Bentham (06/Q0502/97) and written informed consent was 
obtained from all participants. 
5.2.2 Periodontal examination 
Measures of exposure to periodontitis are a controversial matter for debate and our 
group has previously supported the use of both continuous and categorical measures 
of periodontal exposure when available in epidemiological studies (D’Aiuto et al. J 
Clin Endocrinol Metab. 2008 Oct;93(10):3989-94; Stewart et al. Psychosom Med. 
2008 Oct;70(8):936-41; Tsakos et al. J Hypertens. 2010 Dec;28(12):2386-93; Suvan 
et al. Obes Rev. 2011 May;12(5):e381-404; Tu et al. J Clin Periodontol. 2013 Aug 
14). In this survey the periodontal examination consisted of a single recording of 
periodontal probing pocket depth based on the Basic Periodontal Examination (BPE) 
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index derived from the WHO CPITN score (524;525). This screening tool was 
performed in each sextant of the whole dentition (scores ranging from 0 to 4) on and 
the highest score of the whole mouth was entered as representative of the periodontal 
bleeding and deeper probing pocket depth status for each participant. Radiographic 
assessment of current bone levels and more detailed whole mouth gingival 
assessments could not be obtained. According with the BPE score, patients were 
grouped as follows: 
 Group 1 – corresponding to a BPE score of 1 and 2, These included all 
patients without PPD >3.5 mm but either bleeding after probing without 
calculus/overhangs (Score 1), or bleeding after probing and carrying supra- or 
subgingival calculus/overhangs (score 2).  
 Group 2 – corresponding to BPE score 3 which indicate PPD of 4 to 5mm.  
 Group 3 – corresponding to BPE score 4 which indicates PPD of 6mm or 
more. 
 Group 4 – corresponding to patients with no teeth (edentulous). 
No individuals presented with BPE scores 0 which indicates no pockets >3.5 mm, no 
calculus/overhangs and no bleeding after probing. In addition, the sum of all sextants 
(BPE cumulative score) was created to define a continuous measure of extent of the 
disease. Both examiners were previously calibrated on a convenient sample of 10 
individuals and k scores were calculated (>0.90). 
Every participant with BPE scores greater than 2 was asked to attend a further visit for 
a full periodontal examination (consisting of 6 point full mouth periodontal probing 
pocket depth, gingival recession, clinical attachment levels and gingival bleeding 
upon probing by a single calibrated examiner).  
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5.2.3 Biochemical tests 
Blood samples were collected from all patients after an overnight fast for 
biochemical tests and telomere length assay. Lipid profile, glucose, glycated 
haemoglobin (HbA1c), creatinine and CRP levels were assessed on an automated 
analyser (Cobas Integra analyser; Roche Diagnostics). Estimated glomerular filtration 
rate (eGFR) was calculated with the abbreviated MDRD (Modification of Diet in 
Renal Disease Study) equation and expressed in mL/min/1.73m
2
 (526).  
Serum levels of insulin were quantified with high sensitivity ELISA 
(Mercodia, Sweden), which uses a direct sandwich technique (described in the general 
methods) and does not cross-react to C-peptide or proinsulin. Insulin resistance index 
was calculated as previously described (527). Serum endotoxin activity was 
determined by the Limulus Amebosyte Lysate test kit with a chromogenic substrate 
(Lonza, Walkersville, MD, US). The steps of the LPS assay are described in the 
general methods. Intra- and inter- coefficients of variation for all assays were < 5%. 
5.2.4 DNA preparation, standardization and LTL assay 
5.2.4.1 DNA preparation, standardization 
DNA was isolated, quantified and standardized from an aliquot of EDTA 
whole blood stored at -80
○C, using the protocols described in the “general methods”.   
5.2.4.2 LTL assay 
The real time PCR assay described in the general methods was used to 
measure LTL in a blinded fashion. To test the reproducibility of the qPCR technique 
in this cohort, a subset of 16 randomly selected DNA samples were run on two 
different days. The r
2




All data is presented as mean and standard deviations unless otherwise specified. All 
biochemical variables were log-transformed if normality assumptions were not met. 
Descriptive analyses were performed on all survey participants, comparing a number 
of confounders/variables across different levels of periodontal exposure (Groups 1-4) 
using a test for trend (Jonckheere Trend Test) for continuous and chi-square test for 
categorical variables. Non-parametric correlation analyses between LTL and age, 
body composition, and biomarkers were performed using Spearman Rank testing. 
Linear regression models were used to investigate the univariate association between 
LTL and all common confounders. All those factors found to be statistically 
significant at the 0.10 level in the univariate analyses, were then included in 
generalized linear models. Adjustment was made for: Age, Gender, Ethnicity, 
Diabetes Type, Smoking, Waist circumference (Model 1) and in addition for 
Endotoxin, Medication use, Insulin and CRP (Model 2). Fully adjusted models were 
used to compare slopes of LTL by age across groups of prevalent periodontal 
inflammation. Despite the limited sample size of the group of edentulous individuals, 
all analyses were performed including and excluding this group in all multivariate 
models in order to confirm the results (data are presented with this group included). 
229 (70%) of the 327 participants of the survey who had deeper periodontal pockets 
(Group 2-3) received a full mouth periodontal examination. In this subset sample we 
used the most current case definition of periodontitis (based on the CDC and AAP 
consensus, Eke et al J Periodontol. 2012 Dec;83(12):1449-54) and performed a ROC 
discriminatory analysis to define the sensitivity and specificity of this definition with 
our categorization of Group 2 and Group 3 as moderate and severe periodontitis. The 
analysis confirmed high sensitivity (0.85) and low specificity (0.4) scores when using 
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BPE as measure of exposure for a clinical diagnosis of periodontitis. Further we 
cross-tabulated Groups 2 and 3 allocations against the CDC-AAP diagnoses of 
moderate and severe periodontitis respectively. When using BPE scoring the analysis 
underestimated the diagnosis of severe versus moderate periodontitis in 25% of cases. 
Further the BPE cumulative score was positively correlated with common periodontal 
clinical parameters of severity and extent: the number of periodontal pockets greater 
than 4mm (R=0.6, p<0.001), full mouth probing pocket depths (R=0.4, p<0.001) and 







A total of 255 participants were included in Group 1 with only gingival 
bleeding (sign of gingivitis), 327 with deeper periodontal pockets (114 with moderate 
and with 213 severe pockets) and 48 individuals were edentulous (Table 5.1).  














Age, years 50.0±17.3 58.3±15.4 61.7±11.5 71.6±8.2 <0.001 
Gender, Male 131(51.4%) 79(69.3%) 138(65.1%) 26(54.2%) 0.002 
Smoking, Current 33(12.9%) 26(22.8%) 30(14.1%) 7(15.2%) 0.022 
Ethnicity, 
Caucasian 
203(79.6%) 81(71.7%) 119(55.9%) 29(60.4%) <0.001 
Diabetes, Type II 104(40.8%) 69(60.5%) 154(72.3%) 44(91.7%) <0.001 
BMI, kg/m
2
 27.5±6.6 28.8±7.0 28.7±9.2 30.0±5.1 0.004 
Waist 
circumference, cm 
100.1±13.1 103.4±12.1 103.1±16.1 108.1±11.0 <0.001 
Systolic BP, 
mmHg 
129.0±19.7 131.4±21.0 131.2±18.2 136.1±16.7 0.029 
Diastolic BP, 
mmHg 
74.4±11.3 77.2±11.0 75.2±12.0 74.4±11.5 0.570 
HbA1c, % 8.0±1.6 7.9±1.5 8.1±1.7 7.9±1.8 0.811 
Glucose, mmol/l 8.4±4.8 8.0±4.9 8.5±4.9 8.6±4.0 0.834 
Insulin, pmol/L 79.5±115.5 120.8±187.9 118.2±148.3 212.6±262.8 <0.001 
HOMA Index 0.1±7.4 1.1±11.9 1.3±12.5 2.1±4.5 <0.001 
LPS, EU/ml 10.9±8.0 10.4±10.6 9.8±7.0 12.2±10.0 0.04 
CRP, mg/l 1.3±4.0 1.6±7.3 1.5±5.3 2.9±8.5 0.002 
LDL, mmol/l 2.3±0.8 2.3±0.9 2.1±0.9 2.0±0.9 0.001 
HDL, mmol/l 1.3±0.5 1.1±0.5 1.1±0.4 0.9±0.3 <0.001 
Tot Chol, mmol/l 4.4±0.9 4.3±1.1 4.1±1.0 4.0±1.0 0.002 
Triglycerides, 
mmol/l 
1.1±0.8 1.2±1.1 1.2±.08 1.5±0.9 <0.001 
Creatinine,mg/l 78.5±36.9 80.5±30.1 82.0±56.4 105.0±104.3 <0.001 
eGFR, 
ml/min/1.73m² 
86.6±27.9 86.3±29.2 82.3±27.0 57.3±30.8 <0.001 




All groups with increased signs of periodontal inflammation were generally 
older, with higher prevalence of males, more Caucasians and type 2 diabetes 
diagnosis, but lower number of current smokers, when compared with the Group 1. A 
linear trend of greater values of systolic and diastolic blood pressure as well as 
adiposity (both body mass index and waist circumference) was observed in 
individuals with more severe gingival inflammation and the difference was greatest in 
the edentulous group. There were no statistically significant differences in HbA1c, 
plasma glucose levels between groups, whilst levels of insulin, insulin resistance 
(calculated based on the HOMA IR index), CRP, Endotoxin, triglycerides and 
creatinine were higher in individuals with increasing BPE scores. An inverse 
relationship was observed between serum levels of CRP and BPE scores based on 
diabetes diagnosis. Indeed, whilst in patients with type 1 diabetes Groups 3 and 4 
were associated with lower levels of inflammation, the opposite was observed in type 
2 patients (CRP levels in Groups 3 and 4 were higher than those in Groups 1 and 
2p<0.01). No association was found between LTL and CRP levels (data not shown). 
All study participants with deeper PPD (>4mm, BPE score 3 and 4, 
corresponding to groups 2 and 3) had shorter LTL when compared with healthier 
gingival scores (p=0.04 for the comparison of groups 2+3 vs group 1, when adjusted 
for age), and this difference remained statistically significant after multiple 




Figure 5.1 Difference in LTL between group 1(participants with BPE scores of 1 
and 2, n=280) and groups 2+3 (participants with BPE scores of 3 and 4, n=327) in 
a cohort of individuals with diabetes. 
Cases with deeper periodontal pockets had shorter LTL compared to those in Group 
1. Data are reported as mean ± SE and analysis is adjusted for age, gender, ethnicity, 
diabetes type, smoking, waist circumference, endotoxin, insulin and CRP levels. 
*<0.05 compared to gingivitis. 
 
When results were analysed by increasing BPE scores, cases with higher 
scores (deeper periodontal pockets) exhibited shorter LTL when compared to group 1, 
independently of other confounders (Table 5.2).  
Table 5.2 Means (± SE) telomere length (T/S ratio) of 630 individuals with 











Age-adjusted 1.13±0.01 1.13±0.02 1.10±0.01* 1.19±0.03 0.04 
Model 1 1.16±0.02 1.17±0.03 1.12±0.02* 1.22±0.04 0.01 
Model 2 1.16±0.02 1.17±0.03 1.12±0.02* 1.23±0.04 0.002 
† p value for difference in BPE scores Groups unordered 
Model 1: adjusted for Age, Gender, Ethnicity, Diabetes Type, Smoking, and Waist 
circumference.  
Model 2: Model 1 + circulating levels of Endotoxin, insulin and C-Reactive protein.  
































Edentulous individuals, despite being older, did not have shorter LTL 
compared to Group 1 in the fully adjusted model. The BPE cumulative score (beta= -
0.003, 95%CI -0.005 to -0.001, p=0.013) and circulating levels of endotoxins (beta= -
0.027, 95%CI -0.052 to -0.027, p=0.034) were independently associated with LTL 
when adjusting for all confounders. Indeed there was a negative linear association 
between LTL and increased BPE scores (Figure 5.2A) and circulating endotoxin 
levels (Figure 5.2B).  
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Figure 5.2 Association between LTL (T/S ratio) and cumulative BPE score in each 
individual and circulating level of LPS. 
There was an negative association between LTL and BPE scores (A)(R= -0.11; 
P=0.009), as well as between LTL and LPS levels (B) (R= -0.29; P<0.001). Analysis 
adjusted for age, gender, ethnicity, diabetes type, smoking, waist circumference, and 
circulating levels of LPS, insulin and C-Reactive protein. 
 
When the association between LTL and endotoxin levels was analysed by 
subgroup of BPE scores, a stronger negative correlation was found in patients with 
deeper (>4mm, group 3 and 4, r= -0.14; p=0.04) than in those with mild (<3.5mm, 





Figure 5.3 Scatter plot of predicted T/S ratios vs endotoxin values in individuals 
with mild and severe PPD based on BPE scores. 
Endotoxin values are log-transformed. Analysis was adjusted for age, gender, 
ethnicity, smoking, waist circumference and diabetes type. P value of statistical 
difference in slope between mild (slope=0.023) and severe PPD (slope=-0.051) is 
0.001. 
 
Patients with deeper periodontal pockets as well as edentulous presented with 
higher levels of endotoxemia when compared to cases with mild PPD in the group of 
type 2 diabetes (13.2±1.6 EU/ml severe PPD and 14.5±1.9 EU/ml edentulous versus 
10.5±1.2 EU/ml in the gingivitis group, p=0.025 and p=0.026 respectively). An 
association of opposite direction (lower endotoxin levels with higher level of 
periodontal inflammation) was observed in type 1 diabetes (p<0.001) (data not 
shown). 
Indeed, combined Groups 2 and 3 had shorter LTL than Group 1 in individuals 
with type 2 (p=0.039) but not type 1 diabetes (Figure 3). A progressive reduction of 
LTL was noted with increasing severity of BPE scores only in cases with type 2 




showed shorter LTL when compared to the individuals with mild PPD or no PPD 
(Group 1)(p=0.004) (Figure 5.4).  
 
Figure 5.4 LTL (T/S ratio) of 630 individuals sorted by diabetes type and severity of 
BPE scores. 
Data are reported as mean ± SE and analysis is adjusted (according to Model 2) for 
age, gender, ethnicity, diabetes type, smoking, waist circumference and circulating 
levels of Endotoxin, insulin and C reactive protein. *P<0.01 vs group 1. 
 
 
Amongst all metabolic parameters a strong association was only found 
between LTL and insulin resistance (HOMA IR index) (beta= 0.001, 95%CI 0.001 to 
0.002, p=0.002) in the fully adjusted model.  
Lastly, LTL and eGFR were linearly associated (r=0.164; p<0.001) and 
adjustment for diabetes type, ethnicity, smoking, waist circumference and blood 
pressure did not affect the association (beta= 0.001, 95%CI 0.001 to 0.002, p=0.002) 


































Figure 5.5 Scatter plot of predicted T/S ratios against values of eGFR. 
Analysis is adjusted model for age, gender, ethnicity, diabetes type, smoking, waist 
circumference and circulating levels of endotoxin, insulin and C reactive protein. 
(R=0.17, P<0.001) 
Medication use differed greatly amongst individuals groups but these 
differences were statistically significant only in the subgroup of people with type 1 
diabetes (Table 5.3).  
Table 5.3 Medications history of 630 individuals with diabetes grouped by 
severity of BPE score. 












Insulin  195(76.8%) 68(59.6%) 115(54.0%) 26(56.5%) <0.001 
Sulfonylureas 44(17.3%) 26(22.8%) 65(30.5%) 17(37.0%) 0.003 
Biguanides 98(38.6%) 58(50.9%) 125(58.7%) 28(60.9%) <0.001 
Thiazolidinediones 11(4.3%) 10(8.8%) 28(13.2%) 7(15.2%) 0.007 
Anti-hypertensives 123(48.4%) 67(58.8%) 149(70.3%) 38(82.6%) <0.001 















 Insulin  45(43.3%) 25(36.2%) 58(38.4%) 23(53.5%) 0.256 
Sulfonylureas 40(38.5%) 26(37.7%) 65(42.8%) 17(39.5%) 0.865 
Biguanides 76(73.1%) 49(71.0%) 113(73.9%) 28(65.1%) 0.713 
Thiazolidinediones 11(10.6%) 10(14.5%) 28(18.5%) 7(16.3%) 0.378 
Anti-hypertensives 83(79.8%) 48(69.6%) 115(76.2%) 36(83.7%) 0.290 
Cholesterol lowering 78(75.0%) 54(78.3%) 122(80.3%) 33(76.7%) 0.790 




There was however no association between LTL and class of medications in the 
whole cohort as well as in the group of people with type 2 diabetes (Table 5.4). 
Table 5.4 Mean (± SE) telomere length (T/S ratio) of 630 individuals with 
Diabetes sorted by Medications use (binary). 










 Insulin  1.16±0.02 1.16±0.03 0.996 
Sulfonylureas 1.16±0.02 1.17±0.03 0.396 
Biguanides 1.17±0.02 1.15±0.02 0.366 
Thiazolidinediones 1.16±0.02 1.16±0.04 0.928 
Anti-hypertensives 1.17±0.03 1.16±0.02 0.696 

















Insulin  1.14±0.03 1.14±0.03 0.924 
Sulfonylureas 1.13±0.03 1.15±0.02 0.400 
Biguanides 1.15±0.03 1.14±0.03 0.577 
Thiazolidinediones 1.14±0.04 1.14±0.02 0.973 
Anti-hypertensives 1.15±0.03 1.13±0.03 0.478 
Cholesterol lowering 1.14±0.03 1.14±0.03 0.991 







  In this study we reported for the first time an association between LTL and 
prevalent deeper periodontal pockets in people with diabetes. The main finding was 
that LTL ratio was lower when severe pocket depths were greater and that this 
association was independent of age, diabetes type, adiposity and circulating levels of 
inflammatory bio-markers. We also reported that circulating endotoxin levels, insulin 
resistance (HOMA-IR) and eGFR were associated with LTL in people with diabetes. 
  In our first study we demonstrated shorter LTL in individuals with 
periodontitis when compared to healthy controls, suggesting also that increased 
systemic inflammation and oxidative stress could account for this association. We 
reported increased levels of systemic inflammation/oxidative stress to be associated 
with both diagnosis of periodontitis and shorter LTL (528). In this study we 
documented that these associations are present also in individuals suffering from 
diabetes, a disorder characterized by a chronic state of increased inflammation and 
oxidative stress and we suggested the bacterial burden as  possible factor accounting 
for this association.  
This suggests that the association between inflammation and LTL is continuous, with 
no obvious thresholds. Indeed, a progressive reduction in LTL was observed with 
increasing severity of the oral disease. Current understanding of the LTL dynamic and 
its determinants in humans are in line with our findings. The continuous recruitment 
and differentiation of new inflammatory cells, associated with increased oxidative 
stress exposure, are thought to be the primary mechanisms causing a higher rate of 




  Circulating levels of LPS were inversely associated with LTL. Higher levels 
of LPS commonly mark a higher infective burden, which results in an increased 
mobilization and recruitment of inflammatory cells from the bone marrow. This 
process can lead to faster telomere length attrition in HSCs due to the “end replication 
problem” and oxidative stress exposure (240;529), ultimately resulting in shorter LTL 
(113). Indeed, the inverse association between LTL and LPS was observed only in 
subgroups with shorter LTL compared to the gingivitis group (patients with type 2 
diabetes and those with severe oral disease). Conversely, edentulous patients do not 
have shorter LTL compared to the control group, despite their older age and higher 
levels of circulating LPS. This could result from a survivor effect. The low number of 
patients without teeth suggests that only edentulous individuals with extremely long 
LTL at birth or with an extremely high activity of the telomerase in the HSC might 
have survived at this age, leaving therefore the edentulous population with longer 
LTL compared to the other two groups. The high level of LPS recorded in edentulous 
patient is intriguing, as the lack of teeth is likely to remove the inflammatory trigger 
represented by the PD bacterial aggression. However, this is not unexpected as the 
assay used to measure LPS in this study is not specific for oral bacteria and it is likely 
that old people with type 2 diabetes have multiple sources of infection (i.e. gut) which 
can lead to a significant increase of circulating levels of LPS.  
No associations were observed between circulating levels of inflammatory 
markers and LTL. As in our first study, this could be due to the limited information 
about an individual’s inflammatory burden provided by circulating markers of 
inflammation, particularly in subjects with diabetes and different levels of periodontal 
inflammation. Indeed, in these patients, levels of IL-6 and CRP are likely to be 
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extremely variable and affected by the activity of the underlying oral inflammatory 
processes (254;255) as well as of the quality of gluco-metabolic control (256). In 
contrast, LTL appears to be a measure of the cumulative burden of inflammation and 
oxidative stress over individual’s life span and its dynamic is thus only marginally 
affected by acute changes in inflammatory burden. This might explain the lack of 
association between telomeres and inflammatory markers observed in the current and 
previous study. (530)  
In our survey only people with type 2 diabetes presented a linear reduction in 
LTL with increasing severity of BPE scores. A number of factors could account for 
this finding. Firstly, a relatively low number of individuals with type 1 diabetes 
presented with greater scores of periodontal exposure, reducing the power of our 
analyses. Furthermore, people generally develop type 1 diabetes early in life. They 
become more accustomed and compliant to diabetes treatment than people who 
develops type 2 diabetes in older age (522). This might account for the increased 
levels of cardiometabolic risk factors and inflammatory markers recorded in the type 
2 rather than type 1 diabetes group, also explaining the higher prevalence of moderate 
to severe periodontal pockets in participants with type 2 diabetes. Lastly, in our study 
cohort people with type 1 diabetes were generally younger than those with type 2. 
This might result in a shorter period of exposure to inflammation and periodontal 
inflammation. It is possible that the chronic immuno-inflammatory response related to 
the gingival disease did not have enough time to significantly impact on the relatively 
slow rate of LTL shortening in humans. 
It is possible that the chronic immuno-inflammatory response related to oral 
disease did not have enough time to impact significantly on the relatively slow rate of 
197 
 
LTL shortening. Finally, the high levels of insulin detected in patients with type 2 but 
not in those with type 1 diabetes, could actively contribute to the telomere damage in 
conditions of increased oxidative stress and inflammation. Animal experiments have 
shown that the insulin/insulin like growth factor-1 pathway (IIP) has a crucial role in 
regulating life span, through fine regulation of the intracellular oxidative stress levels 
(531;532). Indeed, binding of insulin and insulin like growth factor-1 (IGF-1) to their 
receptors leads to autophosphorylation of the β-subunits of the insulin or IGF-1 
receptor, recruitment of insulin receptor substrate-1/-2, and subsequently activation of 
mainly phosphatidylinositide 3-kinase (PI3K). The PI3K pathway activates Akt which 
mediates Forkhead-Box O1 (FoxO1) phosphorylation and nuclear exclusion of 
FoxO1. As FoxO1 regulates expression of manganese SOD (MnSOD), the exclusion 
of FoxO1 from the nucleus results in down-regulation of the antioxidant intracellular 
capacities (533;534). Therefore, an increased insulin signal results in reduced 
intracellular antioxidant capacities, possibly increasing susceptibility to DNA 
oxidative stress damage in conditions of increased oxidative stress exposure. 
Hyperinsulinemia is a common feature of type 2 diabetic patients as it is necessary to 
counteract the muscular and adipose tissue insulin resistance. However, immune-
inflammatory cells maintain normal levels of insulin sensitivity in type 2 diabetes and 
can be hyper-stimulated by the high levels of circulating insulin. This can reduce the 
amount of intracellular MnSOD in inflammatory cells of type 2 diabetics, possibly 
increasing the DNA oxidative stress damage due to the presence of PD and explaining 
LTL differences between type 1 and type 2 diabetics. The reduced ability to 
compensate for oxidative stress damage in type 2 diabetics is supported in this study 
by the graded decline in LTL with increasing severity of PD observed in type 2 but 
not in type 1 diabetics.  
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  A robust association was found between LTL and both insulin resistance and 
eGFR. These findings confirm previous evidence suggesting LTL could act as a 
reliable marker of future diabetic complications, especially for nephropathy 
(520;521). Interestingly, the presence of PD has been related to an increased risk of 
mortality in diabetics (particularly from diabetic nephropathy and ischemic heart 
disease), independently from duration of diabetes and gluco-metabolic control (535). 
This suggests that the presence of the oral disease and related systemic inflammatory 
burden are the principal factors accounting for the prognosis. As LTL has been related 
with a higher risk of CV mortality (514) and faster progression of diabetic 
nephropathy (536), our study suggests that the shortened LTL resulting from the high 
level of periodontal exposure of diabetes patients may be a biological pathway 
accounting for their higher cardiorenal mortality risk.  
Our study has several strengths. Firstly, it includes a large population of 
people with diabetes in whom the state of oral health was determined by  oral 
examination performed by two expert periodontists, rather than being self-reported by 
patient with questionnaires (524). Secondly, the detailed characterization of the cohort 
and the availability of several covariates potentially influencing LTL enable extensive 
adjustments, providing an assessment of the relative impact of each parameter on 
LTL.  Finally, the recruitment at a single hospital reduces the potential confounding 
impact of geographical and ethnic variability on LTL (95;537). 
  Nevertheless, important limitations remain. Firstly, the cross-sectional design 
cannot exclude reverse causality. As previously mentioned, short telomere length has 
been associated with aberrant cytokine production and altered immune cell function 
(538). Similarly, the aetiology of PD is currently though to be based on a dysregulated 
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immuno-inflammatory response to local bacterial aggression (539), leading to a 
progressive accumulation of dental plaque biofilm (276;277). Therefore, an 
interesting hypothesis can be generated from current data. In a population of patients 
with diabetes, short LTL may mark those with higher risk of developing severe and 
chronic infections (i.e. PD) due to an age-related deficit or dysregulated activity of 
their immuno-inflammatory system. Secondly, our method of assessment of 
periodontal diagnosis was limited to the WHO/BPE index of prevalent periodontal 
pockets and treatment needs. This is not considered a clinical method of periodontitis 
diagnosis (as lacking of measures of gingival recession/attachment loss and 
radiographic assessment of alveolar bone levels) but rather a method of prevalent 
severity of PPDs in population surveys. Whilst in the past CPITN/BPE has been used 
as method of periodontal exposure, clear limitations of the index have been reported 
especially as it could let an underestimation of the periodontal tissue destruction. The 
subgroup analysis based on full mouth periodontal measures confirmed the positive 
discriminative value of categorizing the survey population in distinctive groups of 
periodontal exposure (i.e. gingivitis, moderate and severe periodontitis) and that if at 
all our approach might have produced an underestimation of the overall exposure to 
periodontitis. Thirdly, the presence of severe oral infection in patients with PD might 
determine a change in the relative proportion of leukocyte subpopulations in 
peripheral blood. As the quantitative PCR-based assay provides only the average 
telomere length across all leukocytes, it is impossible to exclude that this could 
partially account for the associations found. However, it is now well established that 
the high inter-individual variability in telomere length far exceeds the variations 
among cell types within the same individual, resulting in a high synchronization of 
telomere length between different cells and tissues of both healthy (88;90) and 
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diseased subjects (515;516).  Fourth, the LPS assay used in this study measures the 
total amount of LPS activity in peripheral blood, without providing specific 
information on the possible origins of the infectious burden. As diabetics are more 
prone to develop serious infections than the general population (540), it is not possible 
to exclude that subjects with increased severity of periodontal inflammation also had 
other concomitant infections. Finally, while the elimination of the infectious and 
inflammatory stimuli can account for the lack of significant difference in LTL 
between the edentulous and the gingivitis groups, the low number and significantly 
higher age range of these patients compared to the other groups complicate 
interpretation of the results.  
In conclusion, our study shows that in patients with diabetes, prevalent moderate 
to severe periodontal inflammation is associated with shorter LTL, independently 
from metabolic factors. This association can mark an age-related dysfunction of the 
immune-inflammatory system (potentially increasing the individual predisposition to 
chronic infections) or it can be a consequence of the higher levels of inflammatory 




The association between chronic inflammation and LTL in patients with increased 
periodontal inflammation is independent from metabolic factors 
The infective burden reflected by circulating levels of LPS could represent the 
chronic inflammatory trigger which leads to shorter LTL in PD 
The cumulative inflammatory burden reflected by the amount of LTL shortening is 
likely to contribute to the evolution of diabetic complication in patients with PD  
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6 STUDY 3 – Early origins of the association between inflammatory burden 
and LTL: a study in young individuals. 
6.1 Introduction 
This study explored the early origins of the link between chronic inflammation 
and LTL.  
Studies performed in adult populations have described negative associations 
between LTL, clusters of traditional CV risk factors (including dyslipidaemia, 
diabetes mellitus, obesity, and smoking) (541;542), as well as with subclinical (543) 
and clinical measures atherosclerosis (354). However, the biological basis for these 
associations remains unclear. Indeed, while exposure to CV risk factors can increase 
levels of inflammation, it is also well established that higher levels of inflammation 
can lead to emergence of insulin-resistance, hypertension and dyslipidaemia (173). 
Therefore, it is unclear whether adult associations between short LTL and CV disease 
are directly influenced by levels of CV risk factor exposure or it is the common 
pathway of inflammation that affects the risk of developing adverse cardio-metabolic 
patterns, CV disease and short LTL.  Studies of young populations with low CV risk 
factor burden as well as shorter exposure to inflammatory triggers, provides the 
opportunity to identify early biological pathways relevant to LTL dynamics. Any 
association identified in this population would be less confounded by the presence of 
other underlying pro-inflammatory factors. 
The aim of this study was to explore the early origins of the link between 




LTL were therefore measured in adolescents (13–16 years old) who took part in 
the third phase of the Ten Towns Heart Health Study. This study was originally 
designed to determine the early factors accounting for discrepancies in adult CV 
disease risk between areas of England and Wales with high and low adult CV 
mortality. The detailed characterization of the cohort, including measurement of 
traditional and novel CV risk factor as well as CV phenotype, enabled appropriate 
adjustment for most of the environmental factors that have previously been associated 
with short LTL in adults.  
6.2 Specific Methods  
6.2.1 Population 
The Ten Town Heart Health Study is a mixed longitudinal study based on 
children attending a stratified random sample of one hundred primary schools in 10 
towns across England and Wales (544;545). The 406 local authority districts in 
England and Wales were ranked on the basis of their standardised mortality ratios for 
all CV disease for 1979-1983, calculated for men and women aged 35-64 years. The 
five highest and five lowest mortality districts containing a population centre of 
40000-100000 subjects were selected. The geographical distribution of the study 
towns is shown in figure 6.1.  
 
 
Figure 6.1 Ten towns study.  
Geographical distribution of study towns. Adapted 





The study was structured in three different phases. The first was carried 
between January and July 1990 and explored whether values of blood pressure 
recorded in children aged 5-7.5 years differed between towns with exceptionally high 
and exceptionally low adult CV mortality. In 1994, a second phase of the study 
investigated whether patterns of CV risk factors emerged in children aged 8-11 years 
may account for geographic differences in CV mortality risk. In this run, a subgroup 
of 1287 children underwent blood sample collection. Finally, during the third phase of 
the study, carried out in 1998–2000, 1248 European and 90 South Asian adolescents 
(aged 13–16 years) were recruited from 69 secondary schools which included at least 
20 pupils who participated in the earlier phases of the study. Pupils who had 
previously taken part were invited (average 45 pupils per school), together with a 
random sample of new participants (average 13 pupils per school). Information and 
DNA samples collected during the third phase of the project were used in a cross-
sectional study design. Ethical approval was received from the local research ethics 
committees, and written informed consent was obtained from all participants and their 
parents.  
6.2.2 Demographic, anthropometric and behavioural characterization  
Ethnicity was defined on the basis of appearance, cross-checked with parental 
place of birth. Height was measured with a portable stadiometer (CMS Ltd, Camden, 
UK), weight with a digital electronic weighing scale (Soehnle Ltd, Murrhardt, 
Germany). Waist and hip circumferences were measured using standard techniques 
(544) and skinfold thickness was measured at four sites (triceps, biceps, subscapular 
and suprailiac) (546). Bioimpedance was measured with a Bodystat 500 (Bodystat, 
Ltd, IoM); estimates of percentage body fat were determined using the equation of 
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Deurenberg et al (547). Pubertal status was ascertained using a confidential self-
assessment questionnaire based on Tanner pubic hair, penile and breast development 
scales (548). Participants provided questionnaire-based information on how their 
physical activity levels compared with those of their peers, with 5 grades (much less 
active, slightly less active, similar, more active, much more active) (549;550). This 
was cross-checked with information provided by the parents. A parental questionnaire 
sent immediately after examination provided information on infant feeding practices 
in the first 3 months of life (breastfed only, bottle-fed only, and mixed feeding) and 
on the duration of breastfeeding when applicable. Parental occupation was used to 
define social class in accordance with the Registrar General’s (ONS) 1990 coding 
manual (551); head of household’s social class was defined as paternal social class or 
(when not available) maternal social class. Cigarette smoking status was established 
by a questionnaire regarding current and lifelong smoking, in order to separate 
participants into current smokers (>=1 cigarette per day currently), past smokers 
(history of previous but not current cigarette smoking), and non-smokers. Salivary 
cotinine measurements were used to reclassify past or non-smokers as current 
smokers (levels >=14.1 ng/mL) (552). All assessments were made by a trained field 
team (four observers) who visited each town in turn. A blood sample was collected 
after an overnight fast for DNA extraction and measurements of traditional and novel 
markers of CV risk. Finally, brachial artery distensibility was measured to determine, 
non-invasively, the adolescent’s CV phenotype. 
6.2.3 Blood Samples 
Blood samples were frozen (−20°C) within 6 hours of collection and 
transferred to a central laboratory for analysis within 2 weeks or for long-term storage 
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at −70°C. Total serum cholesterol and high-density lipoproteins were measured using 
a Hitachi 747 automated analyser (Roche Diagnostics Corp, Indianapolis, IN) at the 
Royal Free Hospital (553;554), while LDL was calculated using the Friedewald 
equation (555). Triglycerides (maximum 4.7 mmol/L) were within the limit for 
determining LDL (10 mmol/L) using the Friedewald equation. Plasma glucose was 
measured in a fluoride oxalate sample with a Falcor 600 automated analyser and 
serum insulin using a specific ELISA assay which does not cross-react with proinsulin 
(556). The assessment of insulin resistance was based on the homeostasis model 
assessment (HOMA) equation (glucose × insulin/22.5).  
CRP was determined with a high sensitive enzyme immunoassay with DAKO 
reagents (557) and clottable fibrinogen was measured with the Clauss method in 
blood anti-coagulated with 0.109 mol/Ltrisodium citrate (9:1 vol:vol) (558). Plasma 
vitamin C and was measured in samples pre-treated with metaphosphoric acid at the 
point of collection and then snap-frozen with dry ice using high performance liquid 
chromatography (HPLC) (559). Plasma levels of tissue Plasminogen Activator (tPA) 
and von Willebrand factor (vWF) were measured with ELISAs (Biopool AB and 
DAKO, respectively) (560). Serum total homocysteine was measured by a modified 
automated assay, based on pre-column derivatisation with monobromobimane, 
followed by reverse phase high performance liquid chromatography with fluorescence 
detection (561). Serum folate levels were determined by a microbiological assay with 
the use of a chloramphenicol resistant strain of Lactobacillus casei (562). Each assay 




6.2.4 DNA extraction, standardization and LTL assay 
The protocols used for DNA extraction, standardization and LTL assay were 
similar to those reported in the general methods. However, as the LTL technique used 
in previous studies was validated on adult samples, I tested the reproducibility of the 
assay for younger samples, where longer LTL were expected. Thus, I randomly 
selected a subset of 20 DNA samples from the cohort and I ran them in duplicate on 
two different days. The inter-assay coefficient of variation was 3.27%; the correlation 
coefficient between the average T/S ratio determined by the first and second runs was 
0.93 (figure 6.2). 
 
Figure 6.2 Reproducibility of the LTL assay in the Ten Towns Study. 
Scatter plot reporting the strong correlation between T/S values of 20 DNA samples 





The estimate of the coefficient of variation, though potentially an 
underestimate of the true coefficient of variation based on separate DNA extractions, 
was lower than that of several previous studies using similar methods (82;250;479), 
confirming the high reproducibility of the protocol also for higher values of LTL. The 
corresponding LTL in base pairs from the T/S ratio measured in each subject was 
obtained by means of the regression line resulting from comparison between T/S ratio 
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of our Q-PCR assay and the standard terminal restriction fragment (TRF) analysis 
(479). 
6.2.5 Brachial artery distensibility 
Brachial artery distensibility was measured using the protocol reported in the 
general methods. 
6.2.6 Statistical Analysis 
Statistical analyses were carried out using STATA/SE software (Stata/SE 10 for 
Windows; StataCorp LP, College Station, TX). Variables were checked for normality 
and log transformed where necessary. Means and standard deviations (or geometric 
means and standard deviations for log-transformed variables) for adiposity and blood 
analyses were presented unadjusted. Means and differences in LTL were adjusted for 
age, sex, ethnicity, and town using the regress and lincom procedures within STATA. 
Estimates of mean LTL by quintiles of CRP and fibrinogen adjusted for age, sex, 
ethnicity, and town were obtained using the same procedures. Associations between 
anthropometry, blood pressure, blood analytes, and LTL were examined using linear 






Anthropometric, blood, and LTL measurements were available from 1080 
subjects (992 white Europeans, 73 South Asians, and 15 from other ethnicities). 
Measures of LTL were normally distributed (Figure 6.3) with a mean of 1.30 T/S ratio 
(absolute value 8494bp) and a large inter-individual variability (T/S range: 0.65 - 
2.32; absolute range: 5517-13166bp).  
 
Figure 6.3 Distribution of LTL in the Ten Towns Study. 
LTL were normally distributed with a mean T/S ratio of 1.30 corresponding to an 
absolute value 8494bp. There was a large inter-individual variability of LTL (T/S 
range: 0.65 - 2.32; absolute range: 5517-13166bp). 
 
Clinical characteristics of participants are shown in Table 6.1. The same table 
shows the associations between each variable and LTL after adjustment for age, 

















Table 6.1 Characteristics of the Ten Towns population and associations with LTL 
 
 




Difference in T/S ratio for 
one SD / Log SD(†) increase 
in variable (95% CI) 
p (linear 
association) 
Height (cm) 166.9 1.1 0.014 (-0.004, 0.032) 0.12 
BMI (Kg/m
2
)* 20.6 1.2 -0.008 (-0.023, 0.007) 0.32 
Waist Circumference (cm)* 69.7 1.1 0.003 (-0.019, 0.012) 0.66 
Sum of skinfolds (mm)* 46.0 1.6 -0.011 (-0.028, 0.006) 0.21 
Fat mass (%) 25.9 6.5 -0.013 (-0.030, 0.004) 0.12 
Systolic BP (mmHg) 120.7 13.3 0.010 (-0.006, 0.025) 0.21 
Diastolic BP (mmHg) 66.9 7.2 0.012 (-0.003, 0.027) 0.11 
Pulse pressure (mmHg) 53.8 11.3 0.003 (-0.013, 0.019) 0.68 
Total cholesterol (mmol/L) 4.2 0.7 0.007 (-0.008, 0.023) 0.35 
LDL cholesterol (mmol/L) 2.3 0.6 0.005 (-0.010, 0.020) 0.48 
HDL cholesterol (mmol/L) 1.5 0.3 0.013 (-0.002, 0.028) 0.10 
Triglycerides (mmol/L)* 0.9 1.4 -0.007 (-0.023, 0.008) 0.35 
Glucose (mmol/L) 5.1 0.5 0.001 (-0.016, 0.017) 0.93 
Insulin (mU/L)* 8.9 1.6 -0.011 (-0.026, 0.004) 0.15 
Insulin resistance (HOMA)* 0.7 1.1 0.002 (-0.015, 0.018) 0.85 
C-reactive protein (mg/L)* 0.2 3.3 -0.026 (-0.041, -0.011) <0.001 
Fibrinogen (g/L)* 2.5 1.2 -0.025 (-0.040, -0.010) 0.001 
Von Willebrand factor 
(IU/dL)* 
100.6 1.4 -0.011 (-0.026, 0.005) 0.18 
Tissue plasminogen activ. 
(ng/ml)* 
5.4 1.5 0.005 (-0.010, 0.020) 0.53 
Homocysteine (μmol/L)* 8.0 1.3 0.001 (-0.014, 0.016) 0.88 
Vitamin C (μmol/L) 49.9 23.6 -0.003 (-0.020, 0.014) 0.73 
Folate (nmol/L)* 14.2 1.7 0.010 (-0.005, 0.026) 0.18 
Adjusted for sex, age, ethnicity and town. Missing values: Sum of skinfolds (n=27). 
*Geometric mean and geometric SD and difference per log SD change presented for 





A negative linear association was found between LTL and age (β=-0.016, 95% 
CI [-0.032 to -0.001], p=0.04), whereas there were no associations between LTL and 
circulating levels of traditional CV risk factors including dyslipidaemia, hypertension, 
insulin resistance, and obesity. However, there was a strong inverse association 
between LTL and circulating levels of inflammatory markers, CRP (β =-0.026, 95% 
CI [-0.041 to -0.011], p<0.001) and fibrinogen (β =-0.025, 95% CI [-0.040 to -0.010], 
p=0.001). There was a graded decline in mean LTL with increasing levels of CRP, 
and mean LTL was significantly shorter in subjects in the top quintile of CRP levels 
compared with the first quintile (mean difference T/S ratio 0.09, absolute value mean 
difference 408bp, p<0.001) (Figure 6.4A).        
 
Figure 6.4A. Association between LTL and CRP in the Ten Towns Study. 
Graded reduction of LTL was observed with increasing quintile of CRP. Results are 




Similarly, for fibrinogen (Figure 6.4B), the mean LTL was significantly 
shorter in subjects in the top quintile compared with the first quintile (mean difference 
T/S ratio 0.07, absolute value mean difference 331bp, p=0.003). 
 
Figure 6.5B Association between LTL and fibrinogen in the Ten Towns Study. 
Graded reduction of LTL was observed with increasing quintile of Fibrinogen. 
Results are adjusted for sex, age, ethnicity and town.  
 
CRP and fibrinogen levels were strongly associated with each other (r=0.6; 
p<0.001). The associations between CRP, fibrinogen, and LTL were not mutually 
adjusted because these two strongly intercorrelated variables are likely to represent 
the same biological pathway. No sex interaction was found for the associations 
between LTL and inflammatory markers and no differences were found between 
groups of towns with high and low adult CV mortality.  
Males had significantly shorter LTL than females (mean difference T/S ratio 
0.03, absolute value mean difference 138 bp, p=0.03) (Figure 6.5A), whereas subjects 
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of South Asian ethnicity showed longer LTL than white Europeans (mean difference 
T/S ratio 0.10, absolute value mean difference 458 bp,p=0.01) (Figure 6.5B).  
A 
B 
Figure 6.6 Gender and ethnic gap of LTL in the Ten Towns Study. 
Boys had significantly shorter LTL compared to girls (p=0.03) (A). Furthermore, 
South Asian had longer LTL compared to White European participants (p=0.01)(B). 
 
Current and previous smokers had shorter LTL than non-smokers (P=0.06 for 
a difference between the 3 smoking groups) with and without correction for cotinine 
levels. Social class, levels of physical activity and history of breast feeding were not 
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related with LTL (Table 6.2). Furthermore, no differences in LTL were observed 
between different Tanner stages.  
Table 6.2 Difference of LTL for social class, breast feeding, levels of physical 
activity and smoking status 
Variables Categories N Mean (95% CI) p (Diff.) 
Social Class 
1 101 1.32 (1.27, 1.37) 0.53 
2 288 1.32 (1.29, 1.35) 
3 112 1.32 (1.28, 1.37) 
4 127 1.27 (1.23, 1.31) 
5 43 1.28 (1.21, 1.36) 
6 295 1.30 (1.28, 1.33) 
7 58 1.29 (1.22, 1.36) 
Breast Feeding 
(during first 3 
months) 
Breast fed 405 1.31 (1.28, 1.33) 0.92 
Bottle fed 375 1.30 (1.27, 1.33) 
Mixture 230 1.31 (1.27, 1.34) 
Levels of Physical 
Activity (1 = 
Low) 
1 47 1.35 (1.28, 1.42) 0.52 
2 146 1.33 (1.28, 1.37) 
3 434 1.30 (1.28, 1.32) 
4 285 1.30 (1.27, 1.33) 
5 138 1.29 (1.25, 1.33) 
Smoking status* 
Current 260 1.29  (1.26, 1.33) 
0.06 Past 367 1.28  (1.26, 1.31) 
Never 447 1.32  (1.30, 1.34) 
All analyses adjusted for sex, age ethnicity and town. Smoking status difference is 
unsorted 
 
Consequently, the strength of the inverse association between LTL and 
inflammatory markers was not affected by adjustments for behavioural factors 
(physical activity and smoking status), metabolic factors (body mass index, 
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parameters of metabolic syndrome), circulating levels of antioxidant molecules (ie, 
folate, vitamin C), and socioeconomic and puberty status (Tanner stage) (Table 6.3).  
 
Table 6.3 Associations between LTL, CRP and Fibrinogen adjusted for other 
factors 
Variable Additionally adjusted for 
Difference in T/S ratio 
for log SD increase 





No additional adjustments -0.026 (-0.041, -0.011) <0.001 
Physical activity (5 level variable) -0.028 (-0.043, -0.012) <0.001 
Smoking status corrected for 
cotinine 
-0.026 (-0.041, -0.011) 
<0.001 
Folate, Vitamin C -0.026 (-0.041, -0.011) <0.001 
BMI -0.026 (-0.042, -0.010) 0.001 
WC
§




-0.026 (-0.042, -0.010) 
0.001 
All of the above -0.026 (-0.042, -0.010) 0.002 
Fibrinogen  
(g/L) 
No additional adjustments -0.025 (-0.040, -0.010) 0.001 
Physical activity (5 level variable) -0.025 (-0.040, -0.010) 0.001 
Smoking status corrected for 
cotinine 
-0.025 (-0.040, -0.010) 
0.001 
Folate, Vitamin C -0.026 (-0.041, -0.011) <0.001 
BMI -0.025 (-0.041, -0.009) 0.002 
WC
§




-0.024 (-0.040, -0.009) 
0.002 
All of the above -0.023 (-0.039, -0.007) 0.006 
All differences adjusted for sex, age, ethnicity and town. § WC: Waist Circumference, 
¶ SBP: Systolic Blood Pressure. 
The sex and ethnic differences in LTL were not affected by adjustment for 
anthropometric parameters, Tanner stage, smoking status, levels of physical activity, 
socioeconomic status, and CV risk factors. 
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A linear negative association was found between LTL and brachial artery 
distensibility (Table 6.4), which remained also after multiple adjustments for levels of 
traditional and novel CV risk factors.  
Table 6.4 Association between Telomere length (T/S ratio) and distensibility 
 N Difference in T/S ratio for SD 





260 -0.046 (-0.085, -0.007) 0.02 
Adjusted for sex, age, ethnicity, pulse pressure and town (4 towns) 
 
All analyses were repeated in the white European participants alone (Table 
6.5), as well as in females and males separately (Table 6.6), and the results were not 




Table 6.5 Associations between Telomere length (T/S ratio) and other variables – for white Europeans only 
 
 
* Geometric mean and geometric SD and difference per log SD change presented for log transformed variables  
Adjusted for sex, age and town 
Missing values: Sum of skinfolds (n=25) 










Age (years) 15.1 0.6 -0.016 (-0.033, 0.000) 0.06
Height (cm) 167.5 8.5 0.015 (-0.004, 0.033) 0.12
BMI (kg/m2)* 20.7 1.2 -0.006 (-0.022, 0.010) 0.47
Waist circumference (cm)* 69.8 1.1 -0.004 (-0.020, 0.012) 0.64
Sum of skinfolds (mm)* 46.2 1.5 -0.008 (-0.025, 0.010) 0.40
Fat mass % 25.9 6.5 -0.013 (-0.031, 0.005) 0.15
Systolic BP 121.0 13.4 0.010 (-0.006, 0.026) 0.22
Diastolic BP 67.0 7.2 0.012 (-0.004, 0.027) 0.14
Pulse pressure 54.0 11.3 0.004 (-0.012, 0.021) 0.62
Cholesterol (mmol/L) 4.2 0.7 0.009 (-0.007, 0.025) 0.29
LDL cholesterol (mmol/L) 2.3 0.6 0.007 (-0.009, 0.022) 0.41
HDL cholesterol (mmol/L) 1.5 0.3 0.014 (-0.002, 0.030) 0.08
Triglyceride (mmol/L)* 0.9 1.4 -0.008 (-0.025, 0.008) 0.32
Glucose (mmol/L) 5.0 0.5 0.001 (-0.016, 0.019) 0.88
Insulin (mU/L)* 8.9 1.6 -0.010 (-0.025, 0.006) 0.23
Insulin resistance (HOMA)* 0.7 1.1 0.002 (-0.015, 0.018) 0.86
C-reactive protein (mg/L)* 0.2 3.3 -0.022 (-0.038, -0.007) 0.01
Von Willebrand factor (IU/dL)* 99.9 1.4 -0.011 (-0.027, 0.006) 0.20
Tissue plasminogen activator (ng/mL)* 5.3 1.5 0.006 (-0.010, 0.021) 0.49
Homocysteine (μmol/L)* 8.0 1.3 0.001 (-0.014, 0.017) 0.87
Fibrinogen (g/L)* 2.5 1.2 -0.023 (-0.039, -0.007) 0.005
Vitamin C (μmol/L) 51.6 23.1 -0.001 (-0.019, 0.016) 0.87
Folate (nmol/L)* 14.3 1.7 0.010 (-0.006, 0.026) 0.23
Difference in T/S ratio for one 




Table 6.6 Associations between Telomere length (T/S ratio) and other variables by gender 
 
* Geometric mean and geometric SD and difference per log SD change presented for log transformed variables  
Adjusted for age, ethnicity and town 






Height (cm) 0.005 (-0.018, 0.027) 0.69 0.017 (-0.006, 0.041) 0.14 0.82
BMI (kg/m2)* -0.014 (-0.034, 0.006) 0.17 0.002 (-0.021, 0.024) 0.88 0.45
Waist circumference (cm)* -0.008 (-0.028, 0.013) 0.46 0.003 (-0.019, 0.026) 0.77 0.67
Sum of skinfolds (mm)* -0.013 (-0.033, 0.007) 0.21 -0.001 (-0.024, 0.022) 0.93 0.40
Fat mass % -0.012 (-0.032, 0.008) 0.24 -0.006 (-0.028, 0.017) 0.63 0.72
Systolic BP 0.005 (-0.016, 0.026) 0.64 0.015 (-0.008, 0.037) 0.20 0.63
Diastolic BP 0.015 (-0.005, 0.036) 0.13 0.008 (-0.014, 0.030) 0.48 0.70
Pulse pressure -0.004 (-0.025, 0.016) 0.67 0.012 (-0.010, 0.034) 0.29 0.42
Cholesterol (mmol/L) 0.009 (-0.011, 0.030) 0.39 0.007 (-0.016, 0.030) 0.54 0.85
LDL cholesterol (mmol/L) 0.009 (-0.011, 0.029) 0.38 0.004 (-0.019, 0.026) 0.75 0.83
HDL cholesterol (mmol/L) 0.009 (-0.011, 0.029) 0.39 0.016 (-0.006, 0.039) 0.15 0.36
Triglyceride (mmol/L)* -0.004 (-0.025, 0.017) 0.71 -0.013 (-0.036, 0.011) 0.29 0.66
Glucose (mmol/L) -0.015 (-0.037, 0.007) 0.19 0.019 (-0.006, 0.043) 0.13 0.00
Insulin (mU/L)* -0.010 (-0.030, 0.010) 0.34 -0.013 (-0.035, 0.009) 0.25 0.95
Insulin resistance (HOMA)* -0.013 (-0.035, 0.008) 0.23 0.018 (-0.006, 0.041) 0.14 0.01
C-reactive protein (mg/L)* -0.020 (-0.040, 0.000) 0.05 -0.032 (-0.055, -0.010) 0.01 0.61
Von Willebrand factor (IU/dL)* -0.016 (-0.036, 0.004) 0.11 0.001 (-0.021, 0.023) 0.90 0.17
Tissue plasminogen activator (ng/mL)* 0.014 (-0.007, 0.034) 0.19 -0.005 (-0.028, 0.017) 0.64 0.15
Homocysteine (μmol/L)* -0.002 (-0.023, 0.018) 0.81 0.009 (-0.014, 0.032) 0.43 0.53
Fibrinogen (g/L)* -0.014 (-0.034, 0.006) 0.17 -0.034 (-0.057, -0.012) 0.00 0.33
Vitamin C (μmol/L) 0.002 (-0.020, 0.025) 0.84 -0.009 (-0.035, 0.016) 0.46 0.19
Folate (nmol/L)* 0.006 (-0.014, 0.026) 0.56 0.012 (-0.011, 0.034) 0.31 0.70
Difference in T/S ratio for one 
SD / log SD† increase in 
variable (95% CI)
Boys Girls
Difference in T/S ratio for 
one SD / log SD† 






This was the first study to report an association between LTL, inflammatory 
markers and CV phenotype in a young and well-characterized cohort of healthy 
adolescents. The key finding is that LTL was not related to a range of traditional CV 
risk factors but was inversely related to two measures of inflammation, CRP and 
fibrinogen, both of which have been associated with adverse CV outcomes (563-579). 
However, an unexpected negative relationship between LTL and brachial artery 
distensibility was detected, suggesting that adolescents with longer LTL have an 
increased burden of CV damage. Furthermore, this study showed, for the first time, 
that the sex difference in LTL, which has been described in most adult studies, is 
already present early after puberty (at 13–16 years of age) and was not materially 
affected by adjustment for CV risk factors, Tanner stage, or other environmental or 
behavioral factors, suggesting that the contribution of estrogen and environmental 
exposure to this difference was small. Finally, South Asians had longer LTL 
compared to Europeans, despite their higher CV mortality recorded in adult life. 
Two recent studies have measured LTL in children and adolescents. In a cross-
sectional case control study including children of 2–17 years old, Buxton et al (580) 
reported significantly shorter LTL in obese children compared to their lean peers. Our 
findings differ from with those of Buxton and are in agreement with Zhu et al who did 
not document associations between biochemical and anthropometric measures of 
adiposity and LTL in a cohort of 667 young adolescents (581). Our study as that of 
Zhu et al., however, was not designed to explore an association between LTL and 
adiposity. Indeed, <5% of children in both populations were obese and lack of power 
may explain the negative findings. The most important difference in our data 
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compared with those of Buxton et al and Zhu et al is that, while both of these previous 
studies measured LTL in children and young adolescents, neither examined the 
impact of inflammation or other CV risk factors on LTL. 
The relationship between CV risk factors, inflammatory markers, and LTL had 
been previously explored only in older cohorts (62;63). Analysis of the placebo arm 
of a randomized controlled trial found that short LTL was a predictor of early 
myocardial infarction in adulthood, although this relationship was not explained by 
correlation between LTL and established CV risk factors (61). Our current findings 
suggested that the relationship between inflammatory burden and LTL begins early in 
life and persists for physiological levels of inflammation. It is now clear that 
atherosclerosis is an aging-related systemic disease which begins from childhood 
(582;583) and is largely driven by a chronic inflammatory and oxidative stress 
exposure (332;584). Accordingly, it has been suggested that the shortened LTL often 
observed in adult patients who suffer from atherosclerosis
 
may be the result of a 
continuous stimulus to the recruitment, differentiation and replication of new 
inflammatory cells as well as a higher level oxidative stress mediated damage to the 
telomere sequence (75;240). While the inverse relationship between inflammatory 
markers and LTL recorded in our study strongly support this hypothesis, the finding 
that adolescents with longer LTL had a lower brachial distensibility is unexplained. 
Indeed, adolescents with higher brachial artery distensibility (lower level of vascular 
damage) had shorter LTL (normally associated with higher risk of CV disease). 
Several factors could account for this finding. It is possible that adolescents with 
increased CV damage due to higher inflammation tend to mobilize a higher number of 
endothelial progenitor cells from the bone marrow in the attempt to repair the vascular 
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injury. Consequently, at 13-16 year old, subjects exposed to higher levels of 
inflammation during childhood could have shorter LTL but better arterial 
distensibility because of the hyperactivation of vascular repair mechanisms (585). A 
recent study from Charakida et al demonstrated that exposure to CV risk factors 
during the first decade of life is associated with a better vascular phenotype at 11 
years old (586). The hyper-compensation to the vascular damage in early life could 
have significant costs for the future. Indeed, a higher mobilization of endothelial 
progenitor cells is sustained by an increased number of HSC replications, their 
haematopoietic precursors (112). This will further increase the rate of telomere 
attrition in HSC/endothelial progenitor cells, over and above the contribution of the 
inflammatory burden. As production and mobilization of endothelial progenitor cells 
is dependent on telomere length (587), subjects with faster rate of telomere length 
attrition during early life could lack effective vascular repair mechanisms during 
adulthood, as they will be those with shorter telomere length. At this stage, the 
lifelong exposure to inflammation may have caused high levels of vascular damage 
coupled with accumulation of HSC/endothelial progenitor cells with short telomere 
length. Therefore, the increased burden of vascular damage cannot be properly 
repaired due to the reduced ability to mobilize endothelial progenitor cells from the 
bone marrow. These mechanisms would result in the emergence of the expected 
association between LTL and measures of vascular remodelling, normally described 
in adult studies.   
The relationship between CRP and fibrinogen with LTL was observed at levels 
below those associated with CV risk elevation in adults (574). This is remarkable, as 
it suggests that even physiological variations in inflammatory states could have an 
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effect on LTL biology in the young. This is supported by a recent, large meta-analysis 
which demonstrated a continuous relationship between CRP and CV outcome, even 
after adjustment for traditional CV risk factors. 
The inflammatory imprinting on LTL, not explained by levels of environmental 
exposure (socioeconomic class, levels of physical activity, smoking status, etc.), 
suggests that heritable factors could represent the earliest determinants of the 
association between short LTL and inflammation. In the general population, these 
factors could set different levels of inflammatory response generated by a common 
environmental burden, in this way affecting the rate of LTL shortening. An additional 
interpretation of this finding is that peri- and early post-natal exposure to infections 
might cause shorter LTL in adolescents with a higher inflammatory burden. Indeed, 
an ubiquitous and repeated driver of early life inflammation is infection. Childhood 
infections are commoner and more severe in boys, who have shorter LTL (588). 
Furthermore, chronic infections, such as cytomegalovirus (CMV), are associated with 
adult CV disease (589), and also result in shorter LTL, by increasing T cell 
proliferation (515;590). Therefore, infection can determine increase inflammatory 
burden and proliferation of immune cells, possibly accounting for the described 
association between inflammatory markers and LTL. While this represents an 
intriguing hypothesis, it is unlikely that, at this early stage of life, common infections 
might have had a major impact on the rate of LTL shortening. Indeed, among healthy 
children and young adolescents, the most common infections normally present acute 
pathologies. As suggested in our first study, short lasting inflammatory responses 
hardly impact on LTL, even when the infective burden is much more severe and 
longer than that recorded in young adolescents. Furthermore, CMV infection has been 
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shown to short telomere length in middle age populations (515;590), where the 
infective burden and its consequences on LTL dynamic is likely to be much greater 
than those affecting young populations. Finally, CMV infection shortens telomere 
length in small subgroups of inflammatory cells (T-cells) (515;590), while qPCR 
measures the average telomere length across the whole set of peripheral leukocytes. It 
is therefore unlikely that CMV infection could provide a substantial contribution to 
average LTL measured at such young age. 
LTL was shorter in male than female subjects and this difference was not 
affected by adjustment for Tanner pubertal stage. An independent influence of gender 
on LTL has been reported in most adult studies (62;87;95), while in newborns this 
difference does not exist (89). Our current findings fill the gap between adulthood and 
birth, showing that the gender gap in LTL is already present during early adolescence. 
Zhu et al recently reported similar results, showing longer LTL in adolescent females 
compared with males using a smaller cohort of healthy white and black adolescents 
(581). The longer LTL recorded in female as opposed to male subjects has previously 
been attributed to the anti-inflammatory and anti-oxidative effects of endogenous 
oestrogens (591). A short term oestrogen exposure could potentially explain current 
finding, as most of the adolescents in the study had already completed their pubertal 
maturation and the difference in LTL observed was relatively modest. However, at 13 
to 16 years of age, the exposure to sexual hormones is likely to be limited to 3-4 
years, while the gender difference in LTL recorded in our population was similar to 
that reported in middle-age populations with much longer oestrogen burden (87;95). 
Furthermore, the sex difference in LTL is not influenced by adjustments for pubertal 
stage and no gender interaction was found in the relationship between LTL and 
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inflammation. This, together with the longitudinal findings from the Bogalusa Heart 
Study, which did not find differences in the rate of telomere shortening between 
females and males (87), suggests that other factors may account for the gender gap in 
LTL. Robust correlations in LTL have been described between fathers and daughters, 
between mothers and sons and daughters, and among siblings (97). An X-linked 
inheritance of LTL is the most probable explanation for these findings, suggesting 
that gene variance on the X chromosome exerts an important influence on telomere 
length dynamics. Our current findings support this hypothesis and further suggest that 
factors accounting for this X-linked heritance are likely to exert their effects during 
the pre-pubertal period. The gender gap in LTL defined in early adolescence seems to 
be slightly amplified by the oestrogen exposure during reproductive age and could 
account, at least in part, for the sexual dimorphism of the adult association between 
early markers of atherosclerosis and LTL (353;543). 
Considering their higher adult CV risk compared with White Europeans (592), 
it was unexpected to find longer LTL in South Asian subjects. This is the first study 
where LTL has been compared in young and healthy individuals of these two ethnic 
groups. Hunt et al have shown that ethnicity is an important determinant of LTL (95) 
but, similarly to our results, they found that African Americans had longer LTL 
compared to White Americans, despite their higher adult CV risk. They explained this 
difference by calculating the hypothetical rate of telomere shortening in their 
population (starting from the measures of LTL recorded in different individuals with 
different ages). Despite the limitations of this analysis, they showed that the rate of 
telomere attrition across their cohort was higher in Afro-Americans than in their 
peers. Recently, Aviv et al confirmed these results by measuring the longitudinal rate 
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of LTL change in White and African Americans who took part to the Bogalusa Heart 
Study (87). The narrow age range of the population, the relatively low number of 
South Asian subjects and the lack of serial samples available for the LTL measure did 
not permit similar analyses in the present study population, but a similar mechanism 
could explain the observed findings.  
Social class was not associated with LTL. It has been hypothesized that more 
socio-economically deprived individuals age faster and, thus, have shorter telomeres 
than their more affluent counterparts (593). While a positive but weak association 
between white LTL and socio-economic status has previously been reported by 
Cherkas et al in a large heterogeneous sample of females (594), Adams et al could not 
confirm this finding in a study involving 318 individuals from a homogeneous birth 
cohort and Woo et al reported an inverse association between social status and LTL 
(595). The young age of the participants in our study excluded the possibility that 
several co-morbidities commonly found in lower social classes (e.g. obesity and 
smoking) may have a significant impact on LTL. This enables us to study the possible 
relationship between social class and LTL in a less confounded population. Therefore, 
the results of this and previous studies suggest that there may be little or no influence 
of socio-economic status on LTL.  
There was no relationship between levels of physical activity and LTL in the 
whole cohort. These results are in contrast with previous studies reporting longer LTL 
in adults with higher levels of physical activity (596;597). In his cohort of 
adolescents, Zhu et al. found an association between LTL and vigorous levels of 
physical activity, but this association was present only in females and not males (581). 
It has been suggested that the association between longer LTL and increased physical 
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activity level may be mediated through an overall diminished burden of oxidative 
stress and inflammation in adults (581;597). Although this is a possibility, our results 
suggest that regulation of LTL mediated by inflammation is relatively independent 
from levels of physical activity in adolescence. Exercise helps to maintain energy 
balance and to reduce obesity and insulin resistance (598;598). These factors, in the 
long term, may influence on LTL dynamics by influencing levels of oxidative stress 
and inflammation (599;600). However, obesity and insulin resistance had a marginal 
impact on LTL measurements in this cohort. It is not surprising, therefore, that levels 
of physical activity also had a limited impact on LTL in our population. 
The Ten Towns Health Heart Study represents a unique cohort in which several 
aspects of the LTL biology and its relationship with environmental and behavioural 
factors could be explored. For example, the impact of a long term environmental 
exposure, which is hard to quantify in adult studies, is minimized. This has potential 
to identify the initial and prolonged biological pathways which account for the adult 
association between short LTL and age-related diseases. Furthermore, the 
measurement of several covariates potentially influencing LTL, enabled extensive 
adjustments, providing a comprehensive view on the relative impact of each 
parameter on LTL.  
Our study had some limitations. Although it is the first report to describe longer 
LTL in young South Asian adolescents compared to their White European 
counterparts, the biological meaning of this difference remains to be fully explored. 
Indeed, the recruited population included only a low number of South Asian 
adolescents and there is no evidence in the literature to support the assumption that 
LTL is a predictor of morbidity and mortality for age-related disease across different 
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ethnic groups. The cross-sectional design of the study did not permit inferring 
causality from the inverse association between inflammatory markers and LTL. 
However, it is very unlikely that LTL contributed to increased CRP and fibrinogen in 
this population. The presence of critically short telomeres induces a persistent 
activation of the DNA damage response and this has been associated with an 
increased production of pro-inflammatory cytokines in cultured human cells (i.e. IL-
6) (242). While this mechanism could partially account for the association between 
inflammatory markers and LTL recorded in adult studies, the age of our cohort and 
the consequent longer LTL compared to adult population make the activation of the 
DNA damage response triggered by critically short telomeres extremely unlikely. This 
suggests that reverse causality is not the explanation for our results. The high inter-
individual variability of LTL could have reduced the power to detect associations with 
CV risk factors, while the small range and young age of our population reduced the 
capacity to discriminate long term effects, for example, the impact of smoking status 
and/or obesity. This might explain the lack of certain associations compared to other 
reports. On the other hand, these characteristics suggest that the primary effects of CV 
risk factors on LTL are probably associated with the long term inflammatory burden, 
which begins in early adolescence. 
In conclusion, our study showed that, while clinical problems from age-related 
diseases do not usually appear before advanced age, an association between short LTL 
and inflammatory markers in early adolescence may represent a possible 
pathophysiological pathway accounting for the relationship between short LTL and 
higher morbidity and mortality risk seen in adult studies. Levels of exposure to 
environmental and behavioural factors did not appear to contribute importantly to this 
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pathophysiological process in youth. As LTL records long term inflammatory burden, 





● The association between inflammation and LTL: 
A. Emerges from young ages 
B. Remains independent from cardiovascular risk factors, metabolic and 
behavioural factors 
● The association between LTL and cardiovascular phenotype: 
A. Is inverted compared to adult studies 
B. Replicates the direction of the association between cardiovascular risk 
factor and vascular phenotypes in the ALSPAC (a population of similar age)  
C. Suggests that, in the youth, repair mechanisms can efficiently counteract the 
evolution of age-related diseases (i.e. vascular damage) 
228 
 
7 STUDY 4 - A longitudinal study of the association between rate of telomere 
shortening and CV damage in a large british birth cohort 
The first three studies described: 1) the association between LTL and chronic 
inflammation, 2) its determinants and modification by metabolic factors, and 3) its 
origin in the young. The relevance of these pathways in the evolution of age-related 
diseases, however, remains largely unexplored. To answer to this question, the fourth 
study of this thesis explored the relationship between longitudinal variation of LTL 
and markers of age-related disease evolution. As a model of age-related disease we 
used CVD because: 
1. It is a chronic inflammatory disease where inflammation is in the causal 
pathway for disease initiation and evolution 
2. It is common in the general population 
3. The subclinical phases of disease evolution can be easily quantified using 
non-invasive techniques applicable to large populations 
4. Cross-sectional studies have already documented strong associations 
between LTL and CV morbidity and mortality 
7.1 Introduction 
The most striking feature of LTL is that it is highly variable among individuals, 
even after adjustment for age. Three potential causes of this variability are: (i) high 
inter-individual variations in telomere length at birth (89;104;601;602); (ii) high inter-
individual variations in telomere attrition after birth (66;87;117;601); and (iii) 
variations that are attributed to the techniques used to measure telomere length. At 
birth, inter-individual variations in LTL amount to as much as 4 kb (89;104); during 
adulthood, the variations in length may be as wide as or wider than those at birth 
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(62;63;66;67;95;97). This considerable inter-individual variation greatly confounds 
the reported cross-sectional associations between short LTL and increased risk of age-
related diseases. It is not known whether these associations are due to a greater rate of 
telomere shortening through life or due to an inherited short telomere length. This is 
an important issue as the identification of factors which influence the rate of telomere 
shortening may improve prevention of age-related disease and increase the chance of 
healthy aging. 
Longitudinal studies assessing LTL dynamics provide a better opportunity than 
cross-sectional analysis to study the mechanisms linking age-related diseases to LTL. 
However, these investigations are constrained by two major and related limitations. 
The first has to do with the availability of samples, and the second to the ability of 
current methodology to detect small changes in telomere lengths over a limited period 
of follow up. Very few repositories have sequential samples of leukocyte DNA (blood 
or buffy coats) that have been collected longitudinally from the same individuals. 
Furthermore, even when such samples are available, differences in the storage and 
DNA extraction methods between baseline and follow up visits can drastically impact 
on the final results. For example, using the Southern Blot technique, the results 
depend on the size of the TRF, and suboptimal procedures of DNA storing which 
causes non-physiological breaks in the telomere region can lead to the progressive 
accumulation of short TRF (e.g. LTL) in the sample. Assuming that two samples have 
been collected within an interval of few years, the artefact due to DNA degradation 
will be more evident in the baseline than in the follow up sample. Furthermore, 
procedures to extract the DNA can drastically affect longitudinal LTL assay 
preformed using real time PCR. For instance, the use of two different methods to 
extract the DNA can lead to variable levels of protein contamination, differently 
230 
 
affecting the amplification efficiency of the baseline and follow up PCR analyses. The 
second main limitation of longitudinal LTL analysis relies on a sufficient long follow-
up period to allow detection of a meaningful impact of genetic and environmental 
factors, and perhaps therapeutic interventions, on LTL attrition. This limitation is due 
to the relatively low accuracy of the current techniques used to measure LTL when 
compared to the slow LTL dynamics. For example, assuming one individual has LTL 
of 7kb. If we use a LTL assay with an inter-assay coefficient of variation of only 4%, 
we accept an error in repeated LTL measurements equivalent to 280b. If the same 
individual has a rate of LTL attrition of 80b/years, at least 3 years of follow up are 
necessary to have confidence that the detected changes in LTL may be due to the 
impact of genetic or environmental factors rather than to the intrinsic limitations of 
the telomere assay. In reality, the coefficient of variation of the methods that measure 
telomere length may considerably exceed the 4% value. Therefore, prolonged follow-
up periods and large cohorts will be required to attain credible inter-individual 
variations in telomere attrition rates. 
7.1.1 Surrogate measures of disease evolution 
Beyond the limitation of current LTL assays, most of the studies that analysed 
the association between LTL and age-related diseases have adopted case-control 
experimental designs (61;63;603;604). This limits the ability to explore the role of 
LTL dynamics in the evolution of age-related diseases. Indeed, once age-related 
diseases become clinically manifest, they are normally in advanced stages, and only 
limited information can be recovered on the processes involved in their early 
evolution. Over the last 20 years, however, several techniques have been developed to 
follow the preclinical phases of age-related diseases. This has opened up a new field 
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of ‘medical epidemiology’ in which early life influences can be studied on objective 
measures of disease evolution and the effects of treatments determined. 
Atherosclerosis represents the most remarkable example of the utility of surrogate 
markers in understanding the mechanisms involved in disease evolution.  
7.1.2 The relationship between vascular remodelling, aging, inflammation and LTL 
cIMT has been considered a sensitive and reproducible marker of vascular 
remodelling, helping to inform on factors and mechanisms involved in the evolution 
of this process (605). The use of cIMT has enabled the demonstration that a 
physiological process of vascular remodelling occurs with aging, over and above the 
contribution of common CV risk factors. Indeed, values of cIMT increase naturally 
with aging (606). Although the range of factors that contribute to this physiological 
process of vascular remodelling remains unclear, increased exposure to inflammation 
and oxidative stress found in the elderly may well play a crucial role (329;332). 
Increased levels of oxidative stress within the vascular sub-endothelial space 
determine progressive destruction of elastin fibres accompanied by accumulation of 
fibrotic tissue. This process results in a progressive dilation of the vessel with reduced 
elasticity of the vascular wall, commonly observed with aging (607). Furthermore, the 
increased exposure to oxidative stress increases the expression of adhesion molecules 
on endothelial cells, promoting recruitment of inflammatory cells in the sub-
endothelial space and further increasing the oxidative stress damage to local tissues 
(332;584). These processes may lead to a progressive increase of the thickness of the 
intima-media layer which is commonly described in the elderly (608). Growing 
biological evidence supports a role for inflammation and oxidative stress in the 
evolution of the age-related vascular remodelling (607-610). A pro-inflammatory shift 
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in vascular gene expression profile, including an up regulation of inflammatory 
cytokines, chemokines, adhesion molecules, and inducible nitric oxide synthase has 
been described both in rodents and in primates during normal healthy aging (611-
617). Intriguingly, similar pathways are considered central to the evolution of 
atherosclerosis. Indeed, an aging increase in the prevalence of atherosclerotic plaques 
has been described in populations free of overt CV risk factors (618;619). 
Few studies have explored the relationship between cellular aging pathways 
and cIMT. O’Donnell et al have demonstrated an inverse association between LTL 
and IMT of the internal carotid artery (ICA), suggesting that subjects with shorter 
LTL are those with increased risk of atherosclerosis (543). Similar results were 
obtained by Benetos et al in a population of patients with hypertension (60), as well as 
by Panayiotou et al (353). The former study, not only described an inverse association 
between LTL and cIMT, but also between LTL and the total area of the vessel 
occupied by atherosclerotic plaques. This suggests that LTL biology could be 
involved in the evolution of vascular remodelling. However, an important limitation 
of these reports was their cross-sectional design, which did not allow inference of 
causality on the association between LTL and markers of CV remodelling. 
Furthermore, the lack of longitudinal measurements of LTL made it impossible to 
understand whether the potential influence of LTL biology on the process of vascular 
remodelling depends on the rate of LTL attrition or on maintenance of inherited short 
LTL through lifespan.  
 
The aim of this study was to determine whether rate of LTL shortening over 10 
years predicted cardiac and vascular phenotypes independently from established CV 
risk factors.  
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cIMT was used as a marker of age-related disease and lifelong inflammatory 
burden. The association between changes of LTL over 10 years, CV risk factor burden 
and several measures of CV remodelling were investigated in the National Survey of 
Health and Development (NSHD, also known as 1946 birth cohort) study. It 
represents the oldest of the British cohort studies (620), and is unique in providing 
measures of LTL and CV risk factors at the ages of 53 and 60-64 years, together with 
a characterization of the cardiac and vascular phenotypes at the later time point.  
 
7.2 Specific Methods 
7.2.1 Population 
The MRC NSHD is a social class stratified sample of all singleton births to 
married parents in England, Scotland, and Wales during 1 week in March 1946. The 
cohort originally included 2547 women and 2815 men and has been followed up 23 
times since birth. The latest data collection took place when participants were 60-64 
years old (between 2006 and 2010) (621).  
Study members still alive and with a known current address in England, 
Scotland or Wales were invited for an assessment at one of six clinical research 
facilities or to be visited by a research nurse at home. Invitations were not sent to 
those who had died (n=778), who were living abroad (n=570), had previously 
withdrawn from the study (n=594) or had been lost to follow-up (n=564). Of those 
invited, 2229 (78%) were assessed: 1690 (59.2%) attended a CRF and 539 (18.9%) 






Figure 7.1 Response to invitations sent between 2006 and 2010 in the MRC NSHD 
cohort. 
A total of 1690 patients attended the clinical facilities. This represented the target 
sample for vascular phenotype assessment. 
 
 
The participating sample remains broadly representative of native born British 
men and women of the same age (622). At the age of 53 years, a team of trained 
nurses had visited survey members in their own homes (623).  
At both 53 and 60-64 years, height, weight and waist and hip circumference 
were measured according to standardised protocols, two measures of systolic and 
diastolic blood pressure were taken with an OMROM 705 with the participant seated, 
with the second reading used in this analysis. Smoking status at both ages was 
collected by self-report questionnaire and individuals were categorised into current 
smokers and non-smokers. During home visits at 53 years and on postal 
questionnaires at 60-64 years, participants were asked to list all prescribed 
medications and to report doctor diagnosed myocardial infarction. Ethical approval 
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for the study was obtained from the Greater Manchester Local Research Ethics 
Committee and the Scotland A Research Ethics Committee for the 60-64 years 
collection and from the Multicentre Research Ethics Committee for the 53 years 
collection. Written, informed consent was obtained from the study members for each 
component of each data collection.  
7.2.2 Biochemical tests  
During the home visits at age 53 years, nurses took non fasting blood samples. 
Details of the biochemical assay used to estimate total cholesterol, HDL cholesterol 
and triglycerides have been previously provided (624).  HbA1c was measured on a 
Tosoh A1c 2.2 analyser (625).  
7.2.3 LTL assay 
At both ages, DNA was extracted from frozen EDTA blood samples using 
Puregene DNA isolation kits (Flowgen, Leicestershire, UK). LTL at both ages was 
measured in the same laboratory according to a previously validated RT-PCR 
technique in a blinded fashion (71). Measurements were performed in quadruplicate 
on an Applied Biosystems 7900HT Fast Real Time PCR system with 384-well plate 
capacity. The intra-assay coefficient of variation was 2.7% while the inter-assay 
coefficient of variation was 5.1%. To correct for inter-plate variation, four internal 
control DNA samples of known telomere length were run within each plate and used 
to generate a regression line, by which values of relative telomere length for the actual 
samples were converted into absolute LTL in base pairs. LTL measurements were 
available in 2660 individuals at 53 years and 1058 individuals at 60-64 years. Using a 
conservative approach, we considered outliers and excluded from the analyses the 




7.2.4 Vascular Phenotype 
The intima media thickness of the right and left carotid arteries were measured 
using the protocol described in the general methods. Briefly, the right and left carotid 
arteries were imaged longitudinally, one centimetre proximal to the carotid bifurcation 
following a standardized protocol (380). All measures were undertaken using an 
ultrasound scanner (Vivid I or Vivid 7, GE Healthcare) with a high resolution probe 
(12 MHz). Once clear images of the proximal and far walls IMT were obtained, the 
zoom function was used to magnify the region of interest. Ten second cineloops were 
recorded in DICOM format and downloaded for offline analysis. Analysis of the 
cineloops was performed in a core laboratory (Vascular Physiology Unit, Institute of 
Cardiovascular Science, University College, London) using dedicated software 
(Carotid Analyser, Iowa City, Iowa), which allows semi-automatic edge detection of 
the echogenic lines of the intima–media complex. Three end-diastolic frames were 
selected and analysed for mean cIMT of each image, defined as the interface between 
lumen-intima and media-adventitia. All images were analysed by two trained and 
blinded readers; intra- and inter-reader reproducibility were evaluated on a subset of 
10 randomly selected images which were analysed in a blind fashion twice. Intra and 
inter-class correlations were >0.9. In our analyses, we included right (R_cIMT), left 
(L_cIMT) and the average between the two sides (cIMT). 
7.2.5 Cardiac Phenotype 
Participants underwent echocardiography performed by a trained, experienced 
sonographer using GE Vivid I machines. Echocardiographic images were obtained 
from parasternal long axis and short axis, apical 5-chamber, 4-chamber, 3-chamber, 2-
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chamber and aortic views along with conventional and tissue Doppler in the 4-
chamber view. Image analysis, including wall and chamber measurements for the 
evaluation of left ventricular mass, ejection fraction and diastolic function (estimated 
from the ratio between trans-mitral Doppler early filling velocity and tissue Doppler 
early diastolic mitral annular velocity, E/E′ as well as from early and late mitral 
inflow velocity, E/A) was undertaken in a single core laboratory according to 
ASE/EAE guidelines (626) by three experienced readers blinded to patient identity 
using GE EchoPac software (GE Connecticut, USA). Left ventricular mass (LVM) 
was indexed to body surface area (LVMI).  
Quality assurance of echocardiography was performed throughout the study 
and blind duplicate reading reproducibility studies were carried out to establish inter- 
and intra-reader reliability. These showed excellent reproducibility (intra-class 
correlation coefficients were > 0.9). 
7.2.6 Statistical analysis 
Linear regression models were used to investigate the unadjusted association 
between LTL at 53 years, LTL at 60-64 years and their difference with each measure 
of vascular (cIMT) and cardiac (E/A, LVMI) phenotype at 60-64 years. A series of 
multiple regression models were then fitted to examine whether the traditional CV 
risk factors and other potential confounders influenced any associations observed 
between LTL and the vascular and cardiac phenotypes. LTL was standardised to have 
a mean of 0 and standard deviation of 1 for ease of interpretation of regression 
coefficients. First, adjustment was made for those variables which have been 
previously associated with LTL (age, gender, smoking and BMI) and second, 
additional adjustment was made for variables which, in our cohort, showed a 
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borderline association with cross-sectional measure of LTL or its change in linear 
regression models (P<0.2). In this regard we did not find significant associations 
between LTL and traditional CV risk factors (lipid profile, arterial hypertension or 
values of systolic/diastolic/pulse pressures, smoking, ethnicity, diagnosis of diabetes 
or levels of HbA1c and BMI) at 53 and 60-64 years. Only age and gender were 
significantly associated with LTL, while changes in BMI between the two visits 
presented a trend towards an association with LTL at 60-64 as well as its change 
between 53 and 60-64 year old. These associations however did not reach statistical 
significance. Accordantly, two multiple regression models are reported: model 1) 
adjusted for age at clinic visit (for 60-64 years analysis), gender, smoking, and 
difference in BMI (BMI at 60-64 minus BMI at 53); model 2) adjusted for relevant 
CV risk factors (cholesterol, systolic blood pressure), medications use, clinic centre, 
and past history of myocardial infarction. We report results with LTL shortening 
expressed as conditional change (the change is the regression coefficient for LTL at 
60-64 years in a model including both LTL at 53 years and LTL at 60-64 years), 
unless otherwise specified. LTL change was also defined as absolute change 
(arithmetic difference in bp of LTL at 60-64 years minus LTL at 53 years), rate of 
change per year ([absolute change]/[difference in age between visits]), relative change 
([LTL at 60-64 years - LTL at 53 years] / LTL at 53 years * 100) with consistent 
results.  
In sensitivity analyses, we restricted our sample excluding first those using 
medication and then those without plaques. Lastly, participants were categorised into 
those with normal and those with increased cIMT values, using the threshold of the 
75th percentiles of cIMT, as suggested by current guidelines and individuals with or 
without carotid plaque (14). The odds ratio for increased cIMT (binary variable > 75th 
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percentile) was calculated from multivariable logistic regression models with telomere 
length shortening both as continuous and categorical variables (>20%) and adjusting 
for the same confounders considered in the primary analyses. Analyses were 





7.3.1 Descriptive statistics 
Characteristics of the study population at both time points are shown in table 7.1.  
Table 7.1 Demographic, anthropometric and biochemical parameters of the 
MRC NSHD cohort 
Variable 
At 53 years 
(N=2611) 
At 60-64 years 
(N=1207) 
Gender, Male 1297 (49.7%) -- 
BMI, Kg/m2 27.34±4.65 27.93±4.88 
Systolic BP, mmHg 135.96±19.92 137.28±8.12 
Diastolic BP, mmHg 84.34±12.06 78.36±9.83 
HbA1C, %* 5.63±0.69 5.81±0.71 
Cholesterol, mmol/l* 5.99±1.08 5.53±1.19 
Triglycerides, mmol/*l 1.78±1.49 1.16±0.78 
HDL, mmol/l* 1.59±0.48 1.54±0.41 
cIMT  0.683 ±0.129 
R-cIMT  0.666 ±0.134 
L-cIMT  0.692 ±0.151 
Eject. Fr. (%)   68.11 ±9.68 
LA Dia (mm)  3.81 ±0.57 
LVM/BSA (g/m
2
)  92.46 ±27.12 
E/A Ratio  0.97 ±0.27 
Values are presented as mean±standard deviation, *geometric mean±standard 
deviation or absolute number of participants and percentages (%). 
cIMT (Average carotid artery), R_cIMT (Right carotid artery), L_cIMT (Left carotid 
artery), LA Dia (LA Diameter) Eject. Fr. (Left Ventricle Ejection Fraction), LVM/BSA 





The population was overweight with relatively high levels of systolic blood 
pressure, high levels of cholesterol and HbA1c. However, values of cIMT and cardiac 
parameters indicated healthy population, with normal left ventricular systolic and 
diastolic function, normal cIMT and preserved cardiac structure.  
7.3.2 Associations between LTL at 53 and 60-64 years and CV phenotypes 
LTL at 53 years was not associated with any vascular (cIMT) measures at 60-
64 years (Figure 7.2).  
 
 
Figure 7.2 Association between LTL at 53 years and cIMT at 60-64 years. 
LTL at 53 years did not predict the vascular phenotype assessed 10 years later 
 
Similarly, there was no evidence of associations between LTL at 53 years and 





Table 7.2 Mean difference (regression coefficient) of cardiac phenotypes against 
LTL at age 53 years 
Variables LTL 
LA Dia β (95%CI) 0.004  (-0.051, 0.059) 
 P  0.887 
Eject. Fr. β (95%CI) 0.497  (-0.367,1.360) 
 P  0.260 
LVM/BSA β (95%CI) 1.173  (-1.625, 3.970) 
 P  0.411 
E/A Ratio β (95%CI) 0.004  (-0.016, 0.024) 
 P  0.715 
Linear regression model (unadjusted models) 
cIMT (Average carotid artery), R_cIMT (Right carotid artery), L_cIMT (Left carotid 
artery), LA Dia (LA Diameter) Eject. Fr. (Ejection Fraction), LVM/BSA, E/A Ratio 
At the age of 60-64 years, LTL was inversely associated with cIMT 
(regression coefficient (β)=-0.017mm per 1 standard deviation (SD) LTL, 95% 
confidence interval (CI): -0.031, -0.003 p=0.015) (Figure 7.3), although the 
association was greatly attenuated in the fully adjusted model (age, gender, smoking, 
body composition, cholesterol and systolic blood pressure at 60-64 years) (β=-0.008, 
95%CI -0.023, 0.006 p=0.257).  
 
Figure 7.3 Cross-sectional association between LTL and cIMT at 60-64 years 
A significant negative association was present between LTL and cIMT at 60-64 years. 
However, this association was greatly attenuated in the fully adjusted model. 
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No associations were observed between LTL at 60-64 years and cardiac 
measurements (table 7.3). 
Table 7.3 Mean difference (regression coefficient) of cardio-vascular phenotypes 
against LTL at age 60-64 years 
Variables LTL 
cIMT β (95%CI) -0.017 (-0.031, -0.003) 
p 0.015 
R_cIMT β (95%CI) -0.018  (-0.036, 0.001) 
p 0.052 
L_cIMT β (95%CI) -0.010  (-0.021, 0.001) 
p 0.071 
LA Dia β (95%CI) -0.022  (-0.071, 0.026) 
p 0.364 
Eject. Fr. β (95%CI) 0.119  (-0.676,0.914) 
p 0.770 
LVM/BSA β (95%CI) -1.987  (-4.469, 0.494) 
p 0.116 
E/A Ratio β (95%CI) -0.001  (-0.024, 0.021) 
p 0.919 
 
Linear regression model (unadjusted models) 
cIMT (Average carotid artery), R_cIMT (Right carotid artery), L_cIMT (Left carotid 
artery) LA Dia (LA Diameter) Eject. Fr. (Ejection Fraction), LVM/BSA, E/A Ratio 
 
7.3.3 Associations between longitudinal change of LTL and CV phenotypes 
In 74% of subjects, there was telomere shortening over the follow up (Figure 
7.4). A strong and inverse relationship was found between baseline LTL and rate of 
change in LTL during follow up (r=-0.8; p<0.001). Furthermore, men had a faster 
change of LTL during follow up compared to women (p<0.01).  
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A greater decrease in LTL between the ages of 53 and 60-64 years was 
associated with higher cIMT at 60-64 years old (β=-0.020mm per 1 SD decrease in 
LTL, 95%CI -0.027, -0.005 p=0.006) (Figure 7.4).  
 
Figure 7.4 Association between percentage change LTL (LTL %) between 53and 
60-64 years and cIMT at 60-64 years. 
Subjects with faster rate of telomere attrition (or slower rate of telomere elongation) 




The strength of this association was not affected by multiple adjustment as 
described above (model 2: β=-0.015, 95%CI -0.026, -0.004; p=0.009) (table 7.4). The 
right cIMT showed very similar findings, while a weaker association was found with 





Table 7.4 Mean difference (regression coefficient) of cIMT per 1 SD higher 







































Generalized linear model 
Model 1= Age difference in years, Gender, Smoking Status 99, Difference in BMI (99-09), 
Model 2= Model 1+ Cholesterol 2009, Systolic BP 2009, Anti-inflammatory use, OAC, Lipid 
Lowering, Clinic Centre and History of MI 
cIMT (Average carotid artery), R_cIMT (Right carotid artery), L_cIMT (Left carotid artery). 
 
No associations were found between changes in LTL and cardiac phenotype 
measures of left ventricular mass, ejection fraction and diastolic function (Table 7.5).  
Table 7.5 Mean difference (regression coefficient) of cardiac phenotypes per 1 
SD higher change in LTL (change conditional to baseline LTL). 
 (N=672) Unadjusted 
LA Dia (mm) 
β (95%CI) 0.006 (-0.004, 0.015) 
p 0.239 
Eject. Fr. (%) 





β (95%CI) -0.006 (-0.024, 0.012) 
p 0.501 
E/A Ratio 
β (95%CI) -0.001 (-0.020, 0.017) 
p 0.881 
E/E’ Ratio 
β (95%CI) 0.009 (-0.011, 0.029) 
p 0.376 
E’/A’ Ratio 
β (95%CI) 0.007 (-0.015, 0.028) 
p 0.544 
E’ 
β (95%CI) 0.014 (-0.001, 0.029) 
p 0.067 
 
LA Dia (Left Atrial Diameter), Eject. Fr. (Left Ventricular Ejection Fraction), LVM/BSA (Left 
Ventricular Mass indexed to Body Surface Area), E/A Ratio (Early to Late Left Ventricular Filling 
Velocities), E/E’ Ratio (ratio between trans-mitral Doppler early filling velocity and tissue Doppler 
early diastolic mitral annular velocity). 
 
Similarly, a greater shortening of LTL was associated with higher odds of 
increased cIMT (OR 1.97 [1.18-3.29], P= 0.01 for LTL shortening as continuous 
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variable and OR 1.79 [1.19-2.68], P<0.01 for LTL shortening > 20%). Individuals 
with carotid plaques, had higher shortening of LTL during follow up compared to 
those without plaques (P<0.01) . Sensitivity analysis did not affect the results. 
 
7.4 Discussion 
This study explored for the first time the association between changes in LTL 
over 10 years and CV phenotypes. We found, using data from a nationally 
representative cohort of 60-64 year old men and women, that a faster rate of LTL 
attrition over 10 years was associated with increased cIMT. This association was 
slightly weaker for the left compared with the right cIMT, was seen in participants 
with both elongation and shortening of LTL and persisted after adjustment for 
potential confounders and mediators. Cross-sectional and longitudinal variations of 
LTL were not related with cardiac phenotypes. These results suggest that, over and 
above the contribution of classic CV risk factor exposure, part of the variation in 
vascular phenotype in late midlife is influenced by mechanisms regulating the rate of 
cellular aging.  
Several studies have reported cross-sectional associations between shorter LTL 
with subclinical and clinical markers of atherosclerosis in middle age populations 
(353;354;543). The lack of longitudinal data on telomere trajectory, however, limits 
the degree to which causal inferences can be made. This study showed that the 
negative relationship between LTL and cIMT described at 60-64 year old is likely to 
be dependent upon a faster rate of LTL change during follow up, suggesting that 
regulation of cellular aging (reflected by LTL dynamics) has a role in the process of 
vascular remodelling. A recent sub-analysis of the Cardiovascular Health Study 
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supports this hypothesis, demonstrating that single nucleotide polymorphisms in 
genes which regulate LTL dynamic are able to predict CV mortality (627). 
An explanation for the association between short LTL and higher levels of 
vascular damage lies in the unique ability of LTL to provide information on the 
balance between lifelong exposure to injurious factors and the ability to repair within 
the CV system (240). Oxidative stress exposure is currently considered the main 
driver of atherosclerosis (628;629). Similarly, an elevated burden of oxidative stress 
can cause a faster rate of LTL attrition by increasing the oxidative stress-mediated 
damage to the telomere sequence (33;42;43). Therefore, exposure to increased levels 
of oxidative stress may explain our findings. On the other hand, due to the 
hierarchical organization of the hematopoietic system, LTL dynamics mirror at any 
age telomere dynamics in hematopoietic stem cells (HSCs), which also represent the 
haematological precursors of endothelial progenitor cells (113). Therefore, a faster 
rate of LTL shortening may reflect a faster rate of telomere attrition in HSC reserves, 
ultimately resulting in a limited ability of the bone marrow to supply an adequate 
number of endothelial progenitor cells for effective repair of vascular damage (240).  
The lack of relationship of CV risk factors with LTL and its dynamic change is 
intriguing as it supports the hypothesis that, over and above the contribution of CV 
risk factor burden, a proportion of cIMT variability in our cohort depends exclusively 
upon the physiological evolution of cellular aging processes. Several studies have 
reported cross-sectional associations between LTL and smoking, obesity and levels of 
insulin resistance (66;67). Consequently, it has been suggested that an increased CV 
risk factor burden could represent the primary mediator of the association between 
LTL and vascular phenotype, leading to a faster rate of LTL shortening and vascular 
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remodelling (541). Although this hypothesis cannot be excluded, the few 
investigations that have analysed the determinants of LTL shortening in healthy and 
diseased populations found limited or no influence of CV risk factor levels on the rate 
of LTL attrition (87;116;117). This evidence raised doubts on the ability of traditional 
CV risk factors to influence effectively LTL dynamics and to mediate its association 
with CV phenotypes. This study demonstrates that the association between LTL 
dynamics and markers of CV disease is unlikely to be dependent on traditional CV 
risk factor exposure, suggesting that other factors such as oxidative stress or genetic 
mechanisms which regulate the progression of cellular aging could drive this 
association.  
Inconsistent associations have been reported between LTL and cardiac 
phenotypes. In a cross-sectional analysis in the Framingham Heart study, Vasan et al 
found a positive association between LTL and LVM (630). In contrast, the Newcastle 
85+ study reported no cross-sectional association between LVM and LTL, despite 
demonstrating a positive relationship between LTL and left ventricular ejection 
fraction (631). Finally, in a small cohort of 334 participants, Kuznetsova et al reported 
that the baseline measure of LTL predicted LVM over 7.4 years of follow up (632). In 
our study, there was no association between cross-sectional and longitudinal measures 
of LTL and cardiac phenotype, in line with current understanding of the LTL biology 
and its relevance to CV disease. Given that the hematopoietic system is the most 
proliferative among human tissues, age-dependent telomere shortening in HSCs, as 
expressed in LTL dynamics, is unlikely to reflect the evolution of the aging process of 
cells with slow turnover rate, such as cardiomyocytes. Our results supported this view 
and provide the first epidemiological evidence of a possible different role of LTL 
biology in the evolution of cardiac and vascular remodelling.  
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Individuals with longer LTL at baseline had a faster rate of LTL attrition during 
follow up. Obviously, this finding could result from mathematical coupling of the 
baseline and follow-up measure of LTL (see the paragraph “Unexpected findings 
from longitudinal measurements of LTL” in the introduction). However, similar 
results had previously been observed in the Bogalusa Heart study and in the Heart and 
Soul Study (87;116;117). Two possible explanations have been provided for this 
finding. The first allocates a crucial role to post-natal environmental exposure, 
suggesting that longer telomeric regions may be at increased risk of oxidative stress 
damage due to their higher content of guanine bases (124;125). The second 
hypothesis is focused on the regulation of LTL by telomerase activity. Indeed, longer 
telomeres are more likely to acquire a T-loop conformation, which precludes access of 
telomerase to the telomeric region (123). Subsequently, shorter telomeres become 
privileged targets for telomerase activity and are more likely to undergo elongation 
than longer telomere sequences.  
While linear regression analyses showed that the influence of LTL dynamics on 
cIMT was small, it was remarkable that one standard deviation change of LTL almost 
doubled the odds of greater cIMT at 60-64 years old. Brouilette et al. reported similar 
odds when they related baseline measures of LTL with future CV risk (61), 
suggesting the measure of LTL dynamics could represent a novel tool that might help 
identify individuals in the general population at increased risk of CV disease beyond 
traditional risk factors. 
Finally, females had a lower rate of LTL compared to males. While these results 
were in contrast with previous findings (62;87;95;543;630), they confirmed the lack 
of an influence of the oestrogen exposure on the LTL dynamics. If the anti-
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inflammatory and anti-oxidative effects of oestrogens were involved in the regulation 
of LTL dynamics, one would have expected that, at the end of the reproductive age 
(52 years), females had longer LTL than males. Similarly, the lack of oestrogen 
exposure between 52 and 60-64 years, should have led to a similar rate of LTL 
shortening during follow up. These assumptions were not confirmed in this study, as 
women had shorter LTL at baseline and tended to maintain the measure of LTL 
during follow up. This confirmed the hypothesis that genetic, rather than post-natal 
factors may regulate the gender differences in LTL dynamics. As mentioned in our 
third study, several observations suggest that gene variance on the X chromosome 
exerts an important influence on telomere length dynamics (97). 
The MRC NSHD has a number of strengths for the investigation of LTL 
biology and its relationship with CV risk factors and phenotypes. Firstly, the NSHD 
study is the only cohort in which longitudinal measures of LTL have been made 
together with a comprehensive characterization of a range of cardiac and vascular 
phenotypes. Secondly, the 10 year follow up between LTL measures and the 
relatively large number of participants included in the analysis, increases the power of 
the results. The yearly rate of change of LTL is low when compared to the ability of 
current LTL assays to detect small differences in telomere length. Consequently, 
changes in LTL over a long follow up period and a large sample size are necessary to 
detect inter-individual variations in telomere attrition rates with confidence. 
Furthermore, the availability of data on a wide range of established and novel CV risk 
factors and potential confounders at both ages allowed, for the first time, investigation 
of the independent contribution of LTL dynamics to CV phenotype. 
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This study has limitations. Firstly, the reported associations are observational, 
and therefore no definitive conclusions can be made regarding causality. Secondly, 
although we adjusted for multiple potential confounding variables, the possibility of 
residual confounding cannot be excluded. For example, we did not adjust for levels of 
inflammatory markers, oxidant and antioxidant molecules (e.g. homocysteine, vitamin 
D, omega-3 fatty acids, etc.), factors that have been previously shown to influence 
cross-sectional and longitudinal measures of LTL (117;243;251). Thirdly, stored 
whole blood samples were used to measure LTL. This allowed us to document a 
relationship between LTL dynamics and CVD but it is impossible to test whether the 
same relationship holds for other age-related diseases. Leukocytes are inflammatory 
cells which are exposed to the same inflammatory environment of the vascular wall. 
Therefore, the link between CVD and LTL could arise from the common influence of 
CV inflammation on both LTL dynamics and atherosclerosis (75;240). However, 
several reports documented a high synchronization between LTL and telomere length 
of other tissues, suggesting that LTL could be used as a reliable marker of whole body 
rather than CV aging and inflammatory burden (88;89;516). Finally, the qPCR-based 
LTL assay measures the average telomere length across all leukocytes in the 
peripheral blood. We were therefore unable to compare telomere length and their rate 
of shortening between different leukocytes subpopulations. Nevertheless, several 
reports have demonstrated that the common origin of leukocytes from the HSCs 
makes their telomere length highly synchronized at any age (113;515). Larger 
longitudinal studies with measure of LTL at multiple time points are required to 
confirm our findings.   
In conclusion, our results suggested that biological pathways regulating the 
process of cellular aging set a higher risk of vascular damage in adulthood. This 
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process of “vascular aging” was only partially affected by exposure to CV risk 
factors. Factors involved in the post-natal regulation of LTL are likely to play a 
central role in the initiation and evolution of atherosclerosis and may help in 






Faster rate of telomere attrition relates with increased cIMT, suggesting a role of 
biological aging pathway in the progression of vascular disease 
The proportion of cIMT explained by the rate of LTL attrition is independent 
from cardiovascular risk factors, suggesting that, over and above the influence 
of the cardiovascular risk burden, there might be a process of vascular aging 
which contributes to progression of CVD 
LTL is unlikely to influence cardiac phenotypes, probably because of the low 
rate of replication of myocardiocytes 
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8 FINAL DISCUSSION 
This thesis aimed to address the impact of one proposed driver of senescence, the 
cumulative exposure to inflammation and oxidative stress, on a specific cellular aging 
pathway, telomere length, in humans. The key finding is that long term inflammatory 
burden is the most likely mediator of the association between LTL and age related 
diseases. In adulthood, levels of inflammatory markers are unable to inform on the 
cumulative impact of inflammation on LTL and age-related diseases. Only clinical 
markers reflecting the long term exposure to inflammation are strongly associated 
with LTL. Conversely, in young subjects with limited inflammatory burden, 
circulating inflammatory markers may help in identifying people with the higher risk 
of short LTL. Finally, the association between rate of telomere shortening and cIMT 
suggests that the relationship between short LTL and age-related disease, which have 
been reported in several adult studies, is likely to dependent upon post-natal 
mechanisms regulating the LTL dynamics.  
These findings suggest that chronic exposure to low levels of inflammation (such 
as those encountered in normal life) can lead to the evolution of a physiological aging 
process which occurs even in the absence of overt disease and starts very early in life. 
This process can be cranked up by increased levels of inflammatory and oxidative 
stress exposure, leading to emergence of diseases commonly detected in the elderly 
(i.e. CVD). The ability of LTL to record the chronic burden of inflammation makes 
this measure a reliable aging marker as well as a possible predictor of age-related 
diseases. It remains unclear whether the biological processes leading to healthy or 
unhealthy aging can be effectively counteracted by reducing inflammation. However, 
this thesis suggests that potential strategies aimed to reduce inflammatory burden to 
prevent evolution of aging should start from the earliest phase of life. 
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Using two human models of chronic inflammation (chronic PD and 
atherosclerosis), this PhD highlighted the limitations of common inflammatory 
markers (IL-6 and CRP) in informing on the individual's cumulative inflammatory 
burden. Chronic PD induces a mild but chronic state of systemic inflammation which 
has been repeatedly associated with an increased risk of age-associated diseases 
including cancer, atherosclerosis, insulin resistance/diabetes, osteoporosis, decline in 
renal, lung and cognitive functions (299-320). Importantly, while these studies 
repeatedly documented a continuous relationship with markers of oral disease 
severity, none reported an association between circulating markers of inflammation 
and risk of age-related diseases. This is expected, as CRP and IL-6 are acute phase 
reactants and their levels in subjects with an underlying inflammatory disease are 
more likely to reflect the inflammatory state at the moment of blood collection, rather 
than informing on long term inflammatory burden (254-262). In contrast, the 
structural and functional modifications induced in different tissues by the 
inflammatory burden are more likely to reflect long term rather than acute 
inflammation. For example, in patients with PD, the measures of CAL is likely to 
provide more accurate information on the cumulative inflammatory burden than a 
single measure of CRP and IL-6 (501;524;633). CAL is a clinical approximation of 
the loss of connective tissue attachment from the root surface and provides an 
objective site-by-site assessment of the long term amount of periodontal damage and 
inflammation (501). When bacteria accumulate on the teeth, the host mounts an 
inflammatory response in the approximating gingival tissue. Such acute inflammatory 
response can be beneficial because in the short term, as it a) prevents bacterial growth 
in the tissue, b) removes bacterial products such as antigens, LPS, and enzymes that 
have penetrated the tissue and c) is associated with specific antibody formation that, 
255 
 
in some cases, appears to be protective (634;635). However, if the inflammatory 
trigger is not efficiently removed, the persistent perturbation of the local tissue 
homeostasis leads to the definition of new pathological set points, in an attempt to 
deal better with the extreme condition (636-641).  
Atherosclerosis represents another human model of chronic inflammation which 
can be used to study the complex relationship between inflammatory burden, markers 
of inflammation and age-related disease. While atherosclerosis is recognised as a 
chronic inflammatory state of the vascular wall, the ability of CRP, fibrinogen and IL-
6 to predict the risk of CV morbidity and mortality remains highly controversial (642-
646). Several studies have demonstrated that the addition of CRP to the Framingham 
risk score does not provide substantial reclassification improvements of patients at 
intermediate to high risk for CV disease (647-657). Conversely, measures of vascular 
damage (such as cIMT and coronary artery calcium), which integrate the long term 
variable inflammatory burden of each individual, add important prognostic 
information to the common scoring systems used to estimate CV risk (361;647;658). 
While the inflammatory trigger is different, the processes which lead to the 
accumulation of inflammatory cells in the vascular wall of patients with 
atherosclerosis are similar to those described in patient with chronic PD 
(173;332;659;660). The chronic inflammatory process induces structural changes of 
the vascular wall reflected by progressive increased thickness of the intima media 
layer and a progressive reduction of vascular elasticity (607;608). Therefore, as CAL 
provides a reliable marker of chronic gingival inflammation, as well cIMT provides a 
reliable marker of the chronic vascular inflammation and oxidative stress burden in 
each individual.  
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The ability of inflammation to affect LTL relates to the two major factors which 
have been shown to impact on LTL dynamic: the end-replication problem and 
oxidative stress (33;40). When monocytes/macrophages fail to remove the bacterial 
biofilm accumulating on the teeth or oxLDL molecules from the intima layer, they 
shift their pattern of cytokine production to increase the recruitment of novel 
inflammatory cells and to limit the virulence of the inflammatory trigger 
(40;661;662). The highlighted recruitment of inflammatory cells in the gingival or 
vascular inflammatory processes is achieved with the cost of an increased 
proliferation of the bone marrow HSCs, which represent the haematological 
precursors of most of the inflammatory cells circulating in peripheral blood (40;663). 
This increased rate of cell replication and differentiation cause faster telomere attrition 
in HSCs, due to the end replication problem. While HSCs have a residual telomerase 
activity, the new homeostatic set point defined by gingival or vascular inflammation 
is likely to overcome the ability of telomerase to replace the telomere sequences loss 
during cells replication (664). As a consequence, subjects with longer history of 
inflammatory burden are likely to represent those with shorter LTL. In this context, 
the increased levels of systemic oxidative stress might further enhance the rate of 
telomere shortening in HSCs. As per its impact on cultured cells (42;43), oxidative 
stress probably augments telomere shortening by two major mechanisms:  
 Inducing single and double strand DNA breaks which increase the telomere loss in 
HSCs per cell replication  
 Diminishing the biological life of a subset of leukocytes which replicate in the 
peripheral circulation (i.e. lymphocytes), further enhancing HSC replication to 
accommodate peripheral needs.  
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The hypothesis a lifelong rather than acute exposure to inflammation is the main 
driver of LTL shortening is further supported by the third study, which suggests that 
the adult association between LTL and markers of chronic inflammation is likely to 
represent a late reflection of biological pathways acting from younger ages. While the 
association between markers of inflammation (CRP and fibrinogen) and LTL 
described in the Ten Towns cohort is apparently in contrast with the first two studies, 
it is important to remark that the environmental burden is limited in adolescence, 
making levels of common inflammatory markers more likely to reflect the baseline 
inflammatory burden rather than the presence of subclinical underline diseases. 
Concordantly, the concentrations of CRP and fibrinogen reported in this young cohort 
are well below those recorded during acute or chronic inflammatory 
responses/diseases (665). The detailed cohort characterization undertaken in this study 
has allowed clearly demonstration that the impact of inflammation on LTL is 
independent from CV risk factors, behavioural and socio-economic factors, previously 
associated with LTL (67;581;594-597). This suggests that the link between LTL and 
inflammation anticipates and possibly explains the adult associations between LTL 
and patterns of dyslipidaemia, blood pressure, obesity and insulin resistance.  
Patient with diabetes who develop PD have shorter LTL compared to those 
without the oral disease. This evidence suggests that the relationship between clinical 
markers of chronic inflammation and LTL is graded and continuous, without obvious 
thresholds. This is an important finding as it confirms that the oxidative stress damage 
plays a crucial role in regulating the rate of telomere attrition. Indeed, previous studies 
have demonstrated that patient with diabetes have shorter LTL compared to the 
general population (62;63;66;250;518). Cells with significantly short telomere length 
have a reduce replication capacity (28). Therefore, in patients with baseline short LTL 
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(i.e. diabetic subjects), the development of a second inflammatory disease (PD) 
cannot be associated with a significant increase in the rate of cell replication. Indeed, 
several report documented that the number of progenitor cells derived from HSCs is 
decreased in the peripheral circulation of both type 1 and type 2 diabetes and that this 
alteration is likely to be involved in the pathogenesis of diabetic complications (666-
668). Consequently, the shortened LTL recorded in patient with diabetes and PD 
compared to those with diabetes alone is likely to depend more on the oxidative stress 
telomere damage than on the end-replication problem. On the other hand, the 
shortened LTL recorded in diabetic patient with severe PD can compromise the ability 
of the immune system to recruit new inflammatory cells to properly counteract the 
aggression of the oral bacteria. Indeed, with a histological analysis of 22 biopsies of 
untreated PD Chapple at al. demonstrated an apparent failure of recruitment and 
activation of macrophages when compared with 26 biopsies of clinically healthy 
(minimally inflamed) gingival tissue (669). Therefore, the continuous relationship 
between BEP and LTL observed in the second study may underscore an increased rate 
of progression of the periodontal disease resulting from a deficient activity of the 
immune-inflammatory system. 
All this evidence suggests that LTL may represent a new reliable marker to 
record the individual's burden of inflammation and oxidative stress across lifespan. 
Furthermore, because inflammation and oxidative stress are at the centre of 
hypotheses on the development and progress of the aging process, the unique feature 
of LTL as a record of the cumulative burden of inflammation and oxidative stress 




Over and above the influence of inflammation, only gender has an 
independent impact on LTL. In all studies presented in this thesis as well as in most of 
those reported in the literature (62;88;95;543;630), females have longer LTL than 
males. The fourth study suggest that this is likely due to a faster rate of LTL attrition 
in males compared to females, a condition that also predispose to an increased risk of 
age related disease, such as atherosclerosis. In the developed world in modern times, 
life expectancy at birth is some 7 years longer for women than it is for men (670), 
indicating that women age more successfully than man. Reasons which account for 
this longevity gender gap remain unknown, but LTL could provide a possible 
biological pathway accounting for this difference. Indeed, the longer LTL recorded in 
women could protect them from developing age-related diseases and, consequently, it 
could provide them with a survival advantage compared to men. While from this 
thesis it is impossible to identify clear mechanisms leading to longer LTL in females 
than males, several hypotheses can be excluded.  
The predominant thinking has been that centrally controlled processes mediated 
by ovarian steroid hormones--notably estrogen--underlie the longevity gender gap 
(671). Estrogen and its derivatives exert potent antioxidant effects via a number of 
mechanisms, including scavenging free radicals, inhibiting free radical formation, and 
stimulating enzymes which are crucial for free radical detoxification (672). The 
reduced bioavailability of free radicals could protect women from developing age 
related diseases, including atherosclerosis and cancer and, at the same time, it could 
also reduce the level of LTL oxidative stress damage. This anti-oxidant effect 
observed in women together with the ability of estrogen to stimulate the transcription 
of the gene encoding the telomerase reverse transcriptase enzyme, can curtail or slow 
down the rate of telomere erosion (672-674). Although this hormonal hypothesis can 
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explain the longer LTL in female compare to males, there are at least three findings in 
this thesis which suggest that alternative factors may be involved in defining the LTL 
gender gap: 
1. A significant sex difference in LTL of 138bp is detectable already at 13-16 
year old, when the duration of the estrogen exposure is limited to only 2-3 
years. If only 3 years of estrogen exposure can determine a gender gap of 
138bp in LTL, this should correspond to a net gain of 40-70bp telomeric 
repetitions per year of estrogen exposure. Assuming that the impact of 
estrogen on LTL is constant throughout reproductive lifespan and that the 
duration of the reproductive age is 35-40 years, this difference will lead to a 
final gender difference in LTL ranging from 1400 to 2800 bp, which is 
significantly higher than that normally recorded in other adult studies 
(62;87;95;543). 
2. There was no association between grade of pubertal maturation and LTL as 
well as no gender interaction was found in the association between LTL and 
inflammatory markers. This further supports the hypothesis that duration of 
estrogen exposure does not influence LTL by attenuating the impact of 
inflammation.  
3. The rate of LTL attrition between the ages of 53 to 60-64 years remains higher 
in males compared to females. As at 53 year old most females are likely to be 
in menopause, the rate of LTL should be equal between genders, due to the 
lack of the antioxidant effects of estrogen.  
In addition to the possible role for estrogens, two more possible explanations for 
the gender gap in LTL could be conceived. Firstly, several lines of evidence suggest a 
X-linked inheritance and regulation of LTL (96;97;101). In patient with X-linked 
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dyskeratosis congenita, for example, the substitution of an amino acid in dyskerin (a 
protein that modifies ribosomal RNA and binds telomerase), leads to shortened 
telomere length, bone marrow failure, and thus premature demise in affected men 
(675). It is therefore likely that a higher level of expression of genes located on the X 
chromosome in females compared to males is responsible for variation in telomere 
length between genders. The presence of an X linked inheritance and regulation LTL 
dynamic is partially confirmed by a report of Nawrot et al., who described robust 
correlations in adult LTL between fathers and daughters, mothers and sons and 
daughters, and among siblings (97). Secondly, in normal females, one of the X 
chromosomes is stochastically inactivated during early embryogenesis (676), so that 
no more than ~25% of genes on the inactive X chromosome are expressed (677). 
Newborn girls therefore have two populations of somatic cells at an approximate ratio 
of 50:50, exhibiting balanced mosaicism with respect to X inactivation. With 
advancing age, the repeated HSC replications might lead to selection of those cells 
with an activated X chromosome harbouring the genetic code that causes longer 
telomeres. This occurrence was reported in carriers of X-linked dyskeratosis 
congenital (59). TRF length of the inactive X chromosome is closely similar to that of 
the active X chromosome in normal newborn girls, but is shorter than the active X 
chromosome in older women (678). 
 
The relationship between LTL and vascular damage is more complex than that 
observed for other age-related diseases. By virtue of its anatomy, the vascular 
endothelium interacts with elements on its luminal and counter-luminal sides, playing 
key roles not only in the biology of the vasculature but also in that of the blood. 
Importantly, the vascular endothelium is where atherosclerosis evolves (324). Based 
262 
 
on a few autopsy cases, it was proposed that telomere shortening in the endothelium 
and consequently endothelial cell senescence contribute to the atherosclerotic process 
in the coronary arteries (350). Given the relatively low replicative index of endothelial 
cells (and smooth muscle cells) in the vascular wall, it is unlikely that these cells 
would experience senescence from telomere shortening during the human lifespan. If 
telomere dynamics are involved in atherosclerosis, their main impact might be not on 
native endothelial cells in the vascular wall but on EPCs. These cells are engaged in 
maintaining the integrity of the vascular endothelium (679), but their number and 
proliferative potential, relate to their telomere length (680-682). Importantly, as both 
EPCs and leukocytes originate from the same haematopoietic precursor (HSCs), the 
telomere length dynamics in EPCs pool are mirrored by LTL dynamics (113;515). 
Subsequently, by measuring telomere length of peripheral leukocytes it is possible to 
obtain information on the residual repair capacity of EPCs. The shortened LTL 
recorded in individuals with atherosclerosis not only forecasts an increased oxidative 
stress and inflammatory burden, but also marks a reduced ability to repair the vascular 
damage. Indeed, in individuals with atherosclerosis it is common to observe short 
LTL (61;63) and a reduced number and proliferative potential of EPCs (683-687).  
While there is several evidence in support of a strong synchronization of telomere 
length in leukocytes and EPCs (113;515), it remains unknown whether the increased 
risk for atherosclerosis expressed in the form of shortened LTL during adulthood 
results from short telomere length at birth or their accelerated attrition rate afterward. 
Biologically, both these circumstances can confer an increased risk of atherosclerosis. 
In individuals with short LTL/EPC telomere length at birth, the increased risk of 
atherosclerosis is likely to depend on a reduced ability to repair the vascular damage 
(680-682) rather than increased levels of post-natal environmental exposure. On the 
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other hand, individuals with faster rate of LTL attrition may represent those with 
normal ability to repair but increased exposure or susceptibility to inflammation or 
oxidative stress in post-natal life (75;241). In this thesis, it was not possible to report 
measure of LTL at birth with a long term follow up, but the results obtained in the 
1946 Birth Cohort are in agreement with the second rather than the first hypothesis. 
Indeed, LTL at baseline (53 year old) did not predict the amount of vascular 
remodelling recorded 10 years later, suggesting that a primary deficit of the ability to 
repair is unlikely to significantly increase the risk of CVD. Conversely, the rate of 
LTL shortening between the two visits was associated with the burden of vascular 
damage and led to the expected inverse association between LTL and cIMT observed 
at the age of 63 years. These results suggest that post- rather than pre-natal factors are 
the main determinants of the risk of short LTL and atherosclerosis in adulthood. This 
is extremely relevant in the management of patient at risk for CVD. As the rate of 
telomere length attrition, rather than their size at birth, is the main determinant of the 
association between short LTL and CV risk in adulthood, an aggressive treatment of 
all factors increasing the inflammatory burden in post-natal life is likely to reduce the 
risk of CVD, slowing the progression of cellular aging.  
The results obtained from the 1946 Birth Cohort Study highlight a second 
important feature of LTL biology. While LTL dynamics reliably mark the evolution 
of the aging phenotype in highly proliferating tissues, they do not provide similar 
information for tissues with low replicative potential. Indeed, the rate of change of 
LTL is strongly associated with the levels of vascular wall remodelling, but does not 
predict the evolution of cardiac damage. This is expected as endothelial cells lining 
the inner surfaces of the vessels have a turn-over significantly higher than 
myocardiocytes. The hypothesis that LTL dynamics are poor markers of disease 
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evolution for tissues with low replicative activity, such as skeletal muscle or neurons, 
is confirmed by several reports. For example, telomere length biology does not 
explain the evolution and severity of diseases characterised by degeneration of 
skeletal muscle fibres, such as Duchenne muscular dystrophy (688). Further, while 
LTL is reduced in patient with stable mild cognitive impairment (689;690), telomere 
length does not predict conversion to Alzheimer's disease (690). Short LTL however 
is associated with higher risk of idiopathic pulmonary fibrosis and cryptogenic liver 
cirrhosis, diseases characterised by altered function and renewal of the highly 
proliferating pulmonary alveolar cells and hepatocytes, respectively (691;692). This 
evidence, together with the findings of this thesis, suggests that mechanisms 
regulating telomere dynamics in peripheral leukocytes are likely to involve also other 
highly proliferative tissues, making LTL a reliable marker to follow the evolution of 
the aging phenotype in tissues with high replicative potential. This will explain the 
associations between LTL and age-related diseases involving also tissues external to 
the haematological compartment.   
 
8.1 Limitations 
Most studies report cross-sectional associations between LTL and inflammatory 
markers and, therefore, may only suggest causality.  It is impossible to define whether 
short telomeres are cause or result of an increased exposure to inflammation. This 
however does not reduce the relevance of current findings. Indeed, if short telomeres 
lead to a higher inflammation, this could explain the increased levels of inflammatory 
markers recorded in the elderly and, at the same time, their higher predisposition to 
age-related diseases. Secondly, the human population studies performed in this thesis 
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only rely on the mean telomere length of blood cells. Although these studies have 
uncovered the association between lower values of mean telomere length, increased 
inflammation and greater risk to develop several age-related diseases, recent reports 
have documented the importance of measuring the frequency of short telomeres, 
rather than the mean telomere length, as indicator of telomere dysfunction (693;694) 
and, subsequently, of cell and tissue dysfunction. Indeed, critically short telomeres 
cannot be repaired by any of the known DNA repair mechanisms and consequently 
trigger a persistent DNA damage response (DDR), which leads to cellular senescence 
and/or apoptosis (53;54), eventually compromising tissue regenerative capacity and 
function, and contributing to organismal aging (40). Thirdly, the relationship between 
markers of tissue remodelling and LTL has been interpreted as an early exhaustion of 
the regenerative ability of the local tissues which would be reflected by short telomere 
length in peripheral leukocytes. Nevertheless, given the lack of data regarding the 
changes in telomere length from vascular and gingival tissues, this can be only 
considered one hypothesis. Finally, the possible impact of oxidative stress on the 
telomere sequence has not been explored directly. No measures of telomere oxidation 
or telomere oxidative stress damage have been reported. 
 
 
8.2 Clinical relevance of the study 
The key finding of this thesis is that chronic but not acute exposure to 
inflammation and oxidative stress is likely to impact on cellular aging pathways in 
humans. While chronic exposure to inflammation has long been considered the driver 
of human aging (4;225;695), the lack of markers which could inform on the 
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cumulative inflammatory burden has strongly limited the ability to prove this 
hypothesis at a population level. In large epidemiological studies, the addition of 
CRP, IL-6, fibrinogen, etc. to scoring systems used to classify individuals at low, 
intermediate and high risk for age-related did not provide a significant reclassification 
improvement (647-657;696;697). When markers of cumulative inflammatory burden 
are added to scoring systems, they are likely to improve the ability to identify those 
individuals at risk to develop age-related disease in the general population. One 
example is provided by CAD. The addition to the Framingham risk score of 
parameters reflecting the cumulative levels of vascular damage related to 
inflammation (such as cIMT or coronary artery calcium), has shown to improve our 
ability to identify subjects with increased risk of CV morbidity and mortality in the 
future (361;647;658).  
The key role of chronic inflammation in the evolution of aging and age-related 
diseases in humans is confirmed by the ability of anti-inflammatory drugs (i.e. 
aspirin) to reduce the risk of several age related diseases, such as cancer and CVD. 
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have received 
considerable interest as potential cancer chemopreventive agents due to their anti-
inflammatory properties (698-700). Animal studies suggest that these agents may 
inhibit tumor growth by modulating cellular proliferation via suppression of 
endogenous prostaglandin synthesis through inhibition of cyclooxygenase (COX) 
enzymes (701;702). Aspirin is also considered to be a chemopreventive agent because 
of its antioxidant properties (703;704). Observational studies (705-722) and 
randomized trials (723-729) have evaluated the effect of aspirin and non-aspirin 
NSAIDs on site-specific cancer incidence, particularly in the colon (730), breast 
(731), pancreas (732), blood (leukemia, (733)) and, more recently, skin. They have 
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demonstrated chemopreventive benefits from aspirin and/or non-aspirin NSAIDs on 
risk of cancer. Three recent studies by Rothwell and colleagues confirmed the strong 
chemoprotective effect of aspirin (734-736), also showing that the drug is effective in 
reducing the risk of distal metastasis (737). The beneficial effects of aspirin have also 
been detected in CAD prevention. The cardioprotective effects of aspirin are mostly 
related to its anti-platelet activity, which prevent thrombus formation on vulnerable 
plaques. However, the reduction of CVD risk associated with the use of aspirin 
appears to be directly related to the reduction of the C-reactive protein levels, 
suggesting that anti-inflammatory properties of the drug may have clinical benefits in 
preventing CVD (738). 
These reports support chronic inflammation as potential target for a more 
aggressive prevention of age-related frailty and mortality in the general population. 
However, the possible biological pathways explaining the associations between 
inflammation and age-related disease remained unknown. This thesis identifies LTL 
and its dynamic regulation as potential biological mechanisms accounting for 
associations between age-related disease and inflammatory/oxidative stress exposure. 
Remarkably, results of the Ten Towns study suggests that the inflammatory 
imprinting on biological aging pathways is detectable from young ages, suggesting 
that an effective anti-inflammatory prevention should start from early adolescence and 
continue among the entire lifespan.  
Furthermore, as LTL strongly correlates with markers of chronic but not acute 
inflammation, LTL can be used as a new valid marker to estimate the long term 
burden of chronic inflammatory and oxidative stress exposure (75;241;509), 
information which cannot be obtained by simply measuring circulating levels of CRP, 
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IL-6 or fibrinogen. This is another important finding of the current thesis, as it 
provides, for the first time, a potential marker to follow the evolution of chronic 
inflammation in humans. Indeed, while chronic inflammation is currently considered 
a major driver of aging and age-related diseases, the lack of a marker which reliably 
inform on the individuals inflammatory burden, did not allow the correct 
identification of those individuals at greater risk of unhealthy aging. 
Furthermore, the use of LTL as a marker of long term inflammatory burden has 
another important consequence. Indeed, if long term treatment with anti-inflammatory 
medications is likely to reduce the risk of unhealthy aging, the effectiveness of these 
treatment strategies can be monitored by measuring LTL. Similarly to glycated 
haemoglobin in diabetic patients, the measure of LTL could inform on the ability of 
anti-inflammatory drugs to reduce the chronic inflammatory burden, marking the 
inflammatory control over a long period. This characteristic of LTL could be 
particularly useful in patients with chronic inflammatory diseases. In this case, acute 
fluctuation in the activity of the underline pathology could result in variable 




9 FUTURE WORK 
Direct measure of oxidative stress damage to the telomere sequence  
Do intra-cellular levels of oxidative stress relate with the amount of oxidative stress 
damage on the telomere sequence? This may be investigated by combining the use of 
a new real time PCR technique which allows measuring the amount of oxidative DNA 
damage in the telomere sequence with flow cytometric techniques which measures the 
total amount of free radicals produced by a specific cell phenotype. Using the 
periodontal model, it is possible to explore whether, changes in intracellular oxidative 
stress concentrations induced by periodontal treatment relates with an acute increase 
of oxoG on the telomere sequence.  
 
Anti-inflammatory treatments and telomere protection 
Although evidence supports the hypothesis that reduction of the baseline 
inflammatory burden could reduce the risk of age related diseases, it is currently 
unknown whether these approaches can also reduce the rate of telomere shortening 
and delay the telomere dysfunction. A long term study, including patient with PD 
could represent a useful model to explore this hypothesis. Patient could be randomly 
allocated to intensive and nonintensive treatment. After 1 year, the rate of LTL 
shortening within the two groups could be measured by FISH. This will allow testing 
whether the reduction of the inflammatory burden expected in the intensively treated 
group is associated with a slower rate of telomere attrition, as well as with a lower 
accumulation of dysfunctional telomeres in different cell subpopulations.  
 
Mitochondrial and cytosolic oxidative stress production: their relationship with 
telomere oxidative stress damage 
Are mitochondrial or cytosolic pathways those which provide the greater contribution 
to the telomere oxidative stress damage? Several reports suggest mitochondrial 
generation of oxidative species (which is normally up regulated in the elderly) as the 
main source of genomic and telomere DNA damage. The availability of 
flowcytometric probes which selectively measure mitochondrial and cytosolic 
oxidative stress will allow understanding the relative contribution of these two 
pathways to the telomere oxidative stress damage. This is remarkable as it has the 
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potential to identify new possible therapeutic target for a more effective prevention of 
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